0001171843-19-004913.txt : 20190726 0001171843-19-004913.hdr.sgml : 20190726 20190726170025 ACCESSION NUMBER: 0001171843-19-004913 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 71 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190726 DATE AS OF CHANGE: 20190726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Anika Therapeutics, Inc. CENTRAL INDEX KEY: 0000898437 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043145961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14027 FILM NUMBER: 19978592 BUSINESS ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: (781) 457-9000 MAIL ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA THERAPEUTICS INC DATE OF NAME CHANGE: 19970114 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA RESEARCH INC DATE OF NAME CHANGE: 19930309 10-Q 1 f10q_072619p.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 10-Q

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2019

 

  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                  to                  

 

Commission File Number 000-21326

 

Anika Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware 04-3145961
(State or Other Jurisdiction of (I.R.S. Employer Identification No.)
Incorporation or Organization)  
   
32 Wiggins Avenue, Bedford, Massachusetts 01730
(Address of Principal Executive Offices) (Zip Code)

 

(781) 457-9000

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol Name of Each Exchange on Which Registered
     
Common Stock, par value $0.01 per share ANIK NASDAQ Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated
filer 
  Accelerated filer    Non-accelerated filer   

Smaller reporting

company 

Emerging growth

company 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No 

 

APPLICABLE ONLY TO CORPORATE ISSUERS:

 

As of July 18, 2019, there were 13,782,928 outstanding shares of Common Stock, par value $0.01 per share.

 

 1 

 

ANIKA THERAPEUTICS, INC.

TABLE OF CONTENTS

 

 

 

Page

Part I Financial Information  
Item 1. Financial Statements (unaudited): 3
  Condensed Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018 3
  Condensed Consolidated Statements of Operations and Comprehensive Income for the three and six months ended June 30, 2019 and 2018 4
  Condensed Consolidated Statements of Stockholders’ Equity for the six months ended June 30, 2019 and 2018 5
  Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2019 and 2018 6
  Notes to Condensed Consolidated Financial Statements 7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 15
Item 3. Quantitative and Qualitative Disclosures About Market Risk 21
Item 4. Controls and Procedures 22
Part II Other Information  
Item 1. Legal Proceedings 22
Item 1A. Risk Factors 22
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 23
Item 6. Exhibits 24
Signatures 25

 

 

 

References in this Quarterly Report on Form 10-Q to “we,” “us,” “our,” “our company,” and other similar references refer to Anika Therapeutics, Inc. and its subsidiaries unless the context otherwise indicates.

 

ANIKA, ANIKA THERAPEUTICS, CINGAL, HYAFF, MONOVISC, and ORTHOVISC are our registered trademarks. This Quarterly Report on Form 10-Q also contains additional registered marks, trademarks, and trade names, including ones that are the property of other companies and licensed to us.

 

 

 

 2 

 

PART I: FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

Anika Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

(in thousands, except per share data)

(unaudited)

         

 

ASSETS  June 30,
2019
  December 31,
2018
Current assets:          
Cash and cash equivalents  $69,407   $89,042 
Investments   72,045    69,972 
Accounts receivable, net of reserves of $1,089 and $1,525 at June 30, 2019 and December 31, 2018, respectively   23,073    20,775 
Inventories, net   22,986    21,300 
Prepaid expenses and other current assets   2,413    1,854 
Total current assets   189,924    202,943 
Property and equipment, net   52,960    54,111 
Operating lease right-of-use assets   23,495    - 
Other long-term assets   4,884    4,897 
Intangible assets, net   8,303    9,191 
Goodwill   7,798    7,851 
Total assets  $287,364   $278,993 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $2,287   $3,143 
Accrued expenses and other current liabilities   8,101    8,146 
Total current liabilities   10,388    11,289 
Other long-term liabilities   373    550 
Deferred tax liability   3,683    3,542 
Operating lease liabilities   21,974    - 
Commitments and contingencies (Note 13)          
Stockholders’ equity:          
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively   -    - 
Common stock, $0.01 par value; 90,000 shares authorized, 13,785 and 14,210 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively   138    142 
Additional paid-in-capital   24,329    50,763 
Accumulated other comprehensive loss   (5,696)   (5,526)
Retained earnings   232,175    218,233 
Total stockholders’ equity   250,946    263,612 
Total liabilities and stockholders’ equity  $287,364   $278,993 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 3 

 

Condensed Consolidated Statements of Operations and Comprehensive Income

(in thousands, except per share data)

(unaudited)

                 

 

   Three Months Ended June 30,  Six Months Ended June 30,
   2019  2018  2019  2018
Product revenue  $30,413   $30,542   $55,130   $51,800 
Licensing, milestone and contract revenue   5    6    11    12 
Total revenue   30,418    30,548    55,141    51,812 
                     
Operating expenses:                    
Cost of product revenue   6,836    8,152    14,147    15,996 
Research & development   4,165    4,733    8,423    9,895 
Selling, general & administrative   7,502    6,417    15,174    22,507 
Total operating expenses   18,503    19,302    37,744    48,398 
Income from operations   11,915    11,246    17,397    3,414 
Interest and other income, net   533    290    1,031    385 
Income before income taxes   12,448    11,536    18,428    3,799 
Provision for income taxes   3,013    1,444    4,486    394 
Net income  $9,435   $10,092   $13,942   $3,405 
                     
Basic net income per share:                    
Net income  $0.68   $0.69   $0.99   $0.23 
Basic weighted average common shares outstanding   13,916    14,652    14,054    14,666 
Diluted net income per share:                    
Net income  $0.67   $0.68   $0.98   $0.23 
Diluted weighted average common shares outstanding   14,088    14,915    14,203    15,045 
                     
Net income  $9,435   $10,092   $13,942  $3,405 
Foreign currency translation adjustment   145    (951)   (170)   (331)
Comprehensive income  $9,580   $9,141   $13,772  $3,074 

         

 

 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 4 

 

Anika Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders' Equity

(in thousands)

 

   For the six months ended June 30, 2019
   Common Stock     Accumulated
Other
  Total
   Number of
Shares
  $0.01 Par
Value
  Additional Paid
in Capital
  Retained
Earnings
  Comprehensive
Loss
  Stockholders'
Equity
Balance, January 1, 2019   14,210   $142   $50,763   $218,233   $(5,526)  $263,612 
Issuance of common stock for equity awards   7    -    5    -    -    5 
Retirement of common stock for minimum tax withholdings   (3)   -    (124)   -    -    (124)
Stock-based compensation expense   -    -    1,386    -    -    1,386 
Net income   -    -    -    4,507    -    4,507 
Other comprehensive loss   -    -    -    -    (315)   (315)
Balance, March 31, 2019   14,214   $142   $52,030   $222,740   $(5,841)  $269,071 
Issuance of common stock for equity awards   30    1    851    -    -    852 
Forfeiture of restricted stock   (7)   -    -    -    -    - 
Stock-based compensation expense   -    -    1,443    -    -    1,443 
Repurchase of common stock   (452)   (5)   (29,995)   -    -    (30,000)
Net income   -    -    -    9,435    -    9,435 
Other comprehensive income   -    -    -    -    145    145 
Balance, June 30, 2019   13,785   $138   $24,329   $232,175   $(5,696)  $250,946 

 

 

   For the six months ended June 30, 2018
   Common Stock     Accumulated
Other
  Total
   Number of
Shares
  $0.01 Par
Value
  Additional Paid
in Capital
  Retained
Earnings
  Comprehensive
Loss
  Stockholders'
Equity
Balance, January 1, 2018   14,688   $147   $68,617   $199,511   $(4,784)  $263,491 
Issuance of common stock for equity awards   89    1    511    -    -    512 
Retirement of common stock for minimum tax withholdings   (32)   (1)   (1,735)   -    -    (1,736)
Stock-based compensation expense   -    -    7,565    -    -    7,565 
Net loss   -    -    -    (6,686)   -    (6,686)
Other comprehensive income   -    -    -    -    620    620 
Balance, March 31, 2018   14,745   $147   $74,958   $192,825   $(4,164)  $263,766 
Issuance of common stock for equity awards   273    3    2,372    -    -    2,375 
Stock-based compensation expense   -    -    1,322    -    -    1,322 
Repurchase of common stock   (434)   (4)   (29,996)   -    -    (30,000)
Net income   -    -    -    10,091    -    10,091 
Other comprehensive loss   -    -    -    -    (951)   (951)
Balance, June 30, 2018   14,584   $146   $48,656   $202,916   $(5,115)  $246,603 

 

                       

 

 The accompanying notes are an integral part of these consolidated financial statements.

 

 5 

 

Anika Therapeutics, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

 

 

   Six Months Ended June 30,
   2019  2018
Cash flows from operating activities:          
Net income  $13,942   $3,405 
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation and amortization   2,943    2,920 
Non-cash operating lease cost   591    - 
Loss on disposal of fixed assets   721    172 
Loss on impairment of intangible asset   281    - 
Stock-based compensation expense   2,829    8,887 
Deferred income taxes   120    63 
Provision for doubtful accounts   -    (6)
Provision for inventory   601    3,993 
Accretion to amortized cost of investments   (757)   - 
Changes in operating assets and liabilities:          
Accounts receivable   (2,293)   1,926 
Inventories   (3,033)   (5,990)
Prepaid expenses, other current and long-term assets   356   790 
Accounts payable   (906)   (194)
Operating lease liabilities   (534)   - 
Accrued expenses, other current and long-term liabilities   (1,300)   (100)
Income taxes   371    (1,803)
Net cash provided by operating activities   13,932    14,063 
           
Cash flows from investing activities:          
Proceeds from maturity of investments   72,594    24,750 
Purchase of investments   (73,896)   (14,000)
Purchase of property and equipment   (2,131)   (3,283)
Net cash (used in) provided by investing activities   (3,433)   7,467 
           
Cash flows from financing activities:          
Repurchases of common stock   (30,000)   (30,000)
Cash paid for tax withheld on vested restricted stock awards   (125)   (1,735)
Proceeds from exercise of equity awards   6    2,886 
Net cash used in financing activities   (30,119)   (28,849)
           
Exchange rate impact on cash   (15)   110 
           
Decrease in cash and cash equivalents   (19,635)   (7,209)
Cash and cash equivalents at beginning of period   89,042    133,256 
Cash and cash equivalents at end of period  $69,407   $126,047 
Supplemental disclosure of cash flow information:          
Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019  $24,110   $- 
Non-cash activities:          
Purchases of property and equipment included in accounts payable and accrued expenses  $211   $462 

 

 

  The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

 6 

 

ANIKA THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(amounts in thousands, except share and per share amounts or as otherwise noted)

(unaudited)

 

1. Nature of Business

 

Anika Therapeutics, Inc. (the “Company”) is a global, integrated orthopedic and regenerative medicines company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing products based on its proprietary Hyaluronic Acid (“HA”) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, viscosupplements which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

 

The Company is subject to risks common to companies in the biotechnology and medical device industries including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.

 

2.   Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The December 31, 2018 balances reported herein are derived from the audited consolidated financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial statements.

 

The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form 10-K for the year ended December 31, 2018. The results of operations for the three- and six-month periods ended June 30, 2019 are not necessarily indicative of the results to be expected for the year ended December 31, 2019.

 

Recent Accounting Pronouncements

 

In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases, which, among other things, results in the recognition of lease assets and lease liabilities on the Company’s balance sheets for virtually all leases. ASU 2016-02 supersedes most previous lease accounting guidance and is effective for interim and annual periods beginning after December 15, 2018. The Company adopted the new guidance as of January 1, 2019 using the modified retrospective adoption method, which did not require restatement of prior periods. The adoption of this standard did not have a material impact on the condensed consolidated statement of operations. See Note 12 for further details.

 

In August 2018, the FASB issued ASU No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40), which amends ASU No. 2015-05, Customers Accounting for Fees in a Cloud Computing Agreement, to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. The most significant change will align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software and hosting arrangements that include an internal-use software license. Accordingly, the amendments in ASU 2018-15 require an entity in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as assets related to the service contract and which costs to expense. ASU 2018-15 is effective for fiscal years and interim periods beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. The Company is assessing ASU 2018-15 and the impact that adopting this new accounting standard will have on its consolidated financial statements and footnote disclosures. 

 

 7 

 

3.   Revenue

 

The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. As of June 30, 2019, deferred revenue was $50 thousand.

  

The Company has agreements with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc. (“Mitek”) that include the grant of certain licenses, performance of development services, and supply of product. Revenues from the agreements with Mitek represent 68% and 70% of total Company revenues for the three- and six-month periods ended June 30, 2019, respectively. The Company has agreements with other customers that may include the delivery of a license and supply of product.

 

Product revenue by product group was as follows: 

 

   Three Months Ended June 30,  Six Months Ended June 30,
   2019  2018  2019  2018
Orthobiologics  $26,462   $26,192   $48,210   $45,681 
Surgical   2,101    1,263    3,493    2,509 
Dermal   444    623    573    83 
Other   1,406    2,464    2,854    3,527 
Product Revenue  $30,413   $30,542   $55,130   $51,800 

 

Total revenue by geographic location was as follows:

 

   Three Months Ended June 30,
   2019  2018
   Total
Revenue
  Percentage of
Revenue
  Total
Revenue
  Percentage of
Revenue
Geographic Location:                    
United States  $22,937    76%  $24,773    81%
Europe   4,927    16%   3,498    11%
Other   2,554    8%   2,277    8%
Total Revenue  $30,418    100%  $30,548    100%

 

   Six Months Ended June 30,
   2019  2018
   Total
Revenue
  Percentage of
Revenue
  Total
Revenue
  Percentage of
Revenue
Geographic Location:                    
United States  $43,026    78%  $41,682    81%
Europe   7,454    14%   5,889    11%
Other   4,661    8%   4,241    8%
Total Revenue  $55,141    100%  $51,812    100%

 

On May 2, 2018, the Company publicly disclosed a voluntary recall of certain lots of its HYAFF-based products, HYALOFAST, HYALOGRAFT C, and HYALOMATRIX. The Company initiated the recall after internal quality testing, which indicated that the products were at risk of not maintaining certain measures throughout their entire shelf life. While there was no indication of any safety or efficacy issue related to the products at the time, the Company removed the products from the field as a precautionary measure. During the three-month period ended March 31, 2018, the Company recorded a revenue reserve for this voluntary recall of $1.1 million of which $0.9 million was related to revenue recorded in prior periods. The adjustments related to the initial revenue reserve subsequent to June 30, 2018 were immaterial. The revenue reserves impacted Dermal and Orthobiologics product groups and all geographic locations. Recall recovery activities were completed during the fourth quarter of 2018, and product shipments resumed in December 2018.

 

4.   Investments

 

All of the Company’s investments are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income, net of related income taxes. The Company held investments, including U.S. treasury bills totaling $72.0 million and $70.0 million as of June 30, 2019 and December 31, 2018, respectively. Unrealized gains and losses as well as the associated tax impact on the Company’s available-for-sale securities were immaterial as of June 30, 2019 and December 31, 2018.

 

 8 

 

5.   Fair Value Measurements

 

The Company’s investments are all classified within Level 1 of the fair value hierarchy and are valued based on quoted prices in active markets. For cash and cash equivalents, current receivables, accounts payable, and interest accrual, the carrying amounts approximate fair value because of the short maturity of these instruments, and therefore fair value information is not included in the table below. 

 

The fair value hierarchy of the Company's cash equivalents and investments at fair value was as follows:

 

      Fair Value Measurements at Reporting Date Using   
   June 30, 2019  Quoted Prices in
Active Markets
for Identical Assets 
(Level 1)
  Significant Other
Observable Inputs 
(Level 2)
  Significant 
Unobservable Inputs 
(Level 3)
  Amortized Cost
Cash equivalents:                         
Money market funds  $1,305   $1,305   $-   $-   $1,305 
                          
Investments:                         
U.S. treasury bills  $72,045   $72,045   $-   $-   $72,032 

 

 

      Fair Value Measurements at Reporting Date Using   
   December 31, 2018  Quoted Prices in
Active Markets
for Identical Assets 
(Level 1)
  Significant Other
Observable Inputs 
(Level 2)
  Significant 
Unobservable Inputs 
(Level 3)
  Amortized Cost
Cash equivalents:                         
Money market funds  $4,984   $4,984   $-   $-   $4,984 
                          
Investments:                         
U.S. treasury bills  $69,972   $69,972   $-   $-   $69,972 

 

6.Equity Incentive Plan

 

The Company estimates the fair value of stock options and stock appreciation rights (“SARs”) using the Black-Scholes valuation model. Fair value of restricted stock awards (“RSAs”) and restricted stock units (“RSUs”) are measured by the grant-date price of the Company’s shares. Fair value of performance restricted stock units (“PSUs”) is measured by the grant-date price of the Company’s shares with corresponding compensation cost recognized over the requisite service period. Compensation cost is recognized based on the estimated probabilities of achieving the performance goals. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related compensation cost that will be recorded in the period of the change. If the performance targets are not achieved, no compensation cost is recognized, and any previously recognized compensation cost is reversed. 

 

The fair value of each stock option award during the six-month periods ended June 30, 2019 and 2018 was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:

 

   Six Months Ended June 30,
   2019  2018
Risk free interest rate  2.18% - 2.54%  2.15% - 2.75%
Expected volatility  44.05% - 44.72%  37.12% - 40.81%
Expected life (years)   3.5   4.0 - 4.5
Expected dividend yield   0.00%    0.00% 

 

The Company recorded $1.4 million and $1.3 million of stock-based compensation expense for the three-month periods ended June 30, 2019 and 2018, respectively. The Company recorded $2.8 million and $8.9 million of stock-based compensation expense for the six-month periods ended June 30, 2019 and 2018, respectively. Upon the retirement of the Company’s former Chief Executive Officer on March 9, 2018, all of his outstanding stock-based compensation awards vested in full and became exercisable in accordance with their terms, resulting in a one-time expense of $6.2 million that was fully recognized during the three-month period ended March 31, 2018.

  

 9 

 

The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows:

 

   Three Months Ended June 30,  Six Months Ended June 30,
   2019  2018  2019  2018
Cost of product revenue  $82   $(28)  $174   $(244)
Research & development   91    241    268    451 
Selling, general & administrative   1,270    1,109    2,387    8,680 
Total stock-based compensation expense  $1,443   $1,322   $2,829   $8,887 

 

On June 18, 2019, the Company’s stockholders approved an amendment to the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the “2017 Plan”). The amendment increased the number of shares of common stock reserved under the 2017 Plan by 1,500,000 from 1,200,000 to 2,700,000. Additionally, the amendment provided greater clarity with respect to the sections governing minimum vesting and tax withholding to facilitate plan administration. No other provisions of the 2017 Plan were amended.

 

The following table sets forth share information for stock-based compensation awards granted and exercised during the three and six-month periods ended June 30, 2019 and 2018:

 

   Three Months Ended June 30,  Six Months Ended June 30,
   2019  2018  2019  2018
Grants:            
Stock Options   27,325    17,500    131,617    209,800 
RSAs   -    -    -    64,578 
RSUs   8,000    -    173,507    8,130 
PSUs   -    -    114,500    - 
Exercises:                    
Stock Options   22,400    273,123    22,900    284,548 
SARs   -    -    -    - 

 

 During the three- and six-month periods ended June 30, 2019, the Company granted stock-based compensation awards in the form of stock options, PSUs and RSUs to employees and RSUs to non-employee directors, the majority of which become exercisable or vest ratably over a three-year period. The PSUs granted to employees contained performance conditions with business and financial targets. The business target, amounting to 30% of the total performance conditions, will be measured based on achievement in the 2019 fiscal year, while the financial targets, amounting to 70% of the total performance conditions, will ultimately be measured with respect to the Company’s operating results in the 2021 fiscal year. The Company recorded $0.3 million and $0.4 million of stock-based compensation expense associated with PSUs for the three- and six-month periods ended June 30, 2019, respectively.

 

7.   Earnings Per Share (“EPS”)

 

Basic EPS is calculated by dividing net income by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding for purposes of calculating basic earnings per share. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, SARs, RSAs, RSUs, and PSUs using the treasury stock method.

 

The following table provides share information used in the calculation of the Company's basic and diluted earnings per share (in thousands):

 

   Three Months Ended June 30,  Six Months Ended June 30,
   2019  2018  2019  2018
Shares used in the calculation of basic earnings per share   13,916    14,652    14,054    14,666 
Effect of dilutive securities:                    
Stock options, SARs, RSAs, RSUs and PSUs   172    263    149    379 
Diluted shares used in the calculation of earnings per share   14,088    14,915    14,203    15,045 

 

Stock options of 1.0 million and 0.7 million shares were outstanding for the three-month periods ended June 30, 2019 and 2018, respectively, and were not included in the computation of diluted EPS because the awards’ impact on EPS would have been anti-dilutive. Stock options of 1.0 million and 0.6 million shares were outstanding for the six-month periods ended June 30, 2019 and 2018 and were not included in the computation of diluted EPS because the awards’ impact on EPS would have been anti-dilutive. 

 10 

 

On May 2, 2019, the Company announced that its Board of Directors had authorized the repurchase of up to $50.0 million shares of the Company’s common stock with $30.0 million to be repurchased through an accelerated share repurchase program and up to $20.0 million to be potentially repurchased on the open market from time-to-time. Through June 30, 2019, no open market repurchases had been executed. On May 7, 2019, the Company entered into an accelerated share repurchase agreement with Morgan Stanley & Co. LLC (“Morgan Stanley”) pursuant to a Fixed Dollar Accelerated Share Repurchase Transaction (“ASR Agreement") to purchase $30.0 million shares of the Company’s common stock. Pursuant to the terms of the ASR Agreement, the Company delivered $30.0 million cash to Morgan Stanley and received an initial delivery of 0.5 million shares of the Company’s common stock on May 8, 2019 based on a closing market price of $39.85 and the applicable contractual discount. This was approximately 60% of the then estimated total number of shares expected to be repurchased under the ASR Agreement. These shares were restored to the status of authorized but unissued shares. The initial delivery of shares resulted in an immediate reduction of the number of outstanding shares used to calculate the weighted-average of shares of the Company’s common stock outstanding for basic and diluted net income per share on the effective date of the ASR Agreement.

 

As of June 30, 2019, the Company has approximately $12.0 million remaining under the ASR Agreement, which was recorded as an equity forward sale contract and was included in additional paid-in capital in stockholders’ equity in the condensed consolidated balance sheet as it met the criteria for equity accounting. Pursuant to the terms of the ASR Agreement, the final number of shares and the average purchase price will be determined at the end of the applicable purchase period, which is expected to occur in the first quarter of 2020. Upon settlement of the ASR Agreement, the Company may receive additional shares or be required to either pay additional cash or deliver shares of its common stock (at its option) to Morgan Stanley, based on the forward price. If the ASR Agreement had been settled as of June 30, 2019, based on the volume-weighted average price since the effective date of the ASR Agreement, Morgan Stanley would have been required to deliver approximately 0.3 million additional shares to the Company’s common stock. However, the Company cannot predict the final number of shares to be received, or delivered, by it under the ASR Agreement. These shares are not included in the calculation of diluted weighted-average of shares of common stock outstanding during the period because the effect is anti-dilutive.

 

8.Inventories

 

Inventories consist of the following:

 

   June 30,
2019
  December 31,
2018
Raw materials  $12,381   $13,688 
Work-in-process   6,399    4,626 
Finished goods   8,747    6,819 
Total  $27,527   $25,133 
           
Inventories  $22,986   $21,300 
Other long-term assets  $4,541   $3,833 

 

Other long-term assets include $4.5 million and $3.8 million of inventory expected to remain on hand beyond one year as of June 30, 2019 and December 31, 2018, respectively. 

 

9.Intangible Assets

 

Intangible assets as of June 30, 2019 and December 31, 2018 consisted of the following:

 

      June 30, 2019  December 31, 2018   
   Gross Value  Accumulated
Currency
Translation
Adjustment
  Impairment  Accumulated
Amortization
  Net
Book
Value
  Accumulated
Currency
Translation
Adjustment
  Accumulated
Amortization
  Net
Book
Value
  Useful
Life
Developed technology  $17,100   $(2,864)  $(281)  $(9,189)  $4,766   $(2,824)  $(8,672)  $5,604    15 
In-process research & development   4,406    (1,191)   -    -    3,215    (1,168)   -    3,238    Indefinite 
Distributor relationships   4,700    (415)   -    (4,285)   -    (415)   (4,285)   -    5 
Patents   1,000    (172)   -    (506)   322    (169)   (482)   349    16 
Elevess trade name   1,000    -    -    (1,000)   -    -    (1,000)   -    9 
Total  $28,206   $(4,642)  $(281)  $(14,980)  $8,303   $(4,576)  $(14,439)  $9,191      

 

 

 

 11 

 

The aggregate amortization expense related to intangible assets was $0.2 million and 0.3 million for the three-month periods ended June 30, 2019 and 2018, respectively. The aggregate amortization expense related to intangible assets was $0.5 million for the six-month periods ended June 30, 2019 and 2018.

 

The Company recorded a $0.3 million impairment charge for the HYALOSPINE developed technology asset in the three-month period ended March 31, 2019. HYALOSPINE was an adhesion prevention gel for use after spinal surgery and received initial CE Mark approval in January 2015. In March 2019, the Company made the decision not to renew the CE Mark as the product was not aligned with the Company’s core strategic focus. As a result, an impairment charge was recorded. This amount is included in selling, general & administrative expenses on the Company’s condensed consolidated statements of operations. 

 

Through June 30, 2019, except as set forth in this paragraph, there have not been any other events or changes in circumstances that indicate that the carrying value of the other acquired intangible assets may not be recoverable. The Company was notified by the distributor of MEROGEL INJECTIBLE that it would not continue to order the product from the Company or market the product. As a result, the depreciation schedule of the remaining $0.1 million of net book value was accelerated. The Company continues to monitor and evaluate the financial performance of its business including the impact of general economic conditions, to assess the potential for the fair value of the reporting unit to decline below its recorded amount. 

 

10. Goodwill

 

The Company completed its annual impairment review as of November 30, 2018 and concluded that no impairment in the carrying value of goodwill exists as of that date. Through June 30, 2019, there have been no events or changes in circumstances that indicate that the carrying value of goodwill may not be recoverable. Changes in the carrying value of goodwill were as follows:

 

   June 30,
2019
Balance at January 1, 2019  $7,851 
Effect of foreign currency adjustments   (53)
Balance at June 30, 2019  $7,798 

 

11. Accrued Expenses

 

Accrued expenses consist of the following:

 

   June 30,
2019
  December 31,
2018
Compensation and related expenses  $3,584   $4,446 
Professional fees   1,609    1,989 
Operating lease liability - current   1,101    - 
Income taxes payable   757    385 
Research grants   398    400 
Clinical trial costs   320    577 
Other   332    349 
Total  $8,101   $8,146 

 

Included in Compensation and related expenses as of June 30, 2019 are the accrued and unpaid costs related to the retirement of the Company’s former Chief Executive Officer as of March 9, 2018. On the same date, the Company and the former Chief Executive Officer entered into a release agreement related to terms in his employment agreement. Under the terms of these agreements, the former Chief Executive Officer is entitled to receive from the Company, as a result of his retirement, aggregate benefits of $1.7 million over the 18-month period subsequent to March 9, 2018, among other benefits. The unpaid amounts under these agreements are included in accrued expenses. As more fully described in Note 6, all of the former Chief Executive Officer’s outstanding equity awards vested in full and became exercisable upon his retirement. The lease liability as of June 30, 2019 is the result of the Company adopting ASU 2016-02 as of January 1, 2019 as more fully described in Note 12.

 

12. Operating Leases

 

The Company adopted ASU 2016-02 as of January 1, 2019 using the modified retrospective adoption method, which did not require it to restate prior periods, and there was no impact on retained earnings. The transition guidance associated with ASU 2016-02 also permitted certain practical expedients. The Company has elected the “package of 3” practical expedients permitted under the transition guidance which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted the practical expedient to use hindsight to determine the lease term. The Company adopted an accounting policy which provides that leases with an initial term of 12 months or less and no purchase option the Company is reasonably certain of exercising will not be included within the lease right-of-use assets and lease liabilities on its consolidated balance sheet. The Company elected an accounting policy to combine the non-lease components (which include common area maintenance, taxes and insurance) with the related lease component. The Company elected this practical expedient to all asset classes upon the adoption of ASU 2016-02.

 

 12 

 

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities, and, if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding right-of-use assets are recorded based on the present values of lease payments over the lease terms. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liability and are recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid, incentives received or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability by using revised inputs as of the reassessment date, and adjust the right-of-use asset.

 

The Company has two primary leases, which are its real estate leases in Bedford, Massachusetts and Padova, Italy. The Company leases approximately 134,000 square feet of administrative, research and development, and manufacturing space in Bedford, Massachusetts (the “Bedford lease”), and approximately 33,000 square feet of office, research and development, training, and warehousing space in Padova, Italy (the “Padova lease”). The current term of the Bedford lease extends to 2022 with several lease renewal options into 2038, and the current term of the Padova lease extends to 2032, with a right to terminate at the Company’s option in 2026 without penalty.

 

The Company identified and assessed significant assumptions in recognizing the right-of-use asset and lease liability on January 1, 2019 as follows:

 

Incremental borrowing rate. The Company derives its incremental borrowing rate from information available at the lease commencement date in determining the present value of lease payments. The incremental borrowing rate represents a collateralized rate of interest the Company would have to pay to borrow over a similar term an amount equal to the lease payments in a similar economic environment. The Company’s lease agreements do not provide implicit rates. As the Company did not have any external borrowings at the transition date with comparable terms to its lease agreements, the Company estimated its incremental borrowing rate based on its credit quality, line of credit agreement and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of the lease. The weighted average discount rate at June 30, 2019 is 4.1%.

 

Lease term. The Company applied the hindsight practical expedient and as a result the lease term for the Bedford lease was determined to include all lease renewal options. There were no changes to the lease terms for its other leases. For the Padova lease, the Company considered the termination option when determining the lease term. The weighted average lease term at June 30, 2019 is 17.3 years.

 

The components of lease expense and other information are as follows: 

 

   For the three months ended
June 30, 2019
  For the six months ended
June 30, 2019
Lease cost          
Operating lease cost  $521   $1,043 
Short-term lease cost   4    6 
Variable lease cost   60    112 
Total lease cost  $585   $1,161 
           
Other information          
Operating cash flows from operating leases  $497   $994 

  

 

 13 

 

Future commitments due under these lease agreements as of June 30, 2019 are as follows:

 

   Operating Lease Obligation As Of  
Years ending December 31,  June 30, 2019 
2019  $994  
2020   2,025  
2021   2,024  
2022   1,981  
2023   1,965  
Thereafter   23,530  
Present value adjustment   (9,444) 
Present value of lease payments   23,075  
Less current portion included in Accrued expenses and other current liabilities   (1,101) 
Operating lease liabilities  $21,974  

 

The following table summarizes the future minimum payments due for the Company’s operating leases under the prior lease guidance without the hindsight practical expedient for each of the next five years and the total thereafter as of December 31, 2018:

 

2019  $1,879 
2020   1,917 
2021   1,924 
2022   1,672 
2023   414 
2024 and thereafter   897 
Total  $8,703 

 

13.Commitments and Contingencies 

 

In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may also warrant that the products it manufactures do not infringe, violate, or breach any U.S. or international patent or intellectual property right, trade secret, or other proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company’s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had no accrued warranties as of June 30, 2019 or December 31, 2018 and has no history of claims paid.

 

The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these occasional legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.

 

14. Income Taxes

 

The provision for income taxes was $3.0 million and $4.5 million for the three- and six-month periods ended June 30, 2019, based on effective tax rates of 24.2% and 24.3%, respectively. The provision for income taxes was $1.4 million and $0.4 million for the three- and six-month periods ended June 30, 2018, based on effective tax rates of 12.5% and 10.4%, respectively. The net increase in the effective tax rate for the three- and six- month periods ended June 30, 2019, as compared to the same periods in 2018, was primarily due to the limitation on the deductibility of executive compensation for accelerated stock vesting upon the retirement of the Company’s former Chief Executive Officer on March 9, 2018 in addition to the windfall tax benefit the Company realized in June 2018 related to exercises of employee equity awards. The Company realized an immaterial shortfall for the three- and six-month periods ended June 30, 2019.

 

The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in Italy.  The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate.

 

In connection with the preparation of the financial statements, the Company assesses whether it was more likely than not that it would be able to utilize, in future periods, the net deferred tax assets associated with its net operating loss carry-forward. The Company has concluded that the positive evidence outweighs the negative evidence and, thus, the deferred tax assets not otherwise subject to a valuation allowance are realizable on a “more likely than not” basis. As such, the Company did not record a valuation allowance as of June 30, 2019 or December 31, 2018.

 14 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (amounts in thousands, except per share amounts or as otherwise noted)

 

You should read the following discussion in conjunction with our financial statements and related notes appearing elsewhere in this report. In addition to historical information, this report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 concerning our business, consolidated financial condition, and results of operations. The Securities and Exchange Commission ("SEC") encourages companies to disclose forward-looking statements so that investors can better understand a company’s prospects and make informed investment decisions. Forward-looking statements are subject to risks and uncertainties, many of which are outside our control, which could cause actual results to differ materially from these statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements can be identified by such words as "will," "likely," "may," "believe," "expect," "anticipate," "intend," "seek," "designed," "develop," "would," "future," "can," "could," and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters. All statements other than statements of historical facts included in this report regarding our strategies, prospects, financial condition, operations, costs, plans, and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements regarding expected future operating results, expectations regarding the timing and receipt of regulatory results, anticipated levels of capital expenditures, and expectations of the effect on our financial condition of claims, litigation, and governmental and regulatory proceedings.

 

Please also refer to those factors described in “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2018 for important factors that we believe could cause actual results to differ materially from those in our forward-looking statements. Any forward-looking statement made by us in this report is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

 

Management Overview

 

We are a global, integrated orthopedic and regenerative medicines company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. We have over two decades of global expertise developing, manufacturing, and commercializing our products based on our proprietary hyaluronic acid (“HA”) technology. Our orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, viscosupplements which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

 

Our therapeutic offerings consist of products in the following areas: Orthobiologics, Dermal, Surgical, and Other, which includes our ophthalmic and veterinary products. All of our products are based on HA, a naturally occurring, biocompatible polymer found throughout the body. Due to its unique biophysical and biochemical properties, HA plays an important role in a number of physiological functions such as the protection and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to and within cells.

 

Our proprietary technologies for modifying the HA molecule allow product properties to be tailored specifically to therapeutic use. Our patented technology chemically modifies HA to allow for longer residence time in the body. We also offer products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA. Our technologies are protected by an extensive portfolio of owned and licensed patents.

 

Since our inception in 1992, we have utilized a commercial partnership model for the distribution of our products to end-users. Our strong, worldwide network of distributors has historically provided, and continues to provide, a solid foundation for our revenue growth and territorial expansion. For near-term and long-term opportunities in the U.S. market, especially with respect to surgical products utilized in an operating room environment, we are executing a hybrid commercial strategy in the U.S. that balances a small direct model with an optimal form of strategic partnership. We are initially utilizing this model to commercialize our injectable, HA-based, surgical bone repair product in the United States. For longer-term future products in the U.S. market, we intend to evaluate the appropriate commercial model for each instance on a case-by-case basis, based on market dynamics, product type and other factors. These models could include direct sales, distribution partnerships, or a hybrid of those forms. We believe that the combination of the direct and distribution commercial models will maximize the revenue potential from our current and future product portfolio.

 

Please see the section captioned “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations-Management Overview” in our Annual Report on Form 10-K for the year ended December 31, 2018, for a description of each of the above therapeutic areas, including the individual products.

 

On May 2, 2018, we publicly disclosed a voluntary recall of certain production lots of our HYAFF-based products, HYALOFAST, HYALOGRAFT C, and HYALOMATRIX. We communicated with all affected distributors in advance of that announcement, and we are taking all required or otherwise appropriate actions with respect to applicable regulatory bodies. We initiated the recall following internal quality testing, which indicated that the products were at risk of not maintaining certain measures throughout their entire shelf life. While there was no indication of any safety or efficacy issue related to the products, we are committed to the highest standards of quality and removed the products from the field as a precautionary measure. During the fourth quarter of 2018, we resolved this matter and resumed shipment of these products.

 

 15 

 

Key Developments during the Quarter Ended June 30, 2019

 

·We made the decision to advance our U.S. CINGAL development program to achieve FDA approval, initially through the execution of a pilot study.
·We executed a $30.0 million accelerated share repurchase agreement with Morgan Stanley & Co. LLC to repurchase common stock.
·We continued to build our U.S. commercial infrastructure to execute our hybrid commercial strategy for the launch of our injectable, HA-based, surgical bone repair product in the third quarter of 2019.
·We generated total revenue of $30.4 million for the second quarter of 2019.

 

Research and Development

 

Our research and development efforts primarily consist of the development of new medical applications for our HA-based technology, the management of clinical trials for certain product candidates, the preparation and processing of applications for regulatory approvals or clearances at all relevant stages of product development, and process development and scale-up manufacturing activities for our existing and new products. Our development focus is orthopedic and regenerative medicine and includes products for tissue protection, repair, and regeneration. We anticipate that we will continue to commit significant resources in the near future to research and development activities, including in relation to preclinical activities and clinical trials. These activities are aimed at the delivery of a steady cascade of new product development and launches over the next several years.

 

In the third quarter of 2017, we submitted an application to the FDA for 510(k) clearance of an injectable, HA-based surgical bone repair product that is reabsorbed by the body and replaced by the growth of new bone during the healing process. We received the 510(k) clearance from the FDA in December 2017, and we expect to make this bone repair product commercially available in the United States during the third quarter of 2019 utilizing the previously-described hybrid commercial approach. In addition, we are working to expand our regenerative medicine pipeline with a new product candidate in the form of an implant for rotator cuff repair utilizing our proprietary solid HA, which could be used to repair partial and full-thickness rotator cuff tears. We finalized development of an initial product prototype during the fourth quarter of 2018. We are currently working on refining the prototype and performing preclinical testing of and developing the surgical instrumentation for the potential product. We anticipate that we will seek 510(k) clearance for this product during 2020, with a potential commercial launch to occur in mid-2021.

 

Our third generation, single-injection osteoarthritis product under development in the United States, CINGAL, which is composed of our proprietary cross-linked HA material combined with an approved steroid and is designed to provide both short- and long-term pain relief to patients, is a main pipeline product and a component of our growth strategy. We completed an initial CINGAL Phase III clinical trial, including the associated statistical analysis for 368 enrolled patients, during the fourth quarter of 2014 with data indicating that the product met all primary and secondary endpoints relative to placebo set forth for the trial. During the first half of 2015, we completed a CINGAL retreatment study with 242 patients who had participated in the Phase III clinical trial and reported safety data related to the retreatment study. This initial Phase III clinical trial and the associated retreatment study supported the Health Canada and CE Mark approval of the product, and the commercial launch of the product in both Canada and the European Union occurred in the second quarter of 2016. In the United States, after discussions with the U.S. Food and Drug Administration (“FDA”) related to the regulatory pathway for CINGAL, we conducted a formal meeting with the FDA’s Office of Combination Products (“OCP”) to present and discuss our data in September 2015, and we submitted a formal request for designation with OCP a month later. In its response to our formal request for designation, OCP assigned the product to the FDA’s Center for Drug Evaluation and Research (“CDER”) as the lead agency center for premarket review and regulation. We then held discussions with CDER to understand the requirements for submitting a New Drug Application (“NDA”) for CINGAL. We held a meeting with CDER in September 2016 to align on an approval framework and on submission requirements for this NDA for CINGAL, including the execution of an additional Phase III clinical trial to supplement our existing CINGAL pivotal study data. We submitted an IND in late 2016, and discussions with CDER indicated that they did not have objections to our clinical protocol design. As a result, we commenced work on this second Phase III clinical trial (“CINGAL 16-02 Study”) in the first quarter of 2017, and the first patient was treated in the second quarter of 2017. Enrollment of the 576 patients in this second Phase III clinical trial was completed during October 2017, and we completed the six-month patient follow-up in April 2018. We received and analyzed the data from the CINGAL 16-02 Study during the second quarter of 2018, and, while substantial pain reduction associated with CINGAL was evident at each measurement point, we determined based on statistical analysis that it did not meet the primary study endpoint of demonstrating a statistically significant difference in pain reduction between CINGAL and the approved steroid component of CINGAL at the six-month time point. In the third quarter of 2017, we initiated an additional three-month extended follow-up study in conjunction with the CINGAL 16-02 Study to investigate the efficacy of CINGAL over this longer period. The first patients were enrolled in this follow-up study in the fourth quarter of 2017 and we completed the nine-month patient follow-up in the third quarter of 2018. In the first quarter of 2019, we met with the FDA to discuss the potential approval pathway for CINGAL in the United States moving forward in light of the work we have previously done. In the meeting, the FDA indicated that an additional Phase III clinical trial would be necessary to support U.S. marketing approval for CINGAL, and we received feedback from the FDA on the parameters and requirements for this additional clinical trial. After substantial internal review, we have decided to conduct a pilot study to enable us to evaluate our full-scale Phase III clinical trial design, including patient and site selection criteria, and increase the probability of success for the Phase III trial. We expect to begin enrolling patients in the pilot study in the first half of 2020.

  

 16 

 

We have several research and development programs underway for new products, including for HYALOFAST (in the United States), an innovative product for cartilage tissue repair, and other early stage regenerative medicine development programs. HYALOFAST, which received CE Mark approval in September 2009, is commercially available in Europe and certain international countries. During the first quarter of 2015, we submitted an Investigational Device Exemption (“IDE”) for HYALOFAST to the FDA, which was approved in July 2015. We commenced patient enrollment in a clinical trial in December 2015 and advanced site initiations and patient enrollment activities. In the second quarter of 2016, a supplement to the HYALOFAST IDE was approved to expand the inclusion criteria for the clinical study, which was aimed at decreasing the time needed to complete the clinical trial. An additional supplement to the HYALOFAST IDE was approved in June 2019, amending the clinical protocol to allow worldwide trial site locations and to adjust inclusion criteria with the goal of accelerating trial enrollment and maximizing our probability of a successful trial outcome. Given the changing medical landscape with respect to the randomization arm for this trial, the microfracture procedure, we are also actively pursuing other alternative strategies to accelerate patient enrollment. The previously-described voluntary recall of certain production lots of our HYAFF-based products did not impact the HYALOFAST clinical trial, as the product used in the clinical trial is not sourced from the affected production lots.

 

We are also currently proceeding with other research and development programs, one of which utilizes our proprietary HA technology to treat pain associated with common repetitive overuse injuries, such as lateral epicondylitis, also known as tennis elbow. We submitted a CE Mark application for this treatment during the first quarter of 2016 and received a CE Mark for the treatment of pain associated with tennis elbow in December 2016. We began work towards a post-market clinical study in relation to the CE Mark for this product in the fourth quarter of 2018. Outside of the United States, this product is marketed under the trade name ORTHOVISC-T. Additionally, in the second quarter of 2016, we submitted an IDE to the FDA to conduct a Phase III clinical trial for this treatment, which was approved by the FDA in June 2016. Notwithstanding that approval and in light of recent changes to the regulatory environment for HA-based products, in the first quarter of 2019, the FDA requested that we submit this product to OCP for designation, which we did early in the second quarter of 2019. We remain in discussions with the FDA with respect to the designation and approval pathway for this product. We also have several other research and development programs underway focused on expanding the indications of our current products, including MONOVISC. During 2019, we will also be performing post-market clinical work in relation to the CE Mark for MONOVISC.

 

In addition to other early stage research and development initiatives we are undertaking, we entered into an agreement with the University of Liverpool in January 2018 to develop an injectable mesenchymal stem cell therapy for the treatment of age-related osteoarthritis with the goal of bringing a therapeutics candidate through clinical trials to market to meet an unmet therapeutic need. We are currently in the preclinical phase of this program and aim to finalize proof of concept during the second quarter of 2020.

 

Results of Operations

 

Three- and Six-Months Ended June 30, 2019 Compared to Three- and Six-Months Ended June 30, 2018

 

   Three Months Ended June 30,  Six Months Ended June 30,
   2019  2018  $ Inc/(Dec)  % Inc/(Dec)  2019  2018  $ Inc/(Dec)  % Inc/(Dec)
   (in thousands, except percentages)  (in thousands, except percentages)
Product revenue  $30,413   $30,542   $(129)   (0%)  $55,130   $51,800   $3,330    6%
Licensing, milestone and contract revenue   5    6    (1)   (17%)   11    12    (1)   (8%)
Total revenue   30,418    30,548    (130)   (0%)   55,141    51,812    3,329    6%
                                         
Operating expenses:                                        
Cost of product revenue   6,836    8,152    (1,316)   (16%)   14,147    15,996    (1,849)   (12%)
Research & development   4,165    4,733    (568)   (12%)   8,423    9,895    (1,472)   (15%)
Selling, general & administrative   7,502    6,417    1,085    17%   15,174    22,507    (7,333)   (33%)
Total operating expenses   18,503    19,302    (799)   (4%)   37,744    48,398    (10,654)   (22%)
Income from operations   11,915    11,246    669    6%   17,397    3,414    13,983    410%
Interest and other income, net   533    290    243    84%   1,031    385    646    168%
Income before income taxes   12,448    11,536    912    8%   18,428    3,799    14,629    385%
Provision for (benefit from) income taxes   3,013    1,444    1,569    109%   4,486    394    4,092    1,039%
Net income  $9,435   $10,092   $(657)   (7%)  $13,942   $3,405   $10,537    309%
Product gross profit  $23,577   $22,390   $1,187    5%  $40,983   $35,804   $5,179    14%
Product gross margin   77.5%   73.3%             74.3%   69.1%          

 

 17 

 

Product Revenue

 

Product revenue for the three-month period ended June 30, 2019 was $30.4 million, a decrease of $0.1 million as compared to $30.5 million for the three-month period ended June 30, 2018. Product revenue for the six-month period ended June 30, 2019 was $55.1 million, an increase of 6%, or $3.3 million, as compared to $51.8 million for the six-month period ended June 30, 2018. For the three-month period ended June 30, 2019, the decrease in product revenue was driven by growth in our orthobiologics and surgical franchises, offset by decreases resulting from order timing in our dermal and other franchises. For the six-month period ended June 30, 2019, the increase in product revenue was driven by growth in our orthobiologics, dermal and surgical franchises, partially offset by a decrease resulting from order timing in our other franchise.

 

The following tables present product revenue by product group:

 

   Three Months Ended June 30,
   2019  2018  $ Inc/(Dec)  % Inc/(Dec)
   (in thousands, except percentages)
Orthobiologics  $26,462   $26,192   $270    1%
Surgical   2,101    1,263    838    66%
Dermal   444    623    (179)   (29%)
Other   1,406    2,464    (1,058)   (43%)
Total  $30,413   $30,542   $(129)   (0%)

 

   Six Months Ended June 30,
   2019  2018  $ Inc/(Dec)  % Inc/(Dec)
   (in thousands, except percentages)
Orthobiologics  $48,210   $45,681   $2,529    6%
Surgical   3,493    2,509    984    39%
Dermal   573    83    490    591%
Other   2,854    3,527    (673)   (19%)
Total  $55,130   $51,800   $3,330    6%

 

 

Orthobiologics

 

Our orthobiologics franchise consists of orthopedic pain management and regenerative therapies. Overall, sales increased 1% and 6% for the three- and six-month periods ended June 30, 2019, respectively, as compared to the same periods in 2018. For the three-month period ended June 30, 2019, there were increased sales of our international viscosupplement products, led by strong CINGAL sales. This increase was partially offset by a decrease in U.S. viscosupplement revenue in the period. The increase in revenue for the six-month period ended June 30, 2019 was primarily driven by increased revenue from MONOVISC domestically and internationally, as well as increased revenue from CINGAL in international markets. We expect orthobiologics product revenue in 2019 to continue to increase as compared to 2018, primarily due to the growth in international CINGAL and MONOVISC revenue and the commercial launch of our injectable, HA-based surgical bone repair product in the U.S. via the previously-described hybrid commercial approach.

 

Surgical 

 

Our surgical franchise consists of products used to prevent surgical adhesions and to treat ear, nose, and throat (“ENT”) disorders. Sales of our surgical products increased 66% and 39% for the three- and six-month periods ended June 30, 2019, to $2.1 million and $3.5 million, respectively, as compared to the same periods in 2018. The increase in surgical product revenue for the three- and six-month periods was due to increased sales to our worldwide ENT commercial partner and higher sales of surgical anti-adhesion products to our international distributors. We expect surgical product revenue to increase in 2019 as compared to 2018 primarily due to increased worldwide revenue associated with sales of our surgical anti-adhesion product and ENT sales.

 

Dermal

 

Our dermal franchise consists of advanced wound care products, which are based on our HYAFF technology, and aesthetic dermal fillers. Our advanced wound care products treat complex skin wounds ranging from burns to diabetic ulcers, with HYALOMATRIX and HYALOFILL as the lead products. For the three-month period ended June 30, 2019, dermal product sales decreased by $0.2 million as compared to the same period in 2018 resulting primarily from order timing. For the six-month period ended June 30, 2019, sales increased $0.5 million as compared to the same period in 2018. This increase was due to recovery from the previously-described voluntary recall of certain production lots of our HYAFF-based products in 2018. We expect dermal sales to increase in 2019 as a result of resuming HYALOMATRIX shipments in late 2018 after the product was impacted by the voluntary recall in 2018.

 

 18 

 

 Other

 

Other product revenue includes revenues from our ophthalmic and veterinary franchises. Other product revenue decreased for the three-month period ended June 30, 2019 by $1.1 million or 43%, and decreased by $0.7 million or 19%, for the six-month period ended June 30, 2019, each as compared to the corresponding period in 2018. We expect other revenue to decrease modestly in 2019 as compared to 2018, primarily as a result of decreased sales to one of our ophthalmic distributors offset in part by increased revenue from veterinary products.

   

Product Gross Profit and Margin

 

Product gross profit for the three- and six-month periods ended June 30, 2019 increased $1.2 million and $5.2 million to $23.6 and $41.0 million, respectively, representing 77.5% and 74.3% of product revenue. Product gross profit for the three- and six-month periods ended June 30, 2018 was $22.4 million and $35.8 million, respectively, or 73.3% and 69.1% of product revenue for the periods, respectively. The increase in product gross margin for the three- and six-month periods ended June 30, 2019, as compared to the same periods in 2018, was primarily due to favorable changes in revenue mix and certain inventory charges related to our solid HA product lines incurred during the 2018 periods.

  

Research and Development

 

Research and development expenses for the three- and six-month periods ended June 30, 2019 were $4.2 million and $8.4 million, representing 14% and 15% of total revenue for the respective periods, a decrease of $0.6 million and $1.5 million, respectively, as compared to the same periods in 2018. The decrease in research and development expense was primarily due to lower clinical trial expenses related to CINGAL for the three- and six-month periods ended June 30, 2019, as compared to the same periods in 2018, offset in part by higher pre-clinical product development activities associated with the development of product candidates in our research and development pipeline, including our rotator cuff therapy, and additional expenses associated with compliance activities related to the European Union Medical Device Regulation. Research and development expenses may potentially increase in 2019 as compared to 2018 as we further develop new products and clinical trial activities, including preparation for the CINGAL pilot study, perform required post-market clinical follow-ups for our MONOVISC and ORTHOVISC-T products in the European Union, and as a result of current or future changes to the regulatory environments in the jurisdictions in which we do business.

 

Selling, General and Administrative

 

Selling, general and administrative (“SG&A”) expenses for the three- and six-month periods ended June 30, 2019 were $7.5 million and $15.2 million, representing 25% and 28% of total revenue for the period, an increase of $1.1 million and decrease of $7.3 million, respectively, as compared to the same periods in 2018. The increase in SG&A expenses for the three-month period ended June 30, 2019 was primarily the result of increased personnel-related costs and external professional fees. The decrease for the six-month period was primarily due to the one-time, non-cash, stock-based compensation expense of approximately $8.0 million in the three-month period ended March 31, 2018 related to the retirement of our former Chief Executive Officer. We expect SG&A expenses for 2019 to decrease in comparison to 2018 due to the above mentioned one-time charge. The decrease will be partially offset by investments in our global commercial capabilities and the implementation of improved business and financial technology platforms required to grow our business.

 

Income Taxes

 

The provision for income taxes was $3.0 million and $4.5 million for the three- and six-month periods ended June 30, 2019, based on effective tax rates of 24.2% and 24.3%, respectively. The provision for income taxes was $1.4 million and $0.4 million for the three- and six-month periods ended June 30, 2018, based on effective tax rates of 12.5% and 10.4%, respectively. The net increase in the effective tax rate for the three- and six- month periods ended June 30, 2019, as compared to the same periods in 2018, was primarily due to the limitation on the deductibility of executive compensation for accelerated stock vesting upon the retirement of our former Chief Executive Officer on March 9, 2018 in addition to the windfall tax benefit we realized in June 2018 related to exercises of employee equity awards. We realized an immaterial shortfall for the three- and six-month periods ended June 30, 2019.

 

 19 

 

How We Evaluate Our Operations

 

We present information below with respect to adjusted EBITDA, which we define as our net income excluding interest and other income, net, income tax benefit (expense), depreciation and amortization, and stock-based compensation. This financial measure is not based on any standardized methodology prescribed by accounting principles generally accepted in the United States (“GAAP”) and are not necessarily comparable to similarly titled measures presented by other companies.

 

We have presented adjusted EBITDA because it is a key measure used by our management and board of directors to understand and evaluate our operating performance and to develop operational goals for managing our business. We believe this financial measure helps identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we exclude. In particular, we believe that the exclusion of the expenses eliminated in calculating adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance. Accordingly, we believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by our management in its financial and operational decision-making.

 

Adjusted EBITDA is not prepared in accordance with GAAP, and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with GAAP. There are a number of limitations related to the use of adjusted EBITDA rather than net income (loss), which is the nearest GAAP equivalent. Some of these limitations are:

 

  adjusted EBITDA excludes depreciation and amortization and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;

 

  we exclude stock-based compensation expense from adjusted EBITDA although (a) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our compensation strategy and (b) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary expense included in operating expenses would be higher, which would affect our cash position;

 

  the expenses and other items that we exclude in our calculation of adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from adjusted EBITDA when they report their operating results;

 

  adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;

 

  adjusted EBITDA does not reflect provision for (benefit from) income taxes or the cash requirements to pay taxes; and

 

  adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments.

 

The following is a reconciliation of net income to adjusted EBITDA for the three- and six-month periods ended June 30, 2019 and 2018, respectively:

 

   Three Months Ended June 30,  Six Months Ended June 30,
   2019  2018  2019  2018
Net income  $9,435   $10,092   $13,942   $3,405 
Interest and other income, net   (533)   (290)   (1,031)   (385)
Provision for income taxes   3,013    1,444    4,486    394 
Depreciation and amortization   1,466    1,447    2,943    2,920 
Stock-based compensation   1,443    1,322    2,829    8,887 
Adjusted EBITDA  $14,824   $14,015   $23,169   $15,221 

 

Adjusted EBITDA in the three- and six-month periods ended June 30, 2019, increased $0.8 million and $7.9 million, respectively, as compared with the comparable periods in 2018. The increase in adjusted EBITDA for the periods was primarily due to an increase in product gross profit and operating income as a result of a reduction in inventory related charges and a more favorable revenue mix.

 

Liquidity and Capital Resources

 

We require cash to fund our operating expenses and to make capital expenditures. We expect that our requirements for cash to fund these uses will increase as our operations expand. Historically we have generated positive cash flow from operations, which, together with our available cash, investments, and debt, have met our cash requirements. Cash, cash equivalents, and investments aggregated $141.5 million and $159.0 million, and working capital totaled $179.5 million and $191.7 million as of June 30, 2019 and December 31, 2018, respectively. In addition, as of June 30, 2019, we have $50.0 million of available credit under our senior revolving credit facility with Bank of America, N.A. We believe that we have adequate financial resources to support our business for at least the twelve months from the issuance date of our financial statements. As of June 30, 2019, we were in compliance with the terms of our credit agreement with Bank of America, N.A.

 

 20 

 

Cash provided by operating activities was $13.9 million for the six-month period ended June 30, 2019, as compared to cash provided by operating activities of $14.1 million for the same period in 2018. The decrease was primarily related to a decrease in collections of our accounts receivable due to timing of receipts and a decrease in accrued expenses. These factors were partially offset by a decrease in prepayments of income taxes and payments for inventory.

 

Cash used in investing activities was $3.4 million for the six-month period ended June 30, 2019, as compared to cash provided by investing activities of $7.5 million for the same period in 2018. The change was due to increased purchases of investments, partially offset by lower capital expenditures as compared to the same period in 2018.

 

Cash used by financing activities was $30.1 million for the six-month period ended June 30, 2019, as compared to cash used by financing activities of $28.8 million for the same period in 2018. In each period, we executed a $30 million accelerated share repurchase agreement. The increase in cash used in financing activities for the six-month period ended June 30, 2019, was primarily attributable to a $2.9 million decrease in proceeds from the exercise of employee equity awards as compared to the corresponding period in the prior year.

 

Critical Accounting Policies and Estimates

 

There were no other significant changes in our critical accounting policies or estimates during the three months ended June 30, 2019 to augment the critical accounting estimates disclosed under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, other than those described in the Notes to the condensed consolidated financial statements included in this report, including the adoption of the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification, Leases, (ASC 842) effective January 1, 2019. As a result of our adoption of the new lease standard, we re-assessed the estimates, assumptions, and judgments that are most critical in our recognition of leases.  For information regarding the impact of recently adopted accounting standards, refer to Notes 2 and 12 to the condensed financial statements included in this report.

 

Recent Accounting Pronouncements

 

A discussion of Recent Accounting Pronouncements is included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and is updated in the Notes to the condensed consolidated financial statements included in this report.

 

Contractual Obligations and Other Commercial Commitments

 

Our contractual obligations and other commercial commitments are summarized in the section captioned “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Contractual Obligations and Other Commercial Commitments” in our Annual Report on Form 10-K for the year ended December 31, 2018. We had no material changes outside the ordinary course to our contractual obligations reported in our 2018 Annual Report on Form 10-K during the six months ended June 30, 2019. For additional discussion, see Note 13 to the condensed consolidated financial statements included in this report.

 

To the extent that funds generated from our operations, together with our existing capital resources, are insufficient to meet future requirements, we will be required to obtain additional funds through equity or debt financings, strategic alliances with corporate partners and others, or through other sources. No assurance can be given that any additional financing will be made available to us or will be available on acceptable terms should such a need arise.

 

Off-balance Sheet Arrangements

 

We do not use special purpose entities or other off-balance sheet financing techniques that we believe have, or are reasonably likely to have, a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, or capital resources.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Our market risks and the ways we manage them are summarized in the section captioned “Part II, Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2018. There have been no material changes in the first six months of 2019 to our market risks or to our management of such risks.

 

 21 

 

ITEM 4. CONTROLS AND PROCEDURES

 

  (a) Evaluation of disclosure controls and procedures.

 

As required by Rule 13a-15 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), we carried out an evaluation under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, the chief executive officer and chief financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in SEC rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. On an on-going basis, we review and document our disclosure controls and procedures, and our internal control over financial reporting, and may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business. 

  

  (b) Changes in internal controls over financial reporting.

 

There were no changes in our internal control over financial reporting during the three-month period ended June 30, 2019 that have materially affected, or that are reasonably likely to materially affect, our internal controls over financial reporting.

 

PART II: OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We are involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, we do not expect the resolution of these occasional legal proceedings to have a material adverse effect on our financial position, results of operations, or cash flow. There have been no material changes to the information provided in the section captioned “Part I, Item 3. Legal Proceedings” in our Annual Report on Form 10-K for the year ended December 31, 2018.

 

ITEM 1A. RISK FACTORS

 

There have been no material changes to the risk factors described in the section captioned “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018. In addition to the other information set forth in this report, you should carefully consider the factors discussed in the section captioned “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018, which could materially affect our business, financial condition, or future results. The risks described in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may have a material adverse effect on our business, financial condition, and/or operating results.

 

 

 22 

 

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

Issuer Purchases of Equity Securities

 

Under our equity compensation plans, and subject to the specific approval of the Compensation Committee of our Board of Directors, grantees have the option of electing to satisfy tax withholding obligations at the time of vesting or exercise by allowing us to withhold shares of stock otherwise issuable to the grantee. During the three-month period ended June 30, 2019, there were no shares withheld to satisfy grantee tax withholding obligations on restricted stock award vesting events.

 

Following is a summary of stock repurchases for the three-month period ended June 30, 2019 (in thousands, except share data):

 

Period  Total Number 
of Shares
Purchased
  Average 
Price Paid
per Share
  Total Number of 
Shares Purchased as
Part of Publicly
Announced Plans
or Programs
  Maximum Number (or
Approximate Dollar
Value) of Shares that
May Yet be Purchased
Under the Plans or
Programs
April 1 to 30, 2019   -    -    -   $- 
May 1 to 31, 2019   451,694   $39.85    451,694   $32,000 
June 1 to 30, 2019   -    -    -   $32,000 
Total   451,694         451,694      

 

(1)On May 2, 2019, we announced that our Board of Directors approved a $50.0 million share repurchase program with $30.0 million to be utilized for an accelerated share repurchase program and $20.0 million reserved for open market repurchases. On May 7, 2019, we entered into a previously-announced accelerated share repurchase agreement (the “ASR Agreement”) to repurchase an aggregate of $30.0 million of common stock. During the second quarter of 2019, 451,694 shares were delivered to us, constituting the initial delivery of shares and representing 60% of the then estimated total number of shares expected to be repurchased under the ASR Agreement. Through June 30, 2019, we have made no open market repurchases.

 

 

 

 

 

 23 

 

ITEM 6. EXHIBITS

 

Exhibit No.   Description
     
*10.1   Fixed Dollar Accelerated Share Repurchase Transaction, dated May 7, 2019, by and between Anika Therapeutics, Inc. and Morgan Stanley & Co. LLC
     
10.2   Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended effective June 18, 2019)
     
10.3   Consulting Agreement, effective July 5, 2019, by and between Anika Therapeutics, Inc. and Edward S. Ahn, Ph.D.
     
10.4   Separation Agreement, effective July 8, 2019, by and between Anika Therapeutics, Inc. and Edward S. Ahn, Ph.D.
     
(31)   Rule 13a-14(a)/15d-14(a) Certifications
       
*31.1   Certification of Joseph G. Darling, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
       
*31.2   Certification of Sylvia Cheung, pursuant to Rules 13a-15(e) and 15d-15(e), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
       
(32)   Section 1350 Certifications
       
**32.1   Certification of Joseph G. Darling, and Sylvia Cheung, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
       
(101)   XBRL
       
*101   The following materials from Anika Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 as filed with the SEC on July 26, 2019, formatted in XBRL (eXtensible Business Reporting Language), as follows:
     
    i. Condensed Consolidated Balance Sheets as of June 30, 2019 (unaudited) and December 31, 2018 (unaudited)
    ii. Condensed Consolidated Statements of Operations and Comprehensive Income for the Three and Six Months Ended June 30, 2019 and June 30, 2018 (unaudited)
    iii. Condensed Consolidated Statements of Stockholders’ Equity for the Three and Six Months Ended June 30, 2019 and June 30, 2018 (unaudited)
    iv. Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2019 and June 30, 2018 (unaudited)
    v. Notes to Condensed Consolidated Financial Statements (unaudited)

 

* Filed herewith.
**  Furnished herewith.

 

 

 

 

 

 

 24 

 

 SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    ANIKA THERAPEUTICS, INC.
   
Date: July 26, 2019 By: /s/ SYLVIA CHEUNG  
    Sylvia Cheung
    Chief Financial Officer
    (Authorized Officer and Principal Financial Officer)

 

 

 

 

 

25


 

EX-10.1 2 exh_101.htm EXHIBIT 10.1

MORGAN STANLEY & CO. LLC

1585 BROADWAY

NEW YORK, NY 10036-8293

(212) 761-4000

 

May 7, 2019

 

Fixed Dollar Accelerated Share Repurchase Transaction

 

 

Anika Therapeutics, Inc.

32 Wiggins Avenue

Bedford, MA 01730

United States

 

 

Dear Sir/Madam:

 

The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Transaction entered into between Morgan Stanley & Co. LLC (“MSCO”) and Anika Therapeutics, Inc. (“Issuer”) on the Trade Date specified below (the “Transaction”). This confirmation constitutes a “Confirmation” as referred to in the Agreement specified below.

 

The definitions and provisions contained in the 2002 ISDA Equity Derivatives Definitions (as published by the International Swaps and Derivatives Association, Inc. (“ISDA”)) (the “Equity Definitions”) are incorporated into this Confirmation. The Transaction is a Share Forward Transaction for purposes of the Equity Definitions. Any reference to a currency shall have the meaning contained in Section 1.7 of the 2006 ISDA Definitions, as published by ISDA.

 

1. This Confirmation evidences a complete and binding agreement between MSCO and Issuer as to the terms of the Transaction to which this Confirmation relates and shall supersede all prior or contemporaneous written or oral communications with respect thereto. This Confirmation shall be subject to an agreement (the “Agreement”) in the form of the 2002 ISDA Master Agreement as if MSCO and Issuer had executed an agreement in such form without any Schedule but with the elections set forth in this Confirmation (and the election of USD as the Termination Currency).

 

The Transaction shall be the only transaction under the Agreement. If there exists any ISDA Master Agreement between MSCO and Issuer or any confirmation or other agreement between MSCO and Issuer pursuant to which an ISDA Master Agreement is deemed to exist between MSCO and Issuer, then, notwithstanding anything to the contrary in such ISDA Master Agreement, such confirmation or agreement or any other agreement to which MSCO and Issuer are parties, the Transaction shall not be considered a transaction under, or otherwise governed by, such existing or deemed to be existing ISDA Master Agreement.

 

If there is any inconsistency between the Agreement, this Confirmation and the Equity Definitions, the following will prevail for purposes of the Transaction in the order of precedence indicated: (i) this Confirmation; (ii) the Equity Definitions; and (iii) the Agreement.

 

2. The terms of the particular Transaction to which this Confirmation relates are as follows:

 

GENERAL TERMS:

 

Trade Date: As specified in Schedule I

 

Buyer: Issuer

 

Seller: MSCO

 

 

 

Shares: Common Stock, par value USD 0.01 per share, of Issuer (Ticker: ANIK)

 

Forward Price: A price per Share (as determined by the Calculation Agent) equal to (i) the arithmetic mean (not a weighted average) of the 10b-18 VWAP on each Trading Day during the Calculation Period minus (ii) the Discount.
   
Discount: As specified in Schedule I
   
10b-18 VWAP: On any Trading Day, a price per Share equal to the volume-weighted average price of the Rule 10b-18 eligible trades in the Shares for the entirety of such Trading Day as determined by the Calculation Agent by reference to the screen entitled “ANIK  <Equity> AQR SEC” or any successor page as reported by Bloomberg L.P. or any successor (without regard to pre-open or after-hours trading outside of any regular trading session for such Trading Day or block trades (as defined in Rule 10b-18(b)(5) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) on such Trading Day) or, if the price displayed on such screen is clearly erroneous, as determined by the Calculation Agent in good faith and in a commercially reasonable manner.

 

Calculation Period: The period from, and including, the first Trading Day that occurs on the Prepayment Date to, and including, the relevant Valuation Date.

 

Trading Day: Any Exchange Business Day that is not a Disrupted Day in whole.

 

Initial Shares: As specified in Schedule I
   
Initial Share Delivery Date: One Exchange Business Day following the Trade Date.  On the Initial Share Delivery Date, Seller shall deliver to Buyer a number of Shares equal to the Initial Shares in accordance with Section 9.4 of the Equity Definitions, with the Initial Share Delivery Date being deemed to be a “Settlement Date” for purposes of such Section 9.4.

 

Prepayment: Applicable

 

Prepayment Amount: As specified in Schedule I

 

 

 

Prepayment Date: One Exchange Business Day following the Trade Date.  On the Prepayment Date, Buyer shall pay to Seller the Prepayment Amount.

 

Exchange: Nasdaq Global Select Market

 

Related Exchange: All Exchanges on which options or futures on the Shares are traded.

 

Market Disruption Event:

The definition of “Market Disruption Event” in Section 6.3(a) of the Equity Definitions is hereby amended by deleting the words “at any time during the one-hour period that ends at the relevant Valuation Time, Latest Exercise Time, Knock-in Valuation Time or Knock-out Valuation Time, as the case may be,” starting in the third line thereof.

 

Section 6.3(d) of the Equity Definitions is hereby amended by deleting the remainder of the provision following the term “Scheduled Closing Time” in the fourth line thereof.

 

Notwithstanding anything to the contrary in the Equity Definitions, if any Exchange Business Day in the Calculation Period is a Disrupted Day, the Calculation Agent shall have the option in its sole discretion to take one or more of the following actions: (i) determine that such Exchange Business Day is a Disrupted Day in part, in which case the Calculation Agent shall (x) determine the 10b-18 VWAP on such Exchange Business Day based on Rule 10b-18 eligible trades in the Shares on such day taking into account the nature and duration of the relevant Market Disruption Event and (y) determine the Forward Price using an appropriately weighted average of 10b-18 VWAPs instead of an arithmetic mean, and/or (ii) elect to postpone the Scheduled Valuation Date by up to one Scheduled Trading Day for every Trading Day that is a Disrupted Day during the Calculation Period. For the avoidance of doubt, if the Calculation Agent takes the action described in clause (i) above, then such Disrupted Day shall be a Trading Day for purposes of calculating the Forward Price.

 

Any Exchange Business Day on which, as of the date hereof, the Exchange is scheduled to close prior to its normal close of trading shall be deemed not to be an Exchange Business Day; if a closure of the Exchange prior to its normal close of trading on any Exchange Business Day is scheduled following the date hereof, then such Exchange Business Day shall be deemed to be a Disrupted Day in full.

 

If a Disrupted Day occurs during the Calculation Period and each of the nine immediately following Scheduled Trading Days is a Disrupted Day, then the Calculation Agent may, in its good faith and commercially reasonable discretion, deem such ninth Scheduled Trading Day to be an Exchange Business Day that is not a Disrupted Day and determine the 10b-18 VWAP Price for such ninth Scheduled Trading Day using its good faith and commercially reasonable estimate of the value of the Shares on such ninth Scheduled Trading Day based on the volume, historical trading patterns and price of the Shares and such other factors as it deems appropriate.

 

 

 

VALUATION:

 

Valuation Date:

The earlier of (i) the Scheduled Valuation Date and (ii) any earlier accelerated Valuation Date as a result of MSCO’s election in accordance with the immediately succeeding paragraph.

 

MSCO shall have the right, in its absolute discretion but subject to the limitation set forth in the immediately succeeding paragraph, to accelerate the Valuation Date, in whole or in part, to any Exchange Business Day that is on or after the Lock-Out Date and prior to the Scheduled Valuation Date by notice (each such notice, an “Acceleration Notice”) to Issuer by 9:00 p.m., New York City time, on the Exchange Business Day immediately following the accelerated Valuation Date (the “Acceleration Date”).

 

On each Valuation Date, the Calculation Agent shall calculate the Settlement Amount.

   
Scheduled Valuation Date: As specified in Schedule I, subject to postponement in accordance with “Market Disruption Event” above.
   
Lock-Out Date: As specified in Schedule I
   

SETTLEMENT TERMS:

 

Physical Settlement:

 

 

 

Applicable.

 

On the Settlement Date, Seller shall deliver to Buyer a number of Shares equal to (a) (i) the Prepayment Amount divided by (ii) the Forward Price, minus (b) the Initial Shares (such number of Shares, the “Settlement Amount”), rounded to the nearest whole number of Shares; provided, however, that if the Settlement Amount is less than zero, then Buyer shall deliver to Seller a number of Shares which shares shall be delivered to Seller by means of a private placement equal to 101% of the absolute value of the Settlement Amount (such number of Shares, the “Payment Shares”).

 

Notwithstanding the proviso in the immediately preceding paragraph, if the Settlement Amount is less than zero, Buyer may cash settle its obligation to deliver the Payment Shares by delivering to Seller a notice by no later than the Valuation Date (or, if later, the date on which MSCO delivers an Acceleration Notice) electing to cash settle its obligation to deliver the Payment Shares. Any such cash settlement shall be effected in accordance with “Cash Settlement of Payment Shares” below.

 

For the avoidance of doubt, upon the date that (i) Issuer satisfies its obligation to deliver the Payment Shares to MSCO in accordance with the terms of this paragraph or (ii) the Settlement Balance (as defined below) is reduced to zero in connection with the cash settlement of the Issuer’s obligation to deliver Payment Shares (as described under “Cash Settlement of Payment Shares” below), Issuer shall have no further delivery or payment obligations under the terms of the Transaction and the Transaction shall be deemed to have been settled as of such date.

 

 

 

Settlement Currency: USD
   
Settlement Date: The date that falls one Settlement Cycle after the relevant Valuation Date; provided that with respect to any accelerated Valuation Date, the date shall be the date that falls one Settlement Cycle following the Acceleration Date.
   
Cash Settlement of Payment Shares:

If Buyer elects to cash settle its obligation to deliver Payment Shares, then on the Valuation Date a notional Share balance (the “Settlement Balance”) shall be created with an initial balance equal to the absolute value of the Settlement Amount.  On the Settlement Date, Buyer shall deliver to Seller an amount in USD equal to the Payment Shares multiplied by a price per Share as reasonably determined by the Calculation Agent (such cash amount, the “Initial Cash Settlement Amount”).  On the Exchange Business Day immediately following the Valuation Date, Seller may begin purchasing Shares in a commercially reasonable manner (all such Shares purchased, “Cash Settlement Shares”) and a notional cash balance (the “Cash Balance”) shall be created with an initial balance equal to the Initial Cash Settlement Amount.  At the end of each Exchange Business Day on which Seller purchases Cash Settlement Shares, Seller shall reduce (i) the Settlement Balance by the number of Cash Settlement Shares purchased on such Exchange Business Day and (ii) the Cash Balance by the aggregate purchase price (including commissions) of the Cash Settlement Shares purchased on such Exchange Business Day.  If, on any Exchange Business Day, the Cash Balance is reduced to or below zero but the Settlement Balance is greater than zero, the Buyer shall (i) deliver to Seller or as directed by Seller on the next Currency Business Day after such Exchange Business Day an additional amount in USD (an “Additional Cash Settlement Amount”) equal to the Settlement Balance as of such Exchange Business Day multiplied by a price per Share as reasonably determined by the Calculation Agent, and the Cash Balance shall be increased by such amount.  This provision shall be applied successively until the Settlement Balance is reduced to zero.  On the Currency Business Day immediately following the Exchange Business Day that the Settlement Balance is reduced to zero, Seller shall return to Buyer an amount in USD equal to the remaining Cash Balance, if any, as of such Exchange Business Day.  In making any purchases of Cash Settlement Shares contemplated by this paragraph, MSCO shall use commercially reasonable efforts to purchase such Shares in a manner that would qualify for the safe harbor provided by Rule 10b-18 under the Exchange Act (“Rule 10b-18”) if such purchases were made by or on behalf of Issuer and subject to Rule 10b-18.  The period until the Settlement Balance is reduced to zero shall be considered to be part of the Calculation Period for purposes of the representations, warranties and covenants and other provisions herein as the context requires (but, for the avoidance of doubt, not for purposes of determining the Forward Price).

 

 

 

   
Other Applicable Provisions: The last sentence of Section 9.2, Sections 9.8, 9.9, 9.10 and 9.11 (except that the Representation and Agreement contained in Section 9.11 of the Equity Definitions shall be modified by excluding any representations therein relating to restrictions, obligations, limitations or requirements under applicable securities laws arising as a result of the fact that Buyer is the issuer of the Shares) and Section 9.12 of the Equity Definitions will be applicable to the Transaction.

 

SHARE ADJUSTMENTS:

 

Potential Adjustment Event:

Notwithstanding anything to the contrary in Section 11.2(e) of the Equity Definitions, an Extraordinary Dividend shall not constitute a Potential Adjustment Event.

 

It shall constitute a Potential Adjustment Event if a Disrupted Day occurs or, pursuant to Section 11 below, is deemed to occur (in whole or in part) on any Trading Day on or prior to the Valuation Date.

   
Extraordinary Dividend: Any dividend or distribution on the Shares with an ex-dividend date occurring during the period from, and including, the Trade Date to, and including, the later of (i) the last day of the Calculation Period or (ii) the day upon which the transactions contemplated under “Cash Settlement of Payment Shares” are complete.

 

Method of Adjustment: Calculation Agent Adjustment

 

Extraordinary Events:

 

Consequences of Merger Events:

 

Share-for-Share: Modified Calculation Agent Adjustment

 

Share-for-Other: Cancellation and Payment on that portion of the Other Consideration that consists of cash; Modified Calculation Agent Adjustment on the remainder of the Other Consideration

 

Share-for-Combined:

Component Adjustment

 

 

 

 

 
Tender Offer: Applicable

 

Consequences of Tender Offers:

 

Share-for-Share: Modified Calculation Agent Adjustment

 

Share-for-Other: Modified Calculation Agent Adjustment

 

Share-for-Combined: Modified Calculation Agent Adjustment
   
New Shares: In the definition of New Shares in Section 12.1(i) of the Equity Definitions, the text in clause (i) thereof shall be deleted in its entirety (including the word “and” following such clause (i)) and replaced with “publicly quoted, traded or listed on any of the New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or their respective successors)”.

 

For purposes of the Transaction,

 

(i)the definition of Merger Date in Section 12.1(c) of the Equity Definitions shall be amended to read, “Merger Date shall mean the Announcement Date.”;

 

(ii)the definition of Tender Offer Date in Section 12.1(e) of the Equity Definitions shall be amended to read, “Tender Offer Date shall mean the Announcement Date.”;

 

(iii)the definition of “Announcement Date” in Section 12.1(l) of the Equity Definitions is hereby amended by (a) replacing the words “a firm” with the word “any” in the second and fourth lines thereof, (b) replacing the word “leads to the” with the words “, if completed, would lead to a” in the third and the fifth lines thereof, (c) replacing the words “voting shares” with the word “Shares” in the fifth line thereof, (d) inserting the words “by any entity” after the word “announcement” in the second and the fourth lines thereof, (e) inserting the words “or to explore the possibility of engaging in” after the words “engage in” in the second line thereof and (f) inserting the words “or to explore the possibility of purchasing or otherwise obtaining” after the word “obtain” in the fourth line thereof; and

 

(iv)Section 12.2 of the Equity Definitions is hereby amended by inserting the words “Announcement Date in respect of any Merger Event or any potential” before the words “Merger Event” in the final line thereof.

 

Composition of Combined Consideration: Not Applicable

 

Nationalization, Insolvency or Delisting: Cancellation and Payment; provided that in addition to the provisions of Section 12.6(a)(iii) of the Equity Definitions, it shall constitute a Delisting if the Exchange is located in the United States and the Shares are not immediately re-listed, re-traded or re-quoted on any of the New York Stock Exchange, The NASDAQ Global Market or The NASDAQ Global Select Market (or their respective successors); if the Shares are immediately re-listed, re-traded or re-quoted on any such exchange or quotation system, such exchange or quotation system shall thereafter be deemed to be the Exchange.

 

 

 

ADDITIONAL DISRUPTION EVENTS:

 

Change in Law: Applicable; provided that (i) any determination as to whether (A) the adoption of or any change in any applicable law or regulation (including, for the avoidance of doubt and without limitation, (x) any tax law or (y) adoption or promulgation of new regulations authorized or mandated by existing statute) or (B) the promulgation of or any change in the interpretation by any court, tribunal or regulatory authority with competent jurisdiction of any applicable law or regulation (including any action taken by a taxing authority), in each case, constitutes a “Change in Law” shall be made without regard to Section 739 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 or any similar legal certainty provision in any legislation enacted, or rule or regulation promulgated, on or after the Trade Date, and (ii) Section 12.9(a)(ii) of the Equity Definitions is hereby amended by replacing the parenthetical beginning after the word “regulation” in the second line thereof the words “(including, for the avoidance of doubt and without limitation, (x) any tax law or (y) adoption or promulgation of new regulations authorized or mandated by existing statute)”.

 

Failure to Deliver: Applicable

 

Insolvency Filing: Applicable

 

Hedging Disruption: Applicable

 

Increased Cost of Hedging: Applicable
   
Loss of Stock Borrow: Applicable
   
Maximum Stock Loan Rate: 100 bps

 

Increased Cost of Stock Borrow: Applicable
   
Initial Stock Loan Rate: 25 bps

 

Determining Party: For all applicable events, MSCO

 

Hedging Party: For all applicable events, MSCO

 

Additional Termination Event(s): The declaration by the Issuer of any Extraordinary Dividend, the ex-dividend date for which occurs or is scheduled to occur during the Relevant Dividend Period, will constitute an Additional Termination Event, with Issuer as the sole Affected Party and all Transactions hereunder as the Affected Transactions.

 

Relevant Dividend Period: The period from, and including, the Trade Date for the Transaction to, and including, the third Scheduled Trading Day following the Scheduled Valuation Date for the Transaction.

 

Non-Reliance: Applicable

 

 

 

Agreements and Acknowledgements Regarding Hedging Activities: Applicable

 

Additional Acknowledgments: Applicable

 

3.  Calculation Agent: MSCO

 

4. Account Details and Notices:

 

(a)       Account for delivery of Shares to Issuer:

 

Company: 12629

Anika Therapeutics, Inc.

American Stock Transfer & Trust Company, LLC

6201 15th Avenue

Brooklyn, NY 11219

 

(b)        Account for payments to Issuer:

 

Bank of America, NY

ABA#: 026009593

Anika Therapeutics, Inc.

Account#: 9363574995

 

(c)        Account for payments to MSCO:

 

Citibank, NY

ABA #: 021000089

Morgan Stanley & Co.

Account #: 38890774

Anika Therapeutics, Inc.

# 023-05370

 

(d)       For purposes of this Confirmation:

 

(i)       Address for notices or communications to Issuer:

 

Anika Therapeutics, Inc.

32 Wiggins Avenue

Bedford, MA 01730

Attention: Sylvia Cheung

Telephone: 781-457-9214

Facsimile: 781-305-9720

Email Address: scheung@anikatherapeutics.com

 

With a copy to:

Anika Therapeutics, Inc.

32 Wiggins Avenue

Bedford, MA 01730

Attention: Charles Sherwood III

Telephone: 781-457-9261

Facsimile: 781-305-9720

Email: chsherwoodiii@anikatherapeutics.com

 

 

 

(ii)       Address for notices or communications to MSCO:

 

Morgan Stanley & Co. LLC

1585 Broadway

New York, NY 10036-8293

Attention: Usman Khan

Telephone: 212-761-0955

Facsimile: 212-507-4261

Email Address: usman.s.khan@morganstanley.com

 

With a copy to:

Morgan Stanley & Co. LLC

1585 Broadway

New York, NY 10036-8293

Attention: Steven Seltzer

Telephone: 212-761-1719

Email: Steven.Seltzer1@morganstanley.com

 

5. Amendments to the Equity Definitions.

 

(a)        Section 9.2(a)(iii) of the Equity Definitions is hereby amended by deleting the words “the Excess Dividend Amount, if any, and”.

 

(b)       Section 11.2(a) of the Equity Definitions is hereby amended by deleting the words “a diluting or concentrative effect on the theoretical value of the relevant Shares” and replacing them with the words “a material economic effect on the relevant Transaction”.

 

(c)       The first sentence of Section 11.2(c) of the Equity Definitions, prior to clause (A) thereof, is hereby amended to read as follows: ‘(c) If “Calculation Agent Adjustment” is specified as the Method of Adjustment in the related Confirmation of a Share Option Transaction or Share Forward Transaction, then, following the announcement or occurrence of any Potential Adjustment Event, the Calculation Agent will determine whether such Potential Adjustment Event has a material economic effect on the Transaction and, if so, will (i) make appropriate adjustment(s), if any, to any one or more of:’ and the portion of such sentence immediately preceding clause (ii) thereof is hereby amended by deleting the words “diluting or concentrative” and the words “(provided that no adjustments will be made to account solely for changes in volatility, expected dividends, stock loan rate or liquidity relative to the relevant Share)” and replacing such latter phrase with the words “(including adjustments to account for changes in volatility, stock loan rate or liquidity relevant to the Shares or to the Transaction)”.

 

(d)       Section 11.2(e)(vii) of the Equity Definitions is hereby amended by deleting the words “diluting or concentrative effect on the theoretical value of the relevant Shares” and replacing them with the words “material economic effect on the relevant Transaction”.

 

(e)       Section 12.6(c)(ii) of the Equity Definitions is hereby amended by replacing the words “the Transaction will be cancelled,” in the first line with the words “MSCO will have the right to cancel the Transaction,”.

 

(f)       Section 12.9(b)(iv) of the Equity Definitions is hereby amended by (A) deleting (1) subsection (A) in its entirety, (2) the phrase “or (B)” following subsection (A) and (3) the phrase “in each case” in subsection (B); and (B) deleting the phrase “neither the Non-Hedging Party nor the Lending Party lends Shares in the amount of the Hedging Shares or” in the penultimate sentence.

 

 

 

(g)       Section 12.9(b)(v) of the Equity Definitions is hereby amended by (A) adding the word “or” immediately before subsection “(B)” and deleting the comma at the end of subsection (A); and (B)(1) deleting subsection (C) in its entirety, (2) deleting the word “or” immediately preceding subsection (C) and (3) replacing in the penultimate sentence the words “either party” with “the Hedging Party” and (4) deleting clause (X) in the final sentence.

 

6. Certain Payments and Deliveries by MSCO.

Notwithstanding anything to the contrary herein, or in the Equity Definitions, if at any time (i) an Early Termination Date occurs and MSCO would be required to make a payment pursuant to Section 6 of the Agreement or (ii) an Extraordinary Event occurs and MSCO would be required to make a payment pursuant to Article 12 of the Equity Definitions (the amount of any such payment obligation described in Section 6(i) or (ii) above, an “MSCO Payment Amount”), then Issuer shall have the right, by prior written notice to MSCO, to require MSCO to settle such payment obligation in Shares in lieu of cash; provided, however, that Issuer shall not have the right to so elect in the event of (i) an Insolvency, a Nationalization, a Merger Event or a Tender Offer, in each case, in which the consideration or proceeds to be paid to holders of Shares consists solely of cash or (ii) an Event of Default in which Issuer is the Defaulting Party or a Termination Event in which Issuer is an Affected Party, which Event of Default or Termination Event resulted from an event or events within Issuer’s control. If Issuer does not so elect for MSCO to settle an MSCO Payment Amount in Shares, then MSCO shall have the right, in its sole discretion, to elect to settle such MSCO Payment Amount in Shares. If either Issuer or MSCO so elects, then MSCO shall deliver to Issuer, on or within a commercially reasonable time following the date on which such MSCO Payment Amount would have been due, a number of Shares with a market value, as determined by the Calculation Agent, equal to all or a portion (which portion may be zero) of the MSCO Payment Amount. If the market value of such Shares equals a portion, but not all, of the MSCO Payment Amount, then, on the date such MSCO Payment Amount is due, a notional balance (the “Settlement Balance”) shall be established equal to the remaining portion of the MSCO Payment Amount, and MSCO shall commence purchasing Shares for delivery to Issuer. At the end of each Trading Day on which MSCO purchases Shares pursuant to this Section 6, MSCO shall reduce the Settlement Balance by the amount paid by MSCO to purchase the Shares purchased on such Trading Day. MSCO shall deliver any Shares purchased on a Trading Day pursuant to this Section 6 to Issuer on the third Exchange Business Day following such Trading Day. MSCO shall continue so purchasing and delivering Shares until the Settlement Balance has been reduced to zero. In making any purchases of Shares contemplated by this Section 6, MSCO shall use commercially reasonable efforts to purchase such Shares in a manner that would qualify for the safe harbor provided by Rule 10b-18 if such purchases were made by or on behalf of Issuer and subject to Rule 10b-18. The period until the Settlement Balance is reduced to zero shall be considered to be part of the Calculation Period for purposes of the representations, warranties and covenants and other provisions herein as the context requires.

 

7. Certain Payments and Deliveries by Issuer.

 

Notwithstanding anything to the contrary herein, or in the Equity Definitions, if at any time (i) an Early Termination Date occurs and Issuer would be required to make a payment pursuant to Section 6 of the Agreement or (ii) an Extraordinary Event occurs and Issuer would be required to make a payment pursuant to Article 12 of the Equity Definitions (any such payment described in (i) or (ii) above, an “Early Settlement Payment”), then Issuer shall have the right, by prior written notice to MSCO, in lieu of making such cash payment, to settle such payment obligation in Shares (such Shares, “Early Settlement Shares”); provided, however, that Issuer shall not have the right to so elect in the event of (i) an Insolvency, a Nationalization, a Merger Event or a Tender Offer, in each case, in which the consideration or proceeds to be paid to holders of Shares consists solely of cash or (ii) an Event of Default in which Issuer is the Defaulting Party or a Termination Event in which Issuer is an Affected Party, which Event of Default or Termination Event resulted from an event or events within Issuer’s control. In order to elect to deliver Early Settlement Shares, (i) Issuer must notify MSCO of its election by no later than 4:00 p.m., New York City time, on the date that is three Exchange Business Days before the date that the Early Settlement Payment is due, (ii) Issuer must specify whether such Early Settlement Shares are to be sold by means of a registered offering or by means of a private placement and (iii) Issuer must comply with Section 8 below.

 

 

 

8. Provisions Relating to Delivery of Early Settlement Shares.

 

(a)       Issuer may deliver Early Settlement Shares and Make-Whole Shares (as defined below) by means of a registered offering only if the following conditions are satisfied:

 

(i)        On the later of (A) the Trading Day following Issuer’s election to deliver Early Settlement Shares and any Make-Whole Shares by means of a registered offering (the “Registration Notice Date”), and (B) the date on which the Registration Statement is declared effective by the SEC or becomes effective, but in no event later than the date the Early Settlement Payment is due, Issuer shall deliver to MSCO a number of Early Settlement Shares equal to the quotient of (I) the relevant Early Settlement Payment divided by (II) a price per Share as reasonably determined by the Calculation Agent (the date of such delivery, the “Registered Share Delivery Date”).

 

(ii)        Promptly following the Registration Notice Date, Issuer shall file with the SEC a registration statement (“Registration Statement”) covering the public sale by MSCO of the Early Settlement Shares and any Make-Whole Shares (collectively, the “Registered Securities”) on a continuous or delayed basis pursuant to Rule 415 (or any similar or successor rule), if available, under the Securities Act of 1933, as amended (the “Securities Act”); provided that no such filing shall be required pursuant to this paragraph (ii) if Issuer shall have filed a similar registration statement with unused capacity at least equal to the relevant Early Settlement Payment and such registration statement has become effective or been declared effective by the SEC on or prior to the Registration Notice Date and no stop order is in effect with respect to such registration statement as of the Registration Notice Date, in which case such registration statement shall be the Registration Statement.  Issuer shall use its commercially reasonable efforts to file the Registration Statement as an automatic shelf registration statement or have the Registration Statement declared effective by the SEC as promptly as possible. The Registration Statement shall be effective and subject to no stop order as of the Registered Share Delivery Date.

 

(iii)        Promptly following the Registration Notice Date, Issuer shall afford MSCO a reasonable opportunity to conduct a due diligence investigation with respect to Issuer customary in scope for underwritten offerings of equity securities for companies of comparable size, maturity and line of business (including, without limitation, the availability of senior management to respond to questions regarding the business and financial condition of Issuer and the right to have made available to MSCO for inspection all financial and other records, pertinent corporate documents and other information reasonably requested in connection with underwritten offerings of this type by MSCO), and MSCO shall be satisfied in all material respects with the results of such due diligence investigation of Issuer. For the avoidance of doubt, Issuer shall not have the right to deliver Shares pursuant to this Section 8(a) (and the conditions to delivery of Early Settlement Shares specified in this Section 8(a) shall not be satisfied) unless and until MSCO is satisfied in all material respects with the results of such due diligence investigation of Issuer.

 

(iv)        From the effectiveness of the Registration Statement until all Registered Securities have been sold by MSCO, Issuer shall, at the request of MSCO, make available to MSCO a printed prospectus relating to the Registered Securities in form and substance (including, without limitation, any sections describing the plan of distribution) reasonably satisfactory to MSCO (a “Prospectus”, which term shall include any prospectus supplement thereto), in such quantities as MSCO shall reasonably request.

 

(v)        Issuer shall use its commercially reasonable efforts to avoid or prevent the issuance of any stop order suspending the effectiveness of the Registration Statement or of any order preventing or suspending the use of any Prospectus and, if any such order is issued, to obtain the lifting thereof as soon thereafter as is possible.  If the Registration Statement, the Prospectus or any document incorporated therein by reference contains a misstatement of a material fact or omits to state a material fact required to be stated therein or necessary to make any statement therein not misleading, Issuer shall as promptly as practicable file any required document and prepare and furnish to MSCO a reasonable number of copies of such supplement or amendment thereto as may be necessary so that the Prospectus, as thereafter delivered to the purchasers of the Registered Securities, will not contain a misstatement of a material fact or omit to state a material fact required to be stated therein or necessary to make any statement therein not misleading.

 

 

 

(vi)        On or prior to the Registered Share Delivery Date, Issuer shall enter into an agreement (a “Transfer Agreement”) with MSCO (or any affiliate of MSCO designated by MSCO) relating to the public sale of the Registered Securities and substantially similar to underwriting agreements customary for underwritten offerings of equity securities for companies of comparable size, maturity and line of business, in form and substance reasonably satisfactory to MSCO (or such affiliate), which Transfer Agreement shall (without limiting the foregoing) contain provisions substantially similar to those contained in such underwriting agreements relating to:

 

(A)        the indemnification of, and contribution in connection with the liability of, MSCO and its affiliates,

 

(B)        the delivery to MSCO (or such affiliate) of customary letters and opinions (including, without limitation, accountants’ comfort letters, opinions relating to the due authorization, valid issuance and fully paid and non-assessable nature of the Registered Securities and letters of counsel relating to the lack of material misstatements and omissions in the Registration Statement and the Prospectus); and

 

(C)        the payment by Issuer of all fees and expenses in connection with such resale, including all registration costs and all reasonable fees and expenses of one counsel for MSCO (or such affiliate).

 

(vii)        On the Registered Share Delivery Date, a notional balance (the “Early Settlement Balance”) shall be established with an initial balance equal to the amount of the Early Settlement Payment.  Following the delivery of Early Settlement Shares or any Make-Whole Shares, MSCO shall sell all such Early Settlement Shares or Make-Whole Shares in a commercially reasonable manner.

 

(viii)        At the end of each day on which sales have been made pursuant to paragraph 8(a)(vii) above, the Early Settlement Balance shall be (A) reduced by an amount equal to the net proceeds to be received by MSCO upon settlement of such sales, and (B) increased by an amount (as reasonably determined by the Calculation Agent) equal to MSCO’s funding cost with respect to the Early Settlement Balance as of the close of business on the day one Settlement Cycle prior to such day.

 

(ix)        If, on any date, the Settlement Balance has been reduced to zero but not all of the Early Settlement Shares have been sold, no additional Early Settlement Shares shall be sold and MSCO shall promptly deliver to Issuer (A) any remaining Early Settlement Shares and (B) if the Early Settlement Balance has been reduced to an amount less than zero, an amount in cash equal to the absolute value of the then-current Early Settlement Balance.

 

(x)        If, on any date, all of the Early Settlement Shares have been sold and the Settlement Balance has not been reduced to zero, Issuer shall, at its election, either pay the remaining Early Settlement Balance to MSCO in cash or promptly deliver to MSCO an additional number of Shares (“Make-Whole Shares”) equal to (A) the Settlement Balance as of such date divided by (B) a price per Share as reasonably determined by the Calculation Agent. This clause (x) shall be applied successively until the Settlement Balance is reduced to zero.

 

(xi)        If at any time the number of Shares covered by the Registration Statement is less than the number of Registered Securities required to be delivered pursuant to this Section 8(a), Issuer shall, at the request of MSCO, file additional registration statement(s) to register the sale of all Registered Securities required to be delivered to MSCO.

 

(xii)        Issuer shall cooperate with MSCO and use its commercially reasonable efforts to take any other action necessary to effect the intent of the provisions set forth in this Section 8(a).

 

 

 

(xiii)       The provisions of Section 8(b) shall apply to any then-current Early Settlement Balance if (i) on any given day, Issuer cannot satisfy any of the conditions set forth in this Section 8(a) or (ii) for a period of at least 10 consecutive Exchange Business Days, MSCO has determined that it is inadvisable to effect sales of Registered Securities, unless in either case Issuer pays such then-current Early Settlement Balance to MSCO in cash pursuant to the Registration Statement.

 

(b)        If Issuer timely elects to deliver Early Settlement Shares and Make-Whole Shares by means of a private placement, the following provisions shall apply:

 

(i)       All Early Settlement Shares and Make-Whole Shares shall be delivered to MSCO (or any affiliate of MSCO designated by MSCO) pursuant to the exemption from the registration requirements of the Securities Act provided by Section 4(a)(2) thereof.

 

(ii)        Issuer shall afford MSCO and any potential purchaser of any such Shares from MSCO (or any affiliate of MSCO designated by MSCO) identified by MSCO a commercially reasonable opportunity to conduct a due diligence investigation with respect to Issuer customary in scope for private placements of equity securities for companies of comparable size, maturity and line of business (including, without limitation, the right to have made available to them for inspection all financial and other records, pertinent corporate documents and other information reasonably requested by them in connection with underwritten offerings of this type) and Issuer shall not disclose material non-public information in connection with such due diligence investigation.

 

(iii)        Issuer shall enter into an agreement (a “Private Placement Agreement”) with MSCO (or any affiliate of MSCO designated by MSCO) in connection with the private placement of such Shares by Issuer to MSCO (or any such affiliate) and the private resale of such Shares by MSCO (or any such affiliate), substantially similar to private placement purchase agreements customary for private placements of equity securities for companies of comparable size, maturity and line of business, in form and substance commercially reasonably satisfactory to MSCO and Issuer, which Private Placement Agreement shall include, without limitation, provisions substantially similar to those contained in such private placement purchase agreements relating to the indemnification of, and contribution in connection with the liability of, MSCO and its affiliates, and shall provide for the payment by Issuer of all fees and expenses in connection with such resale, including all reasonable fees and expenses of one counsel for MSCO but not including any underwriter or broker discounts and commissions, and shall contain representations, warranties and agreements of Issuer and MSCO reasonably necessary or advisable to establish and maintain the availability of an exemption from the registration requirements of the Securities Act for such resales.

 

(iv)        Issuer shall not take or cause to be taken any action that would make unavailable either (A) the exemption set forth in Section 4(a)(2) of the Securities Act for the sale of any Early Settlement Shares or Make-Whole Shares by Issuer to MSCO or (B) an exemption from the registration requirements of the Securities Act reasonably acceptable to MSCO for resales of Early Settlement Shares and Make-Whole Shares by MSCO.

 

(v)        On the date requested by MSCO, Issuer shall deliver a number of Early Settlement Shares equal to the quotient of (A) the amount of the Early Settlement Payment divided by (B) a per Share value, determined by MSCO in a commercially reasonable manner, which value shall take into account transfer restrictions applicable to such Shares and may be based on indicative bids from institutional “accredited investors” (as defined in Rule 501 under the Securities Act), and the provisions of Section 8(a)(vii) through (x) shall apply to the Early Settlement Shares delivered pursuant to this Section 8(b)(v). For purposes of applying the foregoing, the Registered Share Delivery Date referred to in Section 8(a)(vii) shall be the date on which Issuer delivers the Early Settlement Shares.

 

(c)        If Issuer elects to deliver Early Settlement Shares to settle its obligation to make an Early Settlement Payment, then, if necessary, Issuer shall use its commercially reasonable efforts to cause the number of authorized but unissued Shares of Common Stock to be increased to an amount sufficient to permit Issuer to fulfill its obligations under Sections 8(a) and/or 8(b) above.

 

 

 

9. Special Provisions for Merger Transactions.

 

Notwithstanding anything to the contrary herein or in the Equity Definitions:

 

(a)       Issuer agrees that:

 

(i)       It will not during the term of the Transaction make, or, to the extent within its control, permit to be made, any public announcement (as defined in Rule 165(f) under the Securities Act) of any Merger Transaction or potential Merger Transaction unless such public announcement is made prior to the open or after the close of the regular trading session on the Exchange for the Shares.

 

(ii)       To the extent that an announcement of a potential Merger Transaction occurs during the term of the Transaction and such announcement does not cause the Transaction to be cancelled or terminated in whole pursuant to “Extraordinary Events” in Section 2 above, then as soon as practicable following such announcement (but in any event prior to the next opening of the regular trading session on the Exchange), Issuer shall provide MSCO with written notice of such announcement; promptly (but in any event prior to the next opening of the regular trading session on the Exchange), Issuer shall provide MSCO with written notice specifying (x) Issuer’s average daily “Rule 10b-18 purchases” (as defined in Rule 10b-18) during the three full calendar months immediately preceding the Announcement Date that were not effected through MSCO or its affiliates and (y) the number of Shares purchased pursuant to the block purchase proviso in Rule 10b-18(b)(4) under the Exchange Act for the three full calendar months preceding the Announcement Date. Such written notice shall be deemed to be a certification by Issuer to MSCO that such information is true and correct. Issuer understands that MSCO will use this information in calculating the trading volume for purposes of Rule 10b-18. In addition, Issuer shall promptly notify MSCO of the earlier to occur of the completion of such transaction and the completion of the vote by target shareholders. Issuer acknowledges that any such public announcement may trigger the provision set forth in Section 11 below. Accordingly, Issuer acknowledges that its actions in relation to any such announcement or transaction must comply with the standards set forth in Section 13(b) below.

 

(b)        Upon the occurrence of any public announcement of a Merger Transaction, MSCO in its sole discretion may (i) apply the provisions of Section 11 below and/or (ii) treat the occurrence of such announcement as an Additional Termination Event with respect to which the Transaction shall be the sole Affected Transaction, Issuer shall be the sole Affected Party and MSCO shall be the party entitled to designate an Early Termination Date pursuant to Section 6(b) of the Agreement.

 

Merger Transaction” means any merger, acquisition or similar transaction involving a recapitalization of Issuer as contemplated by Rule 10b-18(a)(13)(iv) under the Exchange Act.

 

10. Special Provisions for Acquisition Transaction Announcements.

 

(a)        If an Acquisition Transaction Announcement occurs on or prior to the final Valuation Date, then the Forward Price shall be determined as if the words “minus (ii) the Discount” were deleted from the definition thereof. If an Acquisition Transaction Announcement occurs after the Trade Date but prior to the Lock-Out Date, the Lock-Out Date shall be deemed to be the date of such Acquisition Transaction Announcement.

 

(b)        “Acquisition Transaction Announcement” means (i) the announcement of an Acquisition Transaction, (ii) an announcement that Issuer or any of its subsidiaries has entered into an agreement, a letter of intent or an understanding designed to result in an Acquisition Transaction, (iii) the announcement of the intention to solicit or enter into, or to explore strategic alternatives or other similar undertaking that may include, an Acquisition Transaction or (iv) any announcement subsequent to an Acquisition Transaction Announcement relating to a material amendment, extension, withdrawal or other material change to the subject matter of the previous Acquisition Transaction Announcement. For the avoidance of doubt, the term “announcement” as used in the definition of Acquisition Transaction Announcement refers to any public announcement whether made by Issuer or by a third party that is reasonably likely to be a party to the Acquisition Transaction.

 

 

 

(c)       “Acquisition Transaction” means (i) any Merger Event (for purposes of this definition, the definition of Merger Event shall be read with the references therein to “100%” being replaced by “25%” and to “50%” by “75%” and without reference to the clause beginning immediately following the definition of Reverse Merger therein to the end of such definition), Tender Offer or Merger Transaction or any other transaction involving the merger of Issuer with or into any third party, (ii) the sale or transfer of all or substantially all of the assets or liabilities of Issuer, (iii) a recapitalization, reclassification, binding share exchange or other similar transaction, (iv) any acquisition, lease, exchange, transfer, disposition (including by way of spin-off or distribution) of assets or liabilities (including any capital stock or other ownership interests in subsidiaries) or other similar event by Issuer or any of its subsidiaries where the aggregate consideration transferable or receivable by or to Issuer or its subsidiaries exceeds 25% of the market capitalization of Issuer and (v) any transaction with respect to which Issuer or its board of directors has a legal obligation to make a recommendation to its shareholders in respect of such transaction (whether pursuant to Rule 14e-2 under the Exchange Act or otherwise).

 

11. MSCO Adjustments.

 

In the event that MSCO reasonably determines, based on advice of counsel, that it is appropriate with regard to any legal, regulatory or self-regulatory requirements or related policies and procedures (whether or not such requirements, policies or procedures are imposed by law or have been voluntarily adopted by MSCO, and including, without limitation, Rule 10b-18, Rule 10b-5, Regulations 13D-G and Regulations 14 D-E under the Exchange Act, provided that such requirements, policies and procedures are generally applicable in similar situations and applied in a consistent manner in similar transactions), for MSCO to refrain from purchasing Shares or engaging in other market activity or to purchase fewer than the number of Shares or to engage in fewer or smaller other market transactions MSCO would otherwise purchase or engage in on any Trading Day on or prior to the last day of the Calculation Period, then MSCO may, in its reasonable discretion, elect that a Market Disruption shall be deemed to have occurred on such Trading Day. Such Trading Day shall be treated as a Disrupted Day in full. MSCO shall notify Issuer upon the exercise of MSCO’s rights pursuant to this Section 11 and shall subsequently notify Issuer on the day MSCO believes that the circumstances giving rise to such exercise have changed.

 

12. Covenants.

 

Issuer covenants and agrees that:

 

(a)        Until the end of the Potential Purchase Period (as defined below), neither it nor any of its affiliated purchasers (as defined in Rule 10b-18 under the Exchange Act) shall directly or indirectly (which shall be deemed to include the writing or purchase of any cash-settled or other derivative or structured Share repurchase transaction with a hedging period, calculation period or settlement valuation period or similar period that overlaps with the Transaction) purchase, offer to purchase, place any bid or limit order relating to a purchase of or commence any tender offer relating to Shares (or any security convertible into or exchangeable for Shares) without the prior written approval of MSCO or take any other action that would cause the purchase by MSCO of any Shares in connection with this Agreement not to qualify for the safe harbor provided in Rule 10b-18 under the Exchange Act (assuming for the purposes of this paragraph that such safe harbor were otherwise available for such purchases).

 

Notwithstanding the immediately preceding paragraph or anything herein to the contrary (i) an agent independent of Issuer may purchase Shares on behalf of an issuer plan sponsored by Issuer or any affiliate in accordance with the requirements of Section 10b-18(a)(13)(ii) under the Exchange Act (with “issuer plan” and “agent independent of Issuer” each being used herein as defined in Rule 10b-18), (ii) Issuer or any “affiliated purchaser” may purchase Shares in (x) unsolicited transactions or (y) privately negotiated (off-market) transactions, in each case, that are not and are not reasonably likely to result in “Rule 10b-18 purchases” (as defined in Rule 10b-18), in each case, without MSCO’s consent, (iii) Issuer may repurchase Shares from holders of awards granted under Issuer’s equity incentive plans for the purpose of paying the tax withholding obligations arising from the vesting of, or paying the exercise price in connection with the exercise of, or reacquiring Shares as a result of the forfeiture of, any such awards, and (iv) Issuer may repurchase Shares on any Exchange Business Day pursuant to any Rule 10b5-1 or Rule 10b-18 repurchase plan entered into with MSCO or an Affiliate of MSCO, so long as, on any such Exchange Business Day, such purchases do not in the aggregate exceed Specified ADTV Percentage (as specified in Schedule I) of the Share’s ADTV (as such term is defined in Rule 10b-18(a)(1)) on such Exchange Business Day (collectively, (i) through (iv) referred to herein as the “Permitted Purchases”).

 

 

 

Potential Purchase Period” means the period from, and including, the Trade Date to, and including, the latest of (i) the last day of the Calculation Period, (ii) the earlier of (A) the date ten Exchange Business Days immediately following the last day of the Calculation Period and (B) the Scheduled Valuation Date and (iii) if an Early Termination Date occurs or the Transaction is cancelled pursuant to Article 12 of the Equity Definitions, a date determined by MSCO in its commercially reasonable discretion and communicated to Issuer no later than the Exchange Business Day immediately following such date.

 

(b)        It will comply with all laws, rules and regulations applicable to it (including, without limitation, the Securities Act and the Exchange Act) in connection with the transactions contemplated by this Confirmation.

 

(c)        Without limiting the generality of Section 13.1 of the Equity Definitions, it is not relying, and has not relied, upon MSCO or any of its representatives or advisors with respect to the legal, accounting, tax or other implications of this Agreement and that it has conducted its own analyses of the legal, accounting, tax and other implications of this Agreement, and that MSCO and its affiliates may from time to time effect transactions for their own account or the account of customers and hold positions in securities or options on securities of Issuer and that MSCO and its affiliates may continue to conduct such transactions during the term of this Agreement. Without limiting the generality of the foregoing, Issuer acknowledges that MSCO is not making any representations or warranties or taking any position or expressing any view with respect to the treatment of the Transaction under any accounting standards including ASC Topic 260, Earnings Per Share, ASC Topic 815, Derivatives and Hedging, or ASC Topic 480, Distinguishing Liabilities from Equity and ASC 815-40, Derivatives and Hedging – Contracts in Entity’s Own Equity (or any successor issue statements) or under FASB’s Liabilities & Equity Project.

 

(d)       Neither it nor any affiliates shall take any action that would cause a restricted period (as defined in Regulation M under the Exchange Act (“Regulation M”)) to be applicable to any purchases of Shares, or of any security for which Shares is a reference security (as defined in Regulation M), by Issuer or any affiliated purchasers (as defined in Regulation M) of Issuer during the Potential Purchase Period.

 

(e)       It will not make any election or take any other action in connection with the Transaction while aware of any material nonpublic information regarding Issuer or the Shares.

 

13. Representations, Warranties and Acknowledgments.

 

(a)        Issuer hereby represents and warrants to MSCO on the date hereof and on and as of the Initial Share Delivery Date that:

 

(i)       (A) None of Issuer and its officers and directors is aware of any material nonpublic information regarding Issuer or the Shares, and Issuer is entering into the Transaction in good faith and not as part of a plan or scheme to evade the prohibitions of federal securities laws, including, without limitation, Rule 10b-5 under the Exchange Act and (B) Issuer agrees not to alter or deviate from the terms of the Agreement or enter into or alter a corresponding or hedging transaction or position with respect to the Shares (including, without limitation, with respect to any securities convertible or exchangeable into the Shares) during the term of the Agreement. Without limiting the generality of the foregoing, all reports and other documents filed by Issuer with the Securities and Exchange Commission pursuant to the Exchange Act when considered as a whole (with the more recent such reports and documents deemed to amend inconsistent statements contained in any earlier such reports and documents) do not contain any untrue statement of a material fact or any omission of a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances in which they were made, not misleading.

 

 

 

(ii)       The transactions contemplated by this Confirmation have been authorized under Issuer’s publicly announced program to repurchase Shares.

 

(iii)        Issuer is not entering into this Agreement to facilitate a distribution of the Shares (or any security convertible into or exchangeable for Shares) or in connection with a future issuance of securities.

 

(iv)        Issuer is not entering into this Agreement to create actual or apparent trading activity in the Shares (or any security convertible into or exchangeable for Shares) or to raise or depress the price of the Shares (or any security convertible into or exchangeable for Shares) in violation of the federal securities laws.

 

(v)        There have been no purchases of Shares in Rule 10b-18 purchases of blocks pursuant to the once-a-week block exception contained in Rule 10b-18(b)(4) by or for Issuer or any of its affiliated purchasers during each of the four calendar weeks preceding the Trade Date and during the calendar week in which the Trade Date occurs (“Rule 10b-18 purchase”, “blocks” and “affiliated purchaser” each being used as defined in Rule 10b-18).

 

(vi)       Issuer is as of the date hereof, and after giving effect to the transactions contemplated hereby will be, Solvent. As used in this paragraph, the term “Solvent” means, with respect to a particular date, that on such date (A) the present fair market value (or present fair saleable value) of the assets of Issuer is not less than the total amount required to pay the liabilities of Issuer on its total existing debts and liabilities (including contingent liabilities) as they become absolute and matured, (B) Issuer is able to realize upon its assets and pay its debts and other liabilities, contingent obligations and commitments as they mature and become due in the normal course of business, (C) assuming consummation of the transactions as contemplated by this Agreement, Issuer is not incurring debts or liabilities beyond its ability to pay as such debts and liabilities mature, (D) Issuer is not engaged in any business or transaction, and does not propose to engage in any business or transaction, for which its property would constitute unreasonably small capital after giving due consideration to the prevailing practice in the industry in which Issuer is engaged, (E) Issuer is not a defendant in any civil action that could reasonably be expected to result in a judgment that Issuer is or would become unable to satisfy, (F) Issuer is not “insolvent” (as such term is defined under Section 101(32) of the U.S. Bankruptcy Code (Title 11 of the United States Code) (the “Bankruptcy Code”)) and (G) Issuer would be able to purchase Shares with an aggregate purchase price equal to the Prepayment Amount in compliance with the corporate laws of the jurisdiction of its incorporation.

 

(vii)        Issuer is not, and after giving effect to the transactions contemplated hereby will not be, required to register as an “investment company” as such term is defined in the Investment Company Act of 1940, as amended.

 

(viii)        No state or local (including non-U.S. jurisdictions) law, rule, regulation or regulatory order applicable to the Shares would give rise to any reporting, consent, registration or other requirement (including without limitation a requirement to obtain prior approval from any person or entity) as a result of MSCO or its affiliates owning or holding (however defined) Shares other than any such law, rule, regulation or regulatory order that applies solely as a result of the business, identity, place of business or jurisdiction of organization of MSCO or any such affiliate.

 

 

 

(b)       Issuer acknowledges and agrees that the Initial Shares may be sold short to Issuer. Issuer further acknowledges and agrees that MSCO may purchase Shares in connection with the Transaction, which Shares may be used to cover all or a portion of such short sale or may be delivered to Issuer. Such purchases and any other market activity by MSCO will be conducted independently of Issuer by MSCO as principal for its own account. All of the actions to be taken by MSCO in connection with the Transaction shall be taken by MSCO independently and without any advance or subsequent consultation with Issuer. It is the intent of the parties that the Transaction comply with the requirements of Rule 10b5-1(c)(1)(i)(B) of the Exchange Act, and the parties agree that this Confirmation shall be interpreted to comply with the requirements of such Rule, and Issuer shall not take any action that results in the Transaction not so complying with such requirements. Without limiting the generality of the preceding sentence, Issuer acknowledges and agrees that (A) Issuer does not have, and shall not attempt to exercise, any influence over how, when or whether MSCO effects any market transactions in connection with the Transaction and (B) neither Issuer nor its officers or employees shall, directly or indirectly, communicate any information regarding Issuer or the Shares to any employee of MSCO or its Affiliates that have been identified by MSCO to Issuer in writing as employees responsible for executing market transactions in connection with the Transaction. Issuer also acknowledges and agrees that any amendment, modification, waiver or termination of this Confirmation must be effected in accordance with the requirements for the amendment or termination of a “plan” as defined in Rule 10b5-1(c) under the Exchange Act. Without limiting the generality of the foregoing, any such amendment, modification, waiver or termination shall be made in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5 under the Exchange Act, and no such amendment, modification or waiver shall be made at any time at which Issuer or any officer or director of Issuer is aware of any material nonpublic information regarding Issuer or the Shares.

 

(c)       Each of Issuer and MSCO represents and warrants to the other that it is an “eligible contract participant” as defined in Section 1a(12) of the U.S. Commodity Exchange Act, as amended.

 

(d)        Each of Issuer and MSCO acknowledges that the offer and sale of the Transaction to it is intended to be exempt from registration under the Securities Act by virtue of Section 4(2) thereof. Accordingly, it represents and warrants to the other party that (i) it has the financial ability to bear the economic risk of its investment in the Transaction and is able to bear a total loss of its investment, (ii) it is an “accredited investor” as that term is defined in Regulation D as promulgated under the Securities Act, (iii) it is entering into the Transaction for its own account and without a view to the distribution or resale thereof and (iv) the assignment, transfer or other disposition of the Transaction has not been and will not be registered under the Securities Act.

 

14. Acknowledgements of Issuer Regarding Hedging and Market Activity.

 

Issuer agrees, understands and acknowledges that:

 

(a)       during the period from (and including) the Trade Date to (and including) the Settlement Date, MSCO and its Affiliates may buy or sell Shares or other securities or buy or sell options or futures contracts or enter into swaps or other derivative transactions in order to adjust its Hedge Position with respect to the Transaction;

 

(b)       MSCO and its Affiliates also may be active in the market for the Shares or options, futures contracts, swaps or other derivative transactions relating to the Shares other than in connection with hedging activities in relation to the Transaction;

 

(c)       MSCO shall make its own determination as to whether, when and in what manner any hedging or market activities in Issuer’s securities or other securities or transactions shall be conducted and shall do so in a manner that it deems appropriate to hedge its price and market risk with respect to the Transaction; and

 

(d)       any such market activities of MSCO and its Affiliates may affect the market price and volatility of the Shares, including the 10b-18 VWAP and the Forward Price, each in a manner that may be adverse to Issuer.

 

 

 

15. Indemnification.

 

In the event that MSCO becomes involved in any capacity in any third-party action, proceeding or investigation brought by or against any person in connection with any matter referred to in this Agreement, Issuer will reimburse MSCO for its reasonable legal and other expenses (including the cost of any investigation and preparation) incurred in connection therewith. Issuer also will indemnify and hold MSCO harmless against any losses, claims, damages or liabilities to which it may become subject in connection with any matter referred to in this Confirmation. If for any reason the foregoing indemnification is unavailable to MSCO or insufficient to hold it harmless, then Issuer shall contribute to the amount paid or payable by MSCO as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of Issuer on one hand and MSCO on the other hand with respect to such loss, claim, damage, or liability and any other relevant equitable considerations. The reimbursement, indemnity and contribution obligations of Issuer under this Section 15 shall be in addition to any liability that Issuer may otherwise have, shall extend upon the same terms and conditions to any Affiliate of MSCO and the partners, directors, officers, agents, employees and controlling persons (if any), as the case may be, of MSCO and any such Affiliate and shall be binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of Issuer, MSCO, any such Affiliate and any such person. Issuer also agrees that neither MSCO nor any of such Affiliates, partners, directors, officers, agents, employees or controlling persons shall have any liability to Issuer for or in connection with any matter referred to in this Confirmation. Notwithstanding the foregoing, the reimbursement, indemnity, contribution and exculpation obligations of Issuer under this Section 15 shall not apply for the benefit of any person to the extent that any losses, claims, damages, liabilities or expenses result from the negligence or bad faith of such person in effecting the Transaction. The foregoing provisions shall survive any termination or completion of the Transaction. The foregoing reimbursement, indemnity and contribution obligations of Issuer shall be paid promptly in cash.

 

16. Other Provisions.

 

(a)       Issuer agrees and acknowledges that MSCO is a “financial institution” and “financial participant” within the meaning of Sections 101(22) and 101(22A) of the Bankruptcy Code. The parties hereto further agree and acknowledge that it is the intent of the parties that (A) this Confirmation is a “securities contract,” as such term is defined in Section 741(7) of the Bankruptcy Code, with respect to which each payment and delivery hereunder or in connection herewith is a “termination value,” “payment amount” or “other transfer obligation” within the meaning of Section 362 of the Bankruptcy Code and a “settlement payment,” within the meaning of Section 546 of the Bankruptcy Code, and (B) MSCO is entitled to the protections afforded by, among other sections, Sections 362(b)(6), 362(b)(17), 362(o), 546(e), 555 and 561 of the Bankruptcy Code.

 

(b)       MSCO and Issuer hereby agree and acknowledge that MSCO has authorized Issuer to disclose the Transaction to any and all persons, and there are no express or implied agreements, arrangements or understandings to the contrary, and authorizes Issuer to use any information that Issuer receives or has received with respect to the Transaction in any manner.

 

(c)       In the event Issuer becomes the subject of proceedings (“Bankruptcy Proceedings”) under the Bankruptcy Code or any other applicable bankruptcy or insolvency statute, any rights or claims of MSCO hereunder in respect of the Transaction shall rank for all purposes no higher than, but on a parity with, the rights or claims of holders of Shares, and MSCO hereby agrees that its rights and claims hereunder shall be subordinated to those of all parties with claims or rights against Issuer (other than common stockholders) to the extent necessary to assure such ranking. Without limiting the generality of the foregoing, after the commencement of Bankruptcy Proceedings, the claims of MSCO hereunder shall for all purposes have rights equivalent to the rights of a holder of a percentage of the Shares equal to the aggregate amount of such claims (the “Claim Amount”) taken as a percentage of the sum of (i) the Claim Amount and (ii) the aggregate fair market value of all outstanding Shares on the record date for distributions made to the holders of such Shares in the related Bankruptcy Proceedings. Notwithstanding any right it might otherwise have to assert a higher priority claim in any such Bankruptcy Proceedings, MSCO shall be entitled to receive a distribution solely to the extent and only in the form that a holder of such percentage of the Shares would be entitled to receive in such Bankruptcy Proceedings, and, from and after the commencement of such Bankruptcy Proceedings, MSCO expressly waives (i) any other rights or distributions to which it might otherwise be entitled in such Bankruptcy Proceedings in respect of its rights and claims hereunder and (ii) any rights of setoff it might otherwise be entitled to assert in respect of such rights and claims.

 

 

 

(d)       Notwithstanding any provision of this Confirmation or any other agreement between the parties to the contrary, neither the obligations of Issuer nor the obligations of MSCO hereunder are secured by any collateral, security interest, pledge or lien.

 

(e)       Each party waives any and all rights it may have to set off obligations arising under the Agreement and the Transaction against other obligations between the parties, whether arising under any other agreement, applicable law or otherwise.

 

(f)       Notwithstanding anything to the contrary herein, MSCO may, by prior notice to Issuer, satisfy its obligation to deliver any Shares or other securities on any date due (an “Original Delivery Date”) by making separate deliveries of Shares or such securities, as the case may be, at more than one time on or prior to such Original Delivery Date, so long as the aggregate number of Shares and other securities so delivered on or prior to such Original Delivery Date is equal to the number required to be delivered on such Original Delivery Date.

 

(g)       It shall constitute an Additional Termination Event with respect to which the Transaction is the sole Affected Transaction and Issuer is the sole Affected Party and MSCO shall be the party entitled to designate an Early Termination Date pursuant to Section 6(b) of the Agreement if, at any time on or prior to the Valuation Date, the price per Share on the Exchange, as determined by the Calculation Agent, is at or below the Threshold Price (as specified in Schedule I).

 

17. Share Cap.

 

Notwithstanding any other provision of this Confirmation or the Agreement to the contrary, in no event shall Issuer be required to deliver to MSCO in the aggregate a number of Shares that exceeds the Share Cap as of the date of delivery (as specified in Schedule I), subject to reduction by the number of Shares delivered hereunder by Issuer on any prior date.

 

18. Transfer and Assignment.

 

MSCO may transfer or assign its rights and obligations hereunder and under the Agreement, in whole or in part, to any of its Affiliates of equivalent credit quality (or whose obligations are guaranteed by an entity of equivalent credit quality) without the consent of Issuer. MSCO will provide prompt written notice of any such transfer to Issuer.

 

19. 2018 ISDA U.S. Resolution Stay Protocol Incorporation by Reference

The parties agree that (i) to the extent that prior to the date hereof both parties have adhered to the 2018 ISDA U.S. Resolution Stay Protocol (the “Protocol”), the terms of the Protocol are incorporated into and form a part of this Agreement, and for such purposes this Agreement shall be deemed a Protocol Covered Agreement and each party shall be deemed to have the same status as Regulated Entity and/or Adhering Party as applicable to it under the Protocol; (ii) to the extent that prior to the date hereof the parties have executed a separate agreement the effect of which is to amend the qualified financial contracts between them to conform with the requirements of the QFC Stay Rules (the “Bilateral Agreement”), the terms of the Bilateral Agreement are incorporated into and form a part of this Agreement and each party shall be deemed to have the status of “Covered Entity” or “Counterparty Entity” (or other similar term)  as applicable to it under the Bilateral Agreement; or (iii) if clause (i) and clause (ii) do not apply, the terms of Section 1 and Section 2 and the related defined terms (together, the “Bilateral Terms”) of the form of bilateral template entitled “Full-Length Omnibus (for use between U.S. G-SIBs and Corporate Groups)” published by ISDA on November 2, 2018 (currently available on the 2018 ISDA U.S. Resolution Stay Protocol page at www.isda.org and, a copy of which is available upon request),  the effect of which is to amend the qualified financial contracts between the parties thereto to conform with the requirements of the QFC Stay Rules, are hereby incorporated into and form a part of this Agreement, and for such purposes this Agreement shall be deemed a “Covered Agreement,” MSCO  shall be deemed a “Covered Entity” and Issuer shall be deemed a “Counterparty Entity.” In the event that, after the date of this Agreement, both parties hereto become adhering parties to the Protocol, the terms of the Protocol will replace the terms of this paragraph. In the event of any inconsistencies between this Agreement and the terms of the Protocol, the Bilateral Agreement or the Bilateral Terms (each, the “QFC Stay Terms”), as applicable, the QFC Stay Terms will govern. Terms used in this paragraph without definition shall have the meanings assigned to them under the QFC Stay Rules. For purposes of this paragraph, references to “this Agreement” include any related credit enhancements entered into between the parties or provided by one to the other.

 

 

“QFC Stay Rules” means the regulations codified at 12 C.F.R. 252.2, 252.81–8, 12 C.F.R. 382.1-7 and 12 C.F.R. 47.1-8, which, subject to limited exceptions, require an express recognition of the stay-and-transfer powers of the FDIC under the Federal Deposit Insurance Act and the Orderly Liquidation Authority under Title II of the Dodd Frank Wall Street Reform and Consumer Protection Act and the override of default rights related directly or indirectly to the entry of an affiliate into certain insolvency proceedings and any restrictions on the transfer of any covered affiliate credit enhancements.

 

20. Governing Law; Jurisdiction; Waiver.

 

THIS CONFIRMATION AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS CONFIRMATION SHALL BE GOVERNED BY THE LAWS OF THE STATE OF NEW YORK. THE PARTIES HERETO IRREVOCABLY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK AND THE UNITED STATES COURT FOR THE SOUTHERN DISTRICT OF NEW YORK IN CONNECTION WITH ALL MATTERS RELATING HERETO AND WAIVE ANY OBJECTION TO THE LAYING OF VENUE IN, AND ANY CLAIM OF INCONVENIENT FORUM WITH RESPECT TO, THESE COURTS.

 

Each PARTY hereby irrevocably waives (on its own behalf and, to the extent permitted by applicable law, on behalf of its stockholders) all right to trial by jury in any action, proceeding or counterclaim (whether based on contract, tort or otherwise) arising out of or relating to the Transaction or the actions of ISSUER or its affiliates in the negotiation, performance or enforcement hereof.

 

 

Remainder of Page Intentionally Blank

 

 

 

 

 

 


 

 

 

 

 

Please confirm that the foregoing correctly sets forth the terms of our agreement by executing this Confirmation and returning it to us by facsimile to the number provided on the attached facsimile cover page.

 

Confirmed as of the date first written above:

 

ANIKA THERAPEUTICS, INC.

 

MORGAN STANLEY & CO. LLC

 

 

By: /s/Joseph Darling________________

Name: Joseph Darling

Title: President and Chief Executive Officer

By: /s/Darren McCarley_________________

Name: Darren McCarley

Title: Managing Director

 

 

 

 
   

 

EX-31.1 3 exh_311.htm EXHIBIT 31.1

Exhibit 31.1

 

Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Joseph G. Darling, certify that:

 

  1.

I have reviewed this report on Form 10-Q for the quarterly period ended June 30, 2019 of Anika Therapeutics, Inc.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

 

Date: July 26, 2019
/s/ JOSEPH G. DARLING
  Joseph G. Darling
  President and Chief Executive Officer
  Principal Executive Officer

EX-31.2 4 exh_312.htm EXHIBIT 31.2

Exhibit 31.2

 

Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Sylvia Cheung, certify that:

 

  1.

I have reviewed this report on Form 10-Q for the quarterly period ended June 30, 2019 of Anika Therapeutics, Inc.;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

 

 

 

 Date:  July 26, 2019
/s/ SYLVIA CHEUNG
  Sylvia Cheung
  Chief Financial Officer
  Principal Financial Officer

EX-32.1 5 exh_321.htm EXHIBIT 32.1

Exhibit 32.1

 

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

The undersigned officers of Anika Therapeutics, Inc. (the “Company”) hereby certify to their knowledge and in their respective capacities that the Company’s quarterly report on Form 10-Q to which this certification is attached (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: July 26, 2019
/s/ JOSEPH G. DARLING
  Joseph G. Darling.
  President and Chief Executive Officer
  Principal Executive Officer
 

 

 

Date: July 26, 2019
/s/ SYLVIA CHEUNG
  Sylvia Cheung
  Chief Financial Officer
  Principal Financial Officer

 

This certification shall not be deemed “filed” for any purpose, nor shall it be deemed to be incorporated by reference into any filing, under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

 

 

EX-101.INS 6 anik-20190630.xml XBRL INSTANCE FILE 320000 577000 398000 400000 2864000 2824000 1191000 1168000 415000 415000 172000 169000 4642000 4576000 1305000 1305000 1305000 4984000 4984000 4984000 -534000 27527000 25133000 300000 P17Y109D 897000 0.76 0.81 0.16 0.11 0.08 0.08 1 1 0.78 0.81 0.14 0.11 0.08 0.08 1 1 0.3 0.7 0.68 0.7 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1pt">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross Value</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated <br /> Currency <br /> Translation <br /> Adjustment</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Impairment</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated <br /> Amortization</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net <br /> Book <br /> Value</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated <br /> Currency <br /> Translation <br /> Adjustment</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated <br /> Amortization</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net <br /> Book <br /> Value</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Useful <br /> Life</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 19%; text-align: left">Developed technology</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,100</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,864</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(281</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(9,189</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,766</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,824</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,672</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,604</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: center">&nbsp;</td> <td style="width: 6%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td style="white-space: nowrap; width: 1%; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">In-process research &amp; development</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,406</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,191</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,215</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,168</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,238</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Indefinite</div></td> <td style="white-space: nowrap; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Distributor relationships</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,700</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(415</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,285</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(415</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,285</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="white-space: nowrap; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Patents</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(172</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(506</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">322</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(169</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(482</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="white-space: nowrap; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Elevess trade name</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,000</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,000</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> <td style="white-space: nowrap; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,206</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,642</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(281</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,980</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,303</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,576</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,439</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,191</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="white-space: nowrap; text-align: center">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br /> Revenue</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Geographic Location:</td> <td style="color: #0000CC; font-weight: bold">&nbsp;</td> <td style="color: #0000CC; font-weight: bold; text-align: left">&nbsp;</td> <td style="color: #0000CC; font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; color: #0000CC; font-weight: bold; text-align: left">&nbsp;</td> <td style="color: #0000CC">&nbsp;</td> <td style="color: #0000CC; text-align: left">&nbsp;</td> <td style="color: #0000CC; text-align: right">&nbsp;</td> <td style="white-space: nowrap; color: #0000CC; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left; padding-left: 10pt">United States</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,937</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">76</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">%</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,773</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Europe</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,927</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,498</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,554</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,277</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 20pt">Total Revenue</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,418</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">%</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,548</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">%</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br /> Revenue</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Geographic Location:</td> <td style="color: #0000CC; font-weight: bold">&nbsp;</td> <td style="color: #0000CC; font-weight: bold; text-align: left">&nbsp;</td> <td style="color: #0000CC; font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; color: #0000CC; font-weight: bold; text-align: left">&nbsp;</td> <td style="color: #0000CC">&nbsp;</td> <td style="color: #0000CC; text-align: left">&nbsp;</td> <td style="color: #0000CC; text-align: right">&nbsp;</td> <td style="white-space: nowrap; color: #0000CC; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left; padding-left: 10pt">United States</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43,026</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">78</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">%</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,682</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Europe</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,454</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,889</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,661</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,241</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 20pt">Total Revenue</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">55,141</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">%</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">51,812</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">%</td> </tr> </table></div> 1700000 P1Y180D 0.6 false --12-31 Q2 2019 2019-06-30 10-Q 0000898437 13782928 Yes false Accelerated Filer Anika Therapeutics, Inc. false anik false <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 40pt; text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.</div></div></div></td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Accrued Expenses</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Accrued expenses consist of the following:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</div> <div> <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center; padding-bottom: 1pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; padding-bottom: 1pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">June 30, <br /> 2019</div></td> <td style="text-align: center; padding-bottom: 1pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">December 31, <br /> 2018</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Compensation and related expenses</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,584</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,446</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,609</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,989</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease liability - current</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,101</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Income taxes payable</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">757</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">385</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research grants</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">398</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">400</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical trial costs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">320</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">577</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">332</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,101</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,146</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Included in Compensation and related expenses as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>are the accrued and unpaid costs related to the retirement of the Company&#x2019;s former Chief Executive Officer as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 9, 2018. </div>On the same date, the Company and the former Chief Executive Officer entered into a release agreement related to terms in his employment agreement. Under the terms of these agreements, the former Chief Executive Officer is entitled to receive from the Company, as a result of his retirement, aggregate benefits of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.7</div> million over the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">18</div>-month period subsequent to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 9, 2018, </div>among other benefits. The unpaid amounts under these agreements are included in accrued expenses. As more fully described in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,</div> all of the former Chief Executive Officer&#x2019;s outstanding equity awards vested in full and became exercisable upon his retirement. The lease liability as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>is the result of the Company adopting ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019 </div>as more fully described in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.</div></div></div> 2287000 3143000 23073000 20775000 757000 385000 8101000 8146000 1609000 1989000 -5696000 -5526000 24329000 50763000 124000 124000 1000 1735000 1736000 1386000 1386000 1443000 1443000 7565000 7565000 1322000 1322000 1443000 1322000 2829000 8887000 6200000 300000 400000 82000 -28000 174000 -244000 91000 241000 268000 451000 1270000 1109000 2387000 8680000 1089000 1525000 200000 300000 500000 500000 1000000 700000 1000000 600000 134000 33000 287364000 278993000 189924000 202943000 72000000 70000000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 35pt; text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div></div></div></td> <td style="width: 5pt">&nbsp;</td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Basis of Presentation</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules&nbsp;and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) and in accordance with accounting principles generally accepted in the United States (&#x201c;US GAAP&#x201d;). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>balances reported herein are derived from the audited consolidated financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial statements.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company&#x2019;s annual financial statements filed with its Annual Report on Form&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-K for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018. </div>The results of operations for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>- and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily indicative of the results to be expected for the year ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> <div style="display: inline; font-style: italic;">Leases</div>, which, among other things, results in the recognition of lease assets and lease liabilities on the Company&#x2019;s balance sheets for virtually all leases. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> supersedes most previous lease accounting guidance and is effective for interim and annual periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018. </div>The Company adopted the new guidance as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019 </div>using the modified retrospective adoption method, which did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> require restatement of prior periods. The adoption of this standard did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on the condensed consolidated statement of operations. See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> for further details.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> August 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div>&nbsp;<div style="display: inline; font-style: italic;">Intangibles &#x2013; Goodwill and Other &#x2013; Internal-Use Software&nbsp;(Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">350</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div>)</div>, which amends ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">05,</div>&nbsp;<div style="display: inline; font-family: Times New Roman, Times, Serif; font-size: 10pt"><div style="display: inline; font-style: italic;">Customers Accounting for Fees in a Cloud Computing Agreement</div>,&nbsp;to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. The most significant change will align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software and hosting arrangements that include an internal-use software license. Accordingly, the amendments in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> require an entity in a hosting arrangement that is a service contract to follow the guidance in Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">350</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div> to determine which implementation costs to capitalize as assets related to the service contract and which costs to expense. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> is effective for fiscal years and interim periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2019. </div>Early adoption is permitted, including adoption in any interim period. The Company is assessing ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> and the impact that adopting this new accounting standard will have on its consolidated financial statements and footnote disclosures.&nbsp;</div></div></div> 211000 462000 69407000 89042000 133256000 126047000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 35pt; text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.</div></div></div></td> <td style="width: 5pt">&nbsp;</td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Investments</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of the Company&#x2019;s investments are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income, net of related income taxes. The Company held investments, including U.S. treasury bills totaling <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$72.0</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$70.0</div> million as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>respectively. Unrealized gains and losses as well as the associated tax impact on the Company&#x2019;s available-for-sale securities were immaterial as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018.</div></div></div> -19635000 -7209000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.</div></div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Commitments and Contingencies&nbsp;</div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>also warrant that the products it manufactures do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> infringe, violate, or breach any U.S. or international patent or intellectual property right, trade secret, or other proprietary information of any <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company&#x2019;s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> accrued warranties as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>and has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> history of claims paid.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect the resolution of these occasional legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.</div></div> 1200000 2700000 0.01 0.01 90000000 90000000 13785000 14210000 13785000 14210000 138000 142000 9580000 9141000 13772000 3074000 50000 6836000 8152000 14147000 15996000 18503000 19302000 37744000 48398000 120000 63000 0 0 3683000 3542000 2943000 2920000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.</div></div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-weight: bold;">Equity Incentive Plan</div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company estimates the fair value of stock options and stock appreciation rights (&#x201c;SARs&#x201d;) using the Black-Scholes valuation model. Fair value of restricted stock awards (&#x201c;RSAs&#x201d;) and restricted stock units (&#x201c;RSUs&#x201d;) are measured by the grant-date price of the Company&#x2019;s shares. Fair value of performance restricted stock units (&#x201c;PSUs&#x201d;) is measured by the grant-date price of the Company&#x2019;s shares with corresponding compensation cost recognized over the requisite service period. Compensation cost is recognized based on the estimated probabilities of achieving the performance goals. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related compensation cost that will be recorded in the period of the change. If the performance targets are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> achieved, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> compensation cost is recognized, and any previously recognized compensation cost is reversed.&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of each stock option award during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td> <td>&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.18% </div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 2.54%</div></td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.15% </div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 2.75%</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td> <td>&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44.05% </div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 44.72%</div></td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">37.12% </div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 40.81%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Expected life (years)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.5</div></td> <td style="white-space: nowrap; width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; text-align: center">&nbsp;</td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.0 </div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 4.5</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td> <td>&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.00%</div></td> <td style="white-space: nowrap; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.00%</div></td> <td style="white-space: nowrap; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recorded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.3</div> million of stock-based compensation expense for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively. The Company recorded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.8</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.9</div> million of stock-based compensation expense for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively. Upon the retirement of the Company&#x2019;s former Chief Executive Officer on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 9, 2018, </div>all of his outstanding stock-based compensation awards vested in full and became exercisable in accordance with their terms, resulting in a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-time expense of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.2</div> million that was fully recognized during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</div> <!-- Field: Page; Sequence: 9 --> <!-- Field: /Page --> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Cost of product revenue</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(28</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">174</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(244</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research&nbsp;&amp; development</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">91</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">241</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">268</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">451</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Selling, general&nbsp;&amp; administrative</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,270</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,109</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,387</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,680</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Total stock-based compensation expense</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,443</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,322</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,829</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,887</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 18, 2019, </div>the Company&#x2019;s stockholders approved an amendment to the Anika Therapeutics, Inc. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Omnibus Incentive Plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x201c;2017</div> Plan&#x201d;). The amendment increased the number of shares of common stock reserved under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Plan by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,500,000</div> from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,200,000</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,700,000.</div> Additionally, the amendment provided greater clarity with respect to the sections governing minimum vesting and tax withholding to facilitate plan administration. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> other provisions of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Plan were amended.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth share information for stock-based compensation awards granted and exercised during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; text-align: left">Grants:</td> <td style="color: #0000CC">&nbsp;</td> <td colspan="3" style="white-space: nowrap; color: #0000CC; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td colspan="3" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td colspan="3" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td colspan="3" style="white-space: nowrap; text-align: right">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left; padding-left: 10pt">Stock Options</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,325</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,500</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">131,617</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">209,800</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">RSAs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">64,578</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">RSUs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,000</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">173,507</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,130</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">PSUs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">114,500</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Exercises:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Stock Options</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,400</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">273,123</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,900</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">284,548</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">SARs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>- and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>the Company granted stock-based compensation awards in the form of stock options, PSUs and RSUs to employees and RSUs to non-employee directors, the majority of which become exercisable or vest ratably over a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-year period. The PSUs granted to employees contained performance conditions with business and financial targets. The business target, amounting to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30%</div> of the total performance conditions, will be measured based on achievement in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> fiscal year, while the financial targets, amounting to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70%</div> of the total performance conditions, will ultimately be measured with respect to the Company&#x2019;s operating results in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2021</div> fiscal year. The Company recorded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.3</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.4</div> million of stock-based compensation expense associated with PSUs for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>- and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>respectively.</div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="white-space: nowrap; text-align: left">Grants:</td> <td style="color: #0000CC">&nbsp;</td> <td colspan="3" style="white-space: nowrap; color: #0000CC; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td colspan="3" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td colspan="3" style="white-space: nowrap; text-align: right">&nbsp;</td> <td>&nbsp;</td> <td colspan="3" style="white-space: nowrap; text-align: right">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left; padding-left: 10pt">Stock Options</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,325</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,500</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">131,617</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">209,800</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">RSAs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">64,578</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">RSUs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,000</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">173,507</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,130</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">PSUs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">114,500</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Exercises:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Stock Options</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,400</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">273,123</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,900</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">284,548</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">SARs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> </table></div> 0.68 0.69 0.99 0.23 0.67 0.68 0.98 0.23 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 35pt; text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.</div></div></div></td> <td style="width: 5pt">&nbsp;</td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Earnings Per Share (&#x201c;EPS&#x201d;)</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Basic EPS is calculated by dividing net income by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> considered outstanding for purposes of calculating basic earnings per share. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, SARs, RSAs, RSUs, and PSUs using the treasury stock method.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><div style="display: inline; background-color: white">The following table provides share information used in the calculation of the Company's basic and diluted earnings per share (in thousands):</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: Red"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Shares used in the calculation of basic earnings per share</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,916</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,652</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,054</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,666</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of dilutive securities:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock options, SARs, RSAs, RSUs and PSUs</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">172</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">263</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">149</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">379</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Diluted shares used in the calculation of earnings per share</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,088</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,915</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,203</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,045</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: Red">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; color: Red"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock options of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.0</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.7</div> million shares were outstanding for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively, and were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in the computation of diluted EPS because the awards&#x2019; impact on EPS would have been anti-dilutive.&nbsp;Stock options of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.0</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.6</div> million shares were outstanding for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in the computation of diluted EPS because the awards&#x2019; impact on EPS would have been anti-dilutive.&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <!-- Field: Page; Sequence: 10 --> <!-- Field: /Page --> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2, 2019, </div>the Company announced that its Board of Directors had authorized the repurchase of up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$50.0</div> million shares of the Company&#x2019;s common stock with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30.0</div> million to be repurchased through an accelerated share repurchase program and up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$20.0</div> million to be potentially repurchased on the open market from time-to-time. Through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> open market repurchases had been executed. On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 7, 2019, </div>the Company entered into an accelerated share repurchase agreement with Morgan Stanley &amp; Co. LLC (&#x201c;Morgan Stanley&#x201d;) pursuant to a Fixed Dollar Accelerated Share Repurchase Transaction (&#x201c;ASR Agreement") to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30.0</div> million shares of the Company&#x2019;s common stock. Pursuant to the terms of the ASR Agreement, the Company delivered <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$30.0</div> million cash to Morgan Stanley and received an initial delivery of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.5</div> million shares of the Company&#x2019;s common stock on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 8, 2019 </div>based on a closing market price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$39.85</div> and the applicable contractual discount. This was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60%</div> of the then estimated total number of shares expected to be repurchased under the ASR Agreement. These shares were restored to the status of authorized but unissued shares. The initial delivery of shares resulted in an immediate reduction of the number of outstanding shares used to calculate the weighted-average of shares of the Company&#x2019;s common stock outstanding for basic and diluted net income per share on the effective date of the ASR Agreement.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>the Company has approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12.0</div> million remaining under the ASR Agreement, which was recorded as an equity forward sale contract and was included in additional paid-in capital in stockholders&#x2019; equity in the condensed consolidated balance sheet as it met the criteria for equity accounting. Pursuant to the terms of the ASR Agreement, the final number of shares and the average purchase price will be determined at the end of the applicable purchase period, which is expected to occur in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020.</div> Upon settlement of the ASR Agreement, the Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>receive additional shares or be required to either pay additional cash or deliver shares of its common stock (at its option) to Morgan Stanley, based on the forward price. If the ASR Agreement had been settled as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>based on the volume-weighted average price since the effective date of the ASR Agreement, Morgan Stanley would have been required to deliver approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.3</div> million additional shares to the Company&#x2019;s common stock. However, the Company cannot predict the final number of shares to be received, or delivered, by it under the ASR Agreement. These shares are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in the calculation of diluted weighted-average of shares of common stock outstanding during the period because the effect is anti-dilutive.</div></div> -15000 110000 0.242 0.243 0.125 0.104 3584000 4446000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements at Reporting Date Using</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">June 30, 2019</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">Quoted Prices in<br /> Active Markets<br /> for Identical Assets&nbsp;<br /> (Level 1)</div></td> <td style="padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center"><div style="display: inline; font-weight: bold;">Significant Other<br /> Observable Inputs&nbsp;<br /> (Level 2)</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">Significant&nbsp;<br /> Unobservable Inputs&nbsp;<br /> (Level 3)</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">Amortized Cost</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash equivalents:</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left">Money market funds</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,305</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,305</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,305</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Investments:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt">U.S. treasury bills</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,045</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,045</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,032</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements at Reporting Date Using</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">December 31, 2018</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">Quoted Prices in<br /> Active Markets<br /> for Identical Assets&nbsp;<br /> (Level 1)</div></td> <td style="padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center"><div style="display: inline; font-weight: bold;">Significant Other<br /> Observable Inputs&nbsp;<br /> (Level 2)</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">Significant&nbsp;<br /> Unobservable Inputs&nbsp;<br /> (Level 3)</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">Amortized Cost</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash equivalents:</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left">Money market funds</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,984</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,984</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,984</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Investments:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt">U.S. treasury bills</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69,972</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69,972</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69,972</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 35pt; text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.</div></div></div></td> <td style="width: 5pt">&nbsp;</td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Fair Value Measurements</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company&#x2019;s investments are all classified within Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> of the fair value hierarchy and are valued based on quoted prices in active markets. For cash and cash equivalents, current receivables, accounts payable, and interest accrual, the carrying amounts approximate fair value because of the short maturity of these instruments, and therefore fair value information is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in the table below.&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value hierarchy of the Company's cash equivalents and investments at fair value was as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements at Reporting Date Using</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">June 30, 2019</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">Quoted Prices in<br /> Active Markets<br /> for Identical Assets&nbsp;<br /> (Level 1)</div></td> <td style="padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center"><div style="display: inline; font-weight: bold;">Significant Other<br /> Observable Inputs&nbsp;<br /> (Level 2)</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">Significant&nbsp;<br /> Unobservable Inputs&nbsp;<br /> (Level 3)</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">Amortized Cost</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash equivalents:</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left">Money market funds</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,305</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,305</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,305</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Investments:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt">U.S. treasury bills</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,045</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,045</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,032</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: Red"></div> <div> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Fair Value Measurements at Reporting Date Using</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">December 31, 2018</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">Quoted Prices in<br /> Active Markets<br /> for Identical Assets&nbsp;<br /> (Level 1)</div></td> <td style="padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: center"><div style="display: inline; font-weight: bold;">Significant Other<br /> Observable Inputs&nbsp;<br /> (Level 2)</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">Significant&nbsp;<br /> Unobservable Inputs&nbsp;<br /> (Level 3)</div></td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">Amortized Cost</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Cash equivalents:</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 35%; text-align: left">Money market funds</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,984</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,984</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,984</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Investments:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt">U.S. treasury bills</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69,972</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69,972</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">69,972</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div></div> 591000 P15Y P5Y P16Y P9Y 9189000 8672000 4285000 4285000 506000 482000 1000000 1000000 14980000 14439000 -721000 -172000 7798000 7851000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.</div></div></div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Intangible Assets</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Intangible assets as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018 </div>consisted of the following:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: Red"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="11" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2018</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; padding-bottom: 1pt">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Gross Value</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated <br /> Currency <br /> Translation <br /> Adjustment</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Impairment</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated <br /> Amortization</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net <br /> Book <br /> Value</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated <br /> Currency <br /> Translation <br /> Adjustment</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Accumulated <br /> Amortization</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Net <br /> Book <br /> Value</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Useful <br /> Life</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 19%; text-align: left">Developed technology</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,100</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,864</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(281</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(9,189</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,766</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,824</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(8,672</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 6%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,604</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: center">&nbsp;</td> <td style="width: 6%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></td> <td style="white-space: nowrap; width: 1%; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">In-process research &amp; development</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,406</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,191</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,215</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,168</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,238</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">Indefinite</div></td> <td style="white-space: nowrap; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Distributor relationships</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,700</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(415</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,285</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(415</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,285</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div></td> <td style="white-space: nowrap; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Patents</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(172</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(506</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">322</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(169</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(482</div></td> <td style="white-space: nowrap; text-align: left">)</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="white-space: nowrap; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Elevess trade name</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,000</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,000</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,000</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9</div></td> <td style="white-space: nowrap; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">28,206</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,642</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(281</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,980</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,303</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4,576</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(14,439</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">)</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,191</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="white-space: nowrap; text-align: center">&nbsp;</td> </tr> </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: Red"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></div> <!-- Field: Page; Sequence: 11 --> <!-- Field: /Page --> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The aggregate amortization expense related to intangible assets was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.2</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.3</div> million for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> respectively. The aggregate amortization expense related to intangible assets was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.5</div></div> million for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recorded a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.3</div> million impairment charge for the HYALOSPINE developed technology asset in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2019. </div>HYALOSPINE was an adhesion prevention gel for use after spinal surgery and received initial CE Mark approval in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2015. </div>In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 2019, </div>the Company made the decision <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to renew the CE Mark as the product was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> aligned with the Company&#x2019;s core strategic focus. As a result, an impairment charge was recorded. This amount is included in selling, general &amp; administrative expenses on the Company&#x2019;s condensed consolidated statements of operations.&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>except as set forth in this paragraph, there have <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> been any other events or changes in circumstances that indicate that the carrying value of the other acquired intangible assets <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. The Company was notified by the distributor of MEROGEL INJECTIBLE that it would <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> continue to order the product from the Company or market the product. As a result, the depreciation schedule of the remaining <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.1</div> million of net book value was accelerated. The Company continues to monitor and evaluate the financial performance of its business including the impact of general economic conditions, to assess the potential for the fair value of the reporting unit to decline below its recorded amount.&nbsp;</div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 40pt; text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.</div></div></div></td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Goodwill</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company completed its annual impairment review as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> November 30, 2018 </div>and concluded that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impairment in the carrying value of goodwill exists as of that date. Through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>there have been <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> events or changes in circumstances that indicate that the carrying value of goodwill <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. Changes in the carrying value of goodwill were as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; color: Red"></div> <div> <table cellpadding="0" align="center" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,<br /> 2019</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%">Balance at January 1, 2019</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,851</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Effect of foreign currency adjustments</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(53</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt">Balance at June 30, 2019</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,798</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div></div> -53000 0 300000 281000 281000 12448000 11536000 18428000 3799000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt; text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.</div></div></div></td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Income Taxes</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision for income taxes was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.5</div> million for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>- and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>based on effective tax rates of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24.2%</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24.3%,</div> respectively.&nbsp;The provision for income taxes was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.4</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.4</div> million for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>- and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div>based on effective tax rates of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.5%</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.4%,</div> respectively. The net increase in the effective tax rate for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>- and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>- month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>as compared to the same periods in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> was primarily due to the limitation on the deductibility of executive compensation for accelerated stock vesting upon the retirement of the Company&#x2019;s former Chief Executive Officer on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 9, 2018 </div>in addition to the windfall tax benefit the Company realized in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2018 </div>related to exercises of employee equity awards. The Company realized an immaterial shortfall for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>- and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in Italy.&nbsp; The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the preparation of the financial statements, the Company assesses whether it was more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> that it would be able to utilize, in future periods, the net deferred tax assets associated with its net operating loss carry-forward. The Company has concluded that the positive evidence outweighs the negative evidence and, thus, the deferred tax assets <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> otherwise subject to a valuation allowance are realizable on a &#x201c;more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not&#x201d;</div> basis. As such, the Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> </div>record a valuation allowance as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018.</div></div></div> 3013000 4486000 1444000 394000 -906000 -194000 2293000 -1926000 371000 -1803000 -1300000 -100000 3033000 5990000 -356000 -790000 17100000 4406000 4700000 1000000 1000000 28206000 100000 8303000 9191000 4766000 5604000 3215000 3238000 322000 349000 533000 290000 1031000 385000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.</div></div></div></td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Inventories</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Inventories consist of the following:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></div> <div> <table cellpadding="0" align="center" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,<br /> 2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<br /> 2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Raw materials</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,381</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,688</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work-in-process</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,399</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,626</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,747</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,819</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,527</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,133</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&nbsp;</td> <td style="color: #0000CC; font-style: italic">&nbsp;</td> <td style="color: #0000CC; font-style: italic; text-align: left">&nbsp;</td> <td style="color: #0000CC; font-style: italic; text-align: right">&nbsp;</td> <td style="white-space: nowrap; color: #0000CC; font-style: italic; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Inventories</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,986</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,300</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other long-term assets</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,541</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,833</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other long-term assets include <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$4.5</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.8</div> million of inventory expected to remain on hand beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>respectively.&nbsp;</div></div> 8747000 6819000 22986000 21300000 4541000 3833000 12381000 13688000 1100000 900000 6399000 4626000 601000 3993000 757000 585000 1161000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ended <br /> June 30, 2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the six months ended <br /> June 30, 2019</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Lease cost</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left">Operating lease cost</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">521</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,043</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short-term lease cost</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Variable lease cost</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt">Total lease cost</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">585</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,161</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Other information</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating cash flows from operating leases</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">497</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">994</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Operating Lease Obligation As Of</td> <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">Years ending December 31,</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2019</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: left">2019</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 13%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">994</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2020</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,025</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2021</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,024</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,981</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,965</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Thereafter</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,530</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Present value adjustment</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(9,444</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="padding-bottom: 1pt">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of lease payments</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,075</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less current portion included in Accrued expenses and other current liabilities</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,101</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="padding-bottom: 1pt">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Operating lease liabilities</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,974</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> </tr> </table></div> 23530000 1965000 1981000 2024000 2025000 994000 9444000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 40pt; text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.</div></div></div></td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Operating Leases</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019 </div>using the modified retrospective adoption method, which did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> require it to restate prior periods, and there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> impact on retained earnings. The transition guidance associated with ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> also permitted certain practical expedients. The Company has elected the &#x201c;package of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3&#x201d;</div> practical expedients permitted under the transition guidance which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted the practical expedient to use hindsight to determine the lease term. The Company adopted an accounting policy which provides that leases with an initial term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12</div> months or less and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> purchase option the Company is reasonably certain of exercising will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be included within the lease right-of-use assets and lease liabilities on its consolidated balance sheet. The Company elected an accounting policy to combine the non-lease components (which include common area maintenance, taxes and insurance) with the related lease component. The Company elected this practical expedient to all asset classes upon the adoption of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <!-- Field: Page; Sequence: 12 --> <!-- Field: /Page --> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. Leases with a term greater than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year are recognized on the balance sheet as right-of-use assets, lease liabilities, and, if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding right-of-use assets are recorded based on the present values of lease payments over the lease terms. The interest rate implicit in lease contracts is typically <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> depend on a rate or index are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> included in the lease liability and are recognized as incurred. Lease contracts do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to the right-of-use assets <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be required for items such as initial direct costs paid, incentives received or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability by using revised inputs as of the reassessment date, and adjust the right-of-use asset.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> primary leases, which are its real estate leases in Bedford, Massachusetts and Padova, Italy. The Company leases approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">134,000</div> square feet of administrative, research and development, and manufacturing space in Bedford, Massachusetts (the &#x201c;Bedford lease&#x201d;), and approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33,000</div> square feet of office, research and development, training, and warehousing space in Padova, Italy (the &#x201c;Padova lease&#x201d;). The current term of the Bedford lease extends to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2022</div> with several lease renewal options into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2038,</div> and the current term of the Padova lease extends to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2032,</div> with a right to terminate at the Company&#x2019;s option in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2026</div> without penalty.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company identified and assessed significant assumptions in recognizing the right-of-use asset and lease liability on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2019 </div>as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><div style="display: inline; font-style: italic;">Incremental borrowing rate</div>. The Company derives its incremental borrowing rate from information available at the lease commencement date in determining the present value of lease payments. The incremental borrowing rate represents a collateralized rate of interest the Company would have to pay to borrow over a similar term an amount equal to the lease payments in a similar economic environment. The Company&#x2019;s lease agreements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> provide implicit rates. As the Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have any external borrowings at the transition date with comparable terms to its lease agreements, the Company estimated its incremental borrowing rate based on its credit quality, line of credit agreement and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of the lease. The weighted average discount rate at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.1%.</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><div style="display: inline; font-style: italic;">Lease term.</div> The Company applied the hindsight practical expedient and as a result the lease term for the Bedford lease was determined to include all lease renewal options. There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> changes to the lease terms for its other leases. For the Padova lease, the Company considered the termination option when determining the lease term. The weighted average lease term at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17.3</div> years.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The components of lease expense and other information are as follows:&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the three months ended <br /> June 30, 2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">For the six months ended <br /> June 30, 2019</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Lease cost</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left">Operating lease cost</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">521</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,043</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Short-term lease cost</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Variable lease cost</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">60</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt">Total lease cost</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">585</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,161</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Other information</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating cash flows from operating leases</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">497</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">994</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></div> <div style=" margin: 0pt 0">&nbsp;&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <!-- Field: Page; Sequence: 13 --> <!-- Field: /Page --> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Future commitments due under these lease agreements as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019 </div>are as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center">Operating Lease Obligation As Of</td> <td style="white-space: nowrap; font-weight: bold; text-align: center">&nbsp;</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">Years ending December 31,</td> <td style="font-weight: bold">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2019</td> <td style="font-weight: bold">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 83%; text-align: left">2019</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 13%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">994</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2020</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,025</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2021</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,024</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,981</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,965</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Thereafter</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,530</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Present value adjustment</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(9,444</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="padding-bottom: 1pt">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Present value of lease payments</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">23,075</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less current portion included in Accrued expenses and other current liabilities</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,101</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> <td style="padding-bottom: 1pt">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Operating lease liabilities</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,974</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> </tr> </table> </div> <div style=" margin: 0">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table summarizes the future minimum payments due for the Company&#x2019;s operating leases under the prior lease guidance without the hindsight practical expedient for each of the next <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years and the total thereafter as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018:</div></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; text-align: left">2019</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,879</div></td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2020</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,917</div></td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2021</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,924</div></td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,672</div></td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">414</div></td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2024 and thereafter</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">897</div></td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,703</div></td> <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> </table> </div></div> 287364000 278993000 10388000 11289000 72045000 69972000 72045000 72045000 72032000 69972000 69972000 69972000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 35pt; text-align: left"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></div> </td> <td style="width: 5pt"></td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Nature of Business</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Anika Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a global, integrated orthopedic and regenerative medicines company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> decades of global expertise developing, manufacturing, and commercializing products based on its proprietary Hyaluronic Acid (&#x201c;HA&#x201d;) technology. The Company&#x2019;s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, viscosupplements which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is subject to risks common to companies in the biotechnology and medical device industries including, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and foreign regulations and approval requirements, as well as the ability to grow the Company&#x2019;s business through appropriate commercial strategies.</div></div> -30119000 -28849000 -3433000 7467000 13932000 14063000 13942000 3405000 9435000 10092000 4507000 4507000 9435000 -6686000 -6686000 10091000 11915000 11246000 17397000 3414000 521000 1043000 23075000 1101000 21974000 497000 994000 23495000 0.041 8703000 1879000 414000 1672000 1924000 1917000 332000 349000 4884000 4897000 145000 -951000 -170000 -331000 -315000 -315000 145000 145000 620000 620000 -951000 -951000 373000 550000 30000000 30000000 30000000 125000 1735000 73896000 14000000 2131000 3283000 0.01 0.01 1250000 1250000 0 0 0 0 0 0 2413000 1854000 72594000 24750000 6000 2886000 0 0 52960000 54111000 -6000 4165000 4733000 8423000 9895000 232175000 218233000 30413000 30542000 55130000 51800000 5000 6000 11000 12000 30418000 30548000 55141000 51812000 26462000 26192000 48210000 45681000 2101000 1263000 3493000 2509000 444000 623000 573000 83000 1406000 2464000 2854000 3527000 22937000 24773000 4927000 3498000 2554000 2277000 43026000 41682000 7454000 5889000 4661000 4241000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; min-width: 700px;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top"> <td style="width: 35pt; text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.</div></div></div></td> <td style="width: 5pt">&nbsp;</td> <td style="text-align: justify"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-weight: bold;">Revenue</div></div></td> </tr> </table> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>deferred revenue was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$50</div> thousand.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has agreements with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc. (&#x201c;Mitek&#x201d;) that include the grant of certain licenses, performance of development services, and supply of product. Revenues from the agreements with Mitek represent <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">68%</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70%</div> of total Company revenues for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>- and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div>-month periods ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2019, </div>respectively. The Company has agreements with other customers that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>include the delivery of a license and supply of product.</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Product revenue by product group was as follows:&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Orthobiologics</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,462</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,192</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,210</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45,681</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Surgical</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,101</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,263</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,493</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,509</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dermal</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">444</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">623</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">573</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">83</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,406</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,464</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,854</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,527</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Product Revenue</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,413</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,542</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">55,130</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">51,800</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Total revenue by geographic location was as follows:</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"></div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br /> Revenue</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Geographic Location:</td> <td style="color: #0000CC; font-weight: bold">&nbsp;</td> <td style="color: #0000CC; font-weight: bold; text-align: left">&nbsp;</td> <td style="color: #0000CC; font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; color: #0000CC; font-weight: bold; text-align: left">&nbsp;</td> <td style="color: #0000CC">&nbsp;</td> <td style="color: #0000CC; text-align: left">&nbsp;</td> <td style="color: #0000CC; text-align: right">&nbsp;</td> <td style="white-space: nowrap; color: #0000CC; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left; padding-left: 10pt">United States</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,937</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">76</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">%</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">24,773</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Europe</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,927</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,498</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,554</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,277</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 20pt">Total Revenue</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,418</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">%</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,548</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">%</td> </tr> </table> </div> <div style=" margin: 0">&nbsp;</div> <div> <table style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="15" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total<br /> Revenue</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Percentage of<br /> Revenue</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Geographic Location:</td> <td style="color: #0000CC; font-weight: bold">&nbsp;</td> <td style="color: #0000CC; font-weight: bold; text-align: left">&nbsp;</td> <td style="color: #0000CC; font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; color: #0000CC; font-weight: bold; text-align: left">&nbsp;</td> <td style="color: #0000CC">&nbsp;</td> <td style="color: #0000CC; text-align: left">&nbsp;</td> <td style="color: #0000CC; text-align: right">&nbsp;</td> <td style="white-space: nowrap; color: #0000CC; text-align: left">&nbsp;</td> <td style="font-weight: bold">&nbsp;</td> <td style="font-weight: bold; text-align: left">&nbsp;</td> <td style="font-weight: bold; text-align: right">&nbsp;</td> <td style="white-space: nowrap; font-weight: bold; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 48%; text-align: left; padding-left: 10pt">United States</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">43,026</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">78</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">%</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">41,682</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 10pt">Europe</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,454</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14</div></td> <td style="white-space: nowrap; text-align: left">%</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,889</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11</div></td> <td style="white-space: nowrap; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,661</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,241</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 20pt">Total Revenue</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">55,141</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">%</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">51,812</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">%</td> </tr> </table> </div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</div> <div style=" font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2, 2018, </div>the Company publicly disclosed a voluntary recall of certain lots of its HYAFF-based products, HYALOFAST, HYALOGRAFT C, and HYALOMATRIX. The Company initiated the recall after internal quality testing, which indicated that the products were at risk of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> maintaining certain measures throughout their entire shelf life. While there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> indication of any safety or efficacy issue related to the products at the time, the Company removed the products from the field as a precautionary measure. During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div>-month period ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> March 31, 2018, </div>the Company recorded a revenue reserve for this voluntary recall of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.9</div> million was related to revenue recorded in prior periods. The adjustments related to the initial revenue reserve subsequent to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>were immaterial. The revenue reserves impacted Dermal and Orthobiologics product groups and all geographic locations. Recall recovery activities were completed during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> and product shipments resumed in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2018.</div></div></div> 24110000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center; padding-bottom: 1pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; padding-bottom: 1pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">June 30, <br /> 2019</div></td> <td style="text-align: center; padding-bottom: 1pt"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td colspan="3" style="white-space: nowrap; text-align: center; border-bottom: Black 1pt solid"><div style="display: inline; font-weight: bold;">December 31, <br /> 2018</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Compensation and related expenses</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,584</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,446</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Professional fees</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,609</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,989</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating lease liability - current</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,101</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Income taxes payable</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">757</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">385</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research grants</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">398</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">400</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Clinical trial costs</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">320</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">577</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">332</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">349</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,101</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,146</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Shares used in the calculation of basic earnings per share</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,916</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,652</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,054</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">&nbsp;</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,666</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Effect of dilutive securities:</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Stock options, SARs, RSAs, RSUs and PSUs</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">172</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">263</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">149</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">379</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Diluted shares used in the calculation of earnings per share</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,088</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,915</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,203</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,045</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Cost of product revenue</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">82</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(28</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">174</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(244</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research&nbsp;&amp; development</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">91</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">241</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">268</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">451</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Selling, general&nbsp;&amp; administrative</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,270</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,109</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,387</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,680</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt">Total stock-based compensation expense</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,443</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,322</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,829</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,887</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; text-align: left">2019</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,879</div></td> <td style="width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2020</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,917</div></td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2021</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,924</div></td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2022</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,672</div></td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2023</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">414</div></td> <td style="text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2024 and thereafter</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">897</div></td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.5pt">&nbsp;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,703</div></td> <td style="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" align="center" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,<br /> 2019</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 85%">Balance at January 1, 2019</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,851</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Effect of foreign currency adjustments</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(53</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.25pt">Balance at June 30, 2019</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,798</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" align="center" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30,<br /> 2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<br /> 2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">Raw materials</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,381</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 12%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,688</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work-in-process</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,399</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,626</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,747</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,819</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27,527</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,133</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">&nbsp;</td> <td style="color: #0000CC; font-style: italic">&nbsp;</td> <td style="color: #0000CC; font-style: italic; text-align: left">&nbsp;</td> <td style="color: #0000CC; font-style: italic; text-align: right">&nbsp;</td> <td style="white-space: nowrap; color: #0000CC; font-style: italic; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right">&nbsp;</td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td>Inventories</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">22,986</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,300</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other long-term assets</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,541</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">$</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,833</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended June 30,</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; text-align: left">Orthobiologics</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,462</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">26,192</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48,210</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> <td style="width: 1%">&nbsp;</td> <td style="width: 1%; text-align: left">$</td> <td style="width: 10%; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45,681</div></td> <td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Surgical</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,101</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,263</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,493</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,509</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dermal</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">444</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">623</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">573</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> <td>&nbsp;</td> <td style="text-align: left">&nbsp;</td> <td style="text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">83</div></td> <td style="white-space: nowrap; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Other</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,406</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,464</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,854</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="padding-bottom: 1pt">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> <td style="border-bottom: Black 1pt solid; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,527</div></td> <td style="white-space: nowrap; border-bottom: Black 1pt solid; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.25pt; padding-left: 10pt">Product Revenue</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,413</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,542</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">55,130</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> <td style="padding-bottom: 2.25pt">&nbsp;</td> <td style="border-bottom: Black 2.25pt double; text-align: left">$</td> <td style="border-bottom: Black 2.25pt double; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">51,800</div></td> <td style="white-space: nowrap; border-bottom: Black 2.25pt double; text-align: left">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; min-; min-width: 700px;"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="7" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six Months Ended June 30,</td> </tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap">&nbsp;</td> <td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td> <td style="font-weight: bold; padding-bottom: 1pt; text-align: center">&nbsp;</td> <td colspan="3" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free interest rate</td> <td>&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.18% </div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 2.54%</div></td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.15% </div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 2.75%</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td> <td>&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44.05% </div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 44.72%</div></td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">37.12% </div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 40.81%</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 68%; text-align: left">Expected life (years)</td> <td style="width: 1%">&nbsp;</td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.5</div></td> <td style="white-space: nowrap; width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; text-align: center">&nbsp;</td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.0 </div></td> <td style="width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="white-space: nowrap; width: 5%; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 4.5</div></td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td> <td>&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.00%</div></td> <td style="white-space: nowrap; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.00%</div></td> <td style="white-space: nowrap; text-align: center"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> </tr> </table></div> 7502000 6417000 15174000 22507000 2829000 8887000 P3Y 64578 8000 173507 8130 114500 0 0 0.4405 0.4472 0.3712 0.4081 0.0218 0.0254 0.0215 0.0275 1500000 27325 17500 131617 209800 39.85 P3Y182D P4Y P4Y182D 14210000 14214000 13785000 14688000 14745000 14584000 3000 32000 4000 6000 7000 7000 30000 89000 273000 22400 273123 22900 284548 5000 5000 1000 851000 852000 1000 511000 512000 3000 2372000 2375000 50000000 30000000 20000000 30000000 12000000 500000 452000 434000 5000 29995000 30000000 4000 29996000 30000000 250946000 263612000 142000 50763000 218233000 -5526000 142000 52030000 222740000 -5841000 269071000 138000 24329000 232175000 -5696000 147000 68617000 199511000 -4784000 263491000 147000 74958000 192825000 -4164000 263766000 146000 48656000 202916000 -5115000 246603000 60000 112000 172000 263000 149000 379000 14088000 14915000 14203000 15045000 13916000 14652000 14054000 14666000 xbrli:shares xbrli:pure utr:sqft iso4217:USD iso4217:USD xbrli:shares 0000898437 2017-01-01 2017-12-31 0000898437 2018-01-01 2018-03-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000898437 anik:CommonStockOutstandingMember 2018-01-01 2018-03-31 0000898437 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000898437 srt:ChiefExecutiveOfficerMember 2018-01-01 2018-03-31 0000898437 2018-01-01 2018-06-30 0000898437 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000898437 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000898437 anik:PerformanceRestrictedStockUnitsMember 2018-01-01 2018-06-30 0000898437 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0000898437 us-gaap:StockAppreciationRightsSARSMember 2018-01-01 2018-06-30 0000898437 us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0000898437 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0000898437 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0000898437 anik:DermalMember 2018-01-01 2018-06-30 0000898437 us-gaap:ManufacturedProductOtherMember 2018-01-01 2018-06-30 0000898437 anik:OrthobiologicsMember 2018-01-01 2018-06-30 0000898437 us-gaap:ProductMember 2018-01-01 2018-06-30 0000898437 us-gaap:ServiceMember 2018-01-01 2018-06-30 0000898437 anik:SurgicalMember 2018-01-01 2018-06-30 0000898437 srt:MaximumMember 2018-01-01 2018-06-30 0000898437 srt:MinimumMember 2018-01-01 2018-06-30 0000898437 srt:EuropeMember 2018-01-01 2018-06-30 0000898437 anik:OtherLocationMember 2018-01-01 2018-06-30 0000898437 country:US 2018-01-01 2018-06-30 0000898437 2018-01-01 2018-12-31 0000898437 anik:FormerChiefExecutiveOfficerMember 2018-03-08 2018-03-08 0000898437 2018-04-01 2018-06-30 0000898437 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0000898437 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0000898437 anik:PerformanceRestrictedStockUnitsMember 2018-04-01 2018-06-30 0000898437 us-gaap:RestrictedStockMember 2018-04-01 2018-06-30 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2018-04-01 2018-06-30 0000898437 us-gaap:StockAppreciationRightsSARSMember 2018-04-01 2018-06-30 0000898437 us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0000898437 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0000898437 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0000898437 anik:DermalMember 2018-04-01 2018-06-30 0000898437 us-gaap:ManufacturedProductOtherMember 2018-04-01 2018-06-30 0000898437 anik:OrthobiologicsMember 2018-04-01 2018-06-30 0000898437 us-gaap:ProductMember 2018-04-01 2018-06-30 0000898437 us-gaap:ServiceMember 2018-04-01 2018-06-30 0000898437 anik:SurgicalMember 2018-04-01 2018-06-30 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0000898437 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000898437 anik:CommonStockOutstandingMember 2018-04-01 2018-06-30 0000898437 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000898437 srt:EuropeMember 2018-04-01 2018-06-30 0000898437 anik:OtherLocationMember 2018-04-01 2018-06-30 0000898437 country:US 2018-04-01 2018-06-30 0000898437 2019-01-01 2019-03-31 0000898437 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-03-31 0000898437 us-gaap:DistributionRightsMember 2019-01-01 2019-03-31 0000898437 anik:ElevessTradeNameMember 2019-01-01 2019-03-31 0000898437 us-gaap:PatentsMember 2019-01-01 2019-03-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000898437 anik:CommonStockOutstandingMember 2019-01-01 2019-03-31 0000898437 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000898437 2019-01-01 2019-06-30 0000898437 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000898437 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000898437 anik:PerformanceRestrictedStockUnitsMember 2019-01-01 2019-06-30 0000898437 us-gaap:PerformanceSharesMember 2019-01-01 2019-06-30 0000898437 us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0000898437 us-gaap:StockAppreciationRightsSARSMember 2019-01-01 2019-06-30 0000898437 anik:StockOptionsPSUsAndRSUsToEmployeesAndRsusToNonemployeeDirectorsMember 2019-01-01 2019-06-30 0000898437 anik:DepuyMitekIncMember 2019-01-01 2019-06-30 0000898437 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-06-30 0000898437 us-gaap:DistributionRightsMember 2019-01-01 2019-06-30 0000898437 anik:ElevessTradeNameMember 2019-01-01 2019-06-30 0000898437 us-gaap:PatentsMember 2019-01-01 2019-06-30 0000898437 us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0000898437 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000898437 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0000898437 us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-06-30 0000898437 anik:DermalMember 2019-01-01 2019-06-30 0000898437 us-gaap:ManufacturedProductOtherMember 2019-01-01 2019-06-30 0000898437 anik:OrthobiologicsMember 2019-01-01 2019-06-30 0000898437 us-gaap:ProductMember 2019-01-01 2019-06-30 0000898437 us-gaap:ServiceMember 2019-01-01 2019-06-30 0000898437 anik:SurgicalMember 2019-01-01 2019-06-30 0000898437 srt:MaximumMember 2019-01-01 2019-06-30 0000898437 srt:MinimumMember 2019-01-01 2019-06-30 0000898437 srt:EuropeMember 2019-01-01 2019-06-30 0000898437 anik:OtherLocationMember 2019-01-01 2019-06-30 0000898437 country:US 2019-01-01 2019-06-30 0000898437 2019-04-01 2019-06-30 0000898437 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000898437 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000898437 anik:PerformanceRestrictedStockUnitsMember 2019-04-01 2019-06-30 0000898437 us-gaap:PerformanceSharesMember 2019-04-01 2019-06-30 0000898437 us-gaap:RestrictedStockMember 2019-04-01 2019-06-30 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0000898437 us-gaap:StockAppreciationRightsSARSMember 2019-04-01 2019-06-30 0000898437 anik:DepuyMitekIncMember 2019-04-01 2019-06-30 0000898437 anik:HYALOSPINEDevelopedTechnologyAssetMember 2019-04-01 2019-06-30 0000898437 us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000898437 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000898437 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0000898437 anik:DermalMember 2019-04-01 2019-06-30 0000898437 us-gaap:ManufacturedProductOtherMember 2019-04-01 2019-06-30 0000898437 anik:OrthobiologicsMember 2019-04-01 2019-06-30 0000898437 us-gaap:ProductMember 2019-04-01 2019-06-30 0000898437 us-gaap:ServiceMember 2019-04-01 2019-06-30 0000898437 anik:SurgicalMember 2019-04-01 2019-06-30 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000898437 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000898437 anik:CommonStockOutstandingMember 2019-04-01 2019-06-30 0000898437 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000898437 srt:EuropeMember 2019-04-01 2019-06-30 0000898437 anik:OtherLocationMember 2019-04-01 2019-06-30 0000898437 country:US 2019-04-01 2019-06-30 0000898437 anik:AcceleratedStockRepurchaseMember 2019-05-07 2019-05-07 0000898437 anik:AcceleratedStockRepurchaseMember 2019-05-07 2019-06-30 0000898437 anik:AcceleratedStockRepurchaseMember 2019-05-08 2019-05-08 0000898437 anik:The2017PlanMember 2019-06-18 2019-06-18 0000898437 2017-12-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000898437 anik:CommonStockOutstandingMember 2017-12-31 0000898437 us-gaap:RetainedEarningsMember 2017-12-31 0000898437 2018-03-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000898437 anik:CommonStockOutstandingMember 2018-03-31 0000898437 us-gaap:RetainedEarningsMember 2018-03-31 0000898437 2018-06-30 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000898437 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000898437 anik:CommonStockOutstandingMember 2018-06-30 0000898437 us-gaap:RetainedEarningsMember 2018-06-30 0000898437 2018-11-30 0000898437 2018-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000898437 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000898437 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000898437 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000898437 us-gaap:USTreasurySecuritiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2018-12-31 0000898437 us-gaap:USTreasurySecuritiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2018-12-31 0000898437 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000898437 us-gaap:DistributionRightsMember 2018-12-31 0000898437 anik:ElevessTradeNameMember 2018-12-31 0000898437 us-gaap:PatentsMember 2018-12-31 0000898437 us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0000898437 us-gaap:USTreasuryBillSecuritiesMember 2018-12-31 0000898437 anik:The2017PlanMember 2018-12-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000898437 anik:CommonStockOutstandingMember 2018-12-31 0000898437 us-gaap:RetainedEarningsMember 2018-12-31 0000898437 2019-03-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000898437 anik:CommonStockOutstandingMember 2019-03-31 0000898437 us-gaap:RetainedEarningsMember 2019-03-31 0000898437 2019-05-02 0000898437 anik:AcceleratedStockRepurchaseMember 2019-05-02 0000898437 anik:RepurchaseFromOpenMarketMember 2019-05-02 0000898437 anik:AcceleratedStockRepurchaseMember 2019-05-07 0000898437 anik:AcceleratedStockRepurchaseMember 2019-05-08 0000898437 anik:The2017PlanMember 2019-06-18 0000898437 2019-06-30 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000898437 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000898437 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000898437 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000898437 us-gaap:USTreasurySecuritiesMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2019-06-30 0000898437 us-gaap:USTreasurySecuritiesMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2019-06-30 0000898437 us-gaap:DevelopedTechnologyRightsMember 2019-06-30 0000898437 us-gaap:DistributionRightsMember 2019-06-30 0000898437 anik:ElevessTradeNameMember 2019-06-30 0000898437 anik:MEROGELINJECTIBLEAssetsMember 2019-06-30 0000898437 us-gaap:PatentsMember 2019-06-30 0000898437 us-gaap:InProcessResearchAndDevelopmentMember 2019-06-30 0000898437 us-gaap:USTreasuryBillSecuritiesMember 2019-06-30 0000898437 anik:AdministrativeResearchAndDevelopmentAndManufacturingSpaceInBedfordMaMember 2019-06-30 0000898437 anik:OfficeResearchAndDevelopmentTrainingAndWarehousingSpaceInPadovaItalyMember 2019-06-30 0000898437 anik:AcceleratedStockRepurchaseMember 2019-06-30 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000898437 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000898437 anik:CommonStockOutstandingMember 2019-06-30 0000898437 us-gaap:RetainedEarningsMember 2019-06-30 0000898437 2019-07-18 EX-101.SCH 7 anik-20190630.xsd XBRL SCHEMA FILE 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Nature of Business link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Revenue link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Investments link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Equity Incentive Plan link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Earnings Per Share ("EPS") link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Inventories link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Intangible Assets link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Goodwill link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Accrued Expenses link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Operating Leases link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 3 - Revenue (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 5 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 6 - Equity Incentive Plan (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 7 - Earnings Per Share ("EPS") (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 8 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 9 - Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 10 - Goodwill (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 11 - Accrued Expenses (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 12 - Operating Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 3 - Revenue (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 3 - Revenue - Product Revenue by Product Group (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 3 - Revenue - Total Revenue by Geographic Location (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 4 - Investments (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 5 - Fair Value Measurements - Fair Value of Financial Instruments (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 6 - Equity Incentive Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 6 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 6 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 6 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 7 - Earnings Per Share ("EPS") (Details Textual) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 7 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 8 - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 8 - Inventories - Summary of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 9 - Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 9 - Intangible Assets - Summary of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 10 - Goodwill (Details Textual) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 10 - Goodwill - Changes in the Carrying Value of Goodwill (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 11 - Accrued Expenses (Details Textual) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 11 - Accrued Expenses - Summary of Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 12 - Operating Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 12 - Operating Leases - Lease Expense and Other Information (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 12 - Operating Leases - Future Minimum Rental Payments for Operating Leases (Details) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 12 - Operating Leases - Future Lease Commitments Under ASU 840 (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 14 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 anik-20190630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 anik-20190630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 anik-20190630_lab.xml XBRL LABEL FILE Document And Entity Information Expected dividend yield Note To Financial Statement Details Textual Note 3 - Revenue Note 5 - Fair Value Measurements 2020 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Note 6 - Equity Incentive Plan Risk free interest rate Note 7 - Earnings Per Share ("EPS") Note 8 - Inventories Note 9 - Intangible Assets Note 10 - Goodwill Note 11 - Accrued Expenses Note 12 - Operating Leases Income Tax Disclosure [Text Block] Note 3 - Revenue - Product Revenue by Product Group (Details) Note 3 - Revenue - Total Revenue by Geographic Location (Details) Note 5 - Fair Value Measurements - Fair Value of Financial Instruments (Details) Lessee, Operating Lease, Liability, Maturity [Table Text Block] Other long-term assets us-gaap_ShareBasedCompensation Stock-based compensation expense Note 6 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) Expected volatility us-gaap_LiabilitiesCurrent Total current liabilities Note 6 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) 2019 us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Note 6 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details) Note 7 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) Note 8 - Inventories - Summary of Inventories (Details) Useful life (Year) Expected life (years) (Year) Note 9 - Intangible Assets - Summary of Intangible Assets (Details) Note 10 - Goodwill - Changes in the Carrying Value of Goodwill (Details) Note 11 - Accrued Expenses - Summary of Accrued Expenses (Details) Note 12 - Operating Leases - Lease Expense and Other Information (Details) Note 12 - Operating Leases - Future Minimum Rental Payments for Operating Leases (Details) Note 12 - Operating Leases - Future Lease Commitments Under ASU 840 (Details) Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Notes To Financial Statements Stock Options, PSUs and RSUs to Employees and RSUs to Non-employee Directors [Member] Represents information about stock options, PSUs and RSUs to employees and RSUs to non-employee directors. Operating expenses: Notes To Financial Statements [Abstract] Performance Restricted Stock Units [Member] Represents information about Performance Restricted Stock Units (PSUs). anik_PerformanceConditionsFinancialTargetPercentageOfPerformanceConditionsBasedOnCompanysOperatingResultsInNextFiscalYear Performance Conditions, Financial Target, Percentage of Performance Conditions Based on Company’s Operating Results in next Fiscal Year Represents the percentage of performance conditions based on company’s operating results in next fiscal year set as business target. anik_PerformanceConditionsBusinessTargetPercentageOfPerformanceConditionsBasedOnAchievementInCurrentFiscalYear Performance Conditions, Business Target, Percentage of Performance Conditions Based on Achievement in Current Fiscal Year Represents the percentage of performance conditions based on achievement in current fiscal year set as business target. Foreign currency translation adjustment Proceeds from maturity of investments US Treasury Securities [Member] HYALOSPINE Developed Technology Asset [Member] Represents HYALOSPINE developed technology asset. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Equity Instruments Other than Options (in shares) us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Retirement of common stock for minimum tax withholdings (in shares) us-gaap_InventoryNoncurrent Inventory, Noncurrent, Total Other comprehensive Income (loss) us-gaap_AssetsCurrent Total current assets Office, Research and Development, Training, and Warehousing Space in Padova, Italy [Member] Represents office, research and development, training, and warehousing space in Padova, Italy. Administrative, Research and Development, and Manufacturing Space in Bedford, MA [Member] Represents information about administrative, research and development, and manufacturing space in Bedford, MA. Interest and other income, net Common stock, $0.01 par value; 90,000 shares authorized, 13,785 and 14,210 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively us-gaap_PaymentsToAcquireMarketableSecurities Purchase of investments us-gaap_GoodwillImpairedAccumulatedImpairmentLoss Goodwill, Impaired, Accumulated Impairment Loss Adjustments to reconcile net income to net cash provided by operating activities: Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Goodwill [Table Text Block] Compensation and related expenses us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance us-gaap_DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance, Total us-gaap_AccruedIncomeTaxesCurrent Income taxes payable Statistical Measurement [Domain] Operating cash flows from operating leases us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised SARs (in shares) Maximum [Member] Lessee, Operating Leases [Text Block] Minimum [Member] MEROGEL INJECTIBLE Assets [Member] Represents MEROGEL INJECTIBLE Assets. Accounts payable Product and Service [Axis] Product and Service [Domain] Statistical Measurement [Axis] Purchases of property and equipment included in accounts payable and accrued expenses Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively Other Preferred stock, shares issued (in shares) us-gaap_PolicyTextBlockAbstract Accounting Policies Geographical [Axis] Geographical [Domain] Preferred stock, shares authorized (in shares) Europe [Member] Inventories, net Portion at Fair Value Measurement [Member] [Default] Professional fees Preferred stock, par value (in dollars per share) Estimate of Fair Value Measurement [Member] Indefinite-lived Intangible Assets [Axis] Accelerated Stock Repurchase [Member] Represents the program of accelerated stock repurchase. Indefinite-lived Intangible Assets, Major Class Name [Domain] Measurement Basis [Axis] Fair Value, Inputs, Level 3 [Member] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Non-cash activities: Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Fair Value Hierarchy and NAV [Axis] Goodwill Disclosure [Text Block] Current liabilities: Developed Technology Rights [Member] Product [Member] us-gaap_Assets Total assets Supplemental disclosure of cash flow information: Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Patents [Member] Plan Name [Axis] Plan Name [Domain] In Process Research and Development [Member] Cash flows from operating activities: Schedule of Segment Reporting Information, by Segment [Table Text Block] Distribution Rights [Member] Statement [Line Items] Accounts receivable, reserves Accounts receivable, net of reserves of $1,089 and $1,525 at June 30, 2019 and December 31, 2018, respectively Share-based Payment Arrangement [Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Investments Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Additional paid-in-capital AOCI Attributable to Parent [Member] us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Retirement of common stock for minimum tax withholdings Stockholders’ equity: Former Chief Executive Officer [Member] Represents the former highest ranking executive officer, who has ultimate managerial responsibility for the entity and who reports to the board of directors. Business Description and Basis of Presentation [Text Block] Award Type [Domain] Chief Executive Officer [Member] Current assets: Fair Value Disclosures [Text Block] Award Type [Axis] Net income Net income us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Accumulated Amortization us-gaap_InvestmentIncomeAmortizationOfDiscount Accretion to amortized cost of investments Intangible assets, net Intangible Assets, Net (Excluding Goodwill), Total Stock Appreciation Rights (SARs) [Member] Restricted Stock Units (RSUs) [Member] us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used in financing activities Restricted Stock [Member] Commitments and contingencies (Note 13) Performance Shares [Member] us-gaap_OperatingIncomeLoss Income from operations Share-based Payment Arrangement, Option [Member] us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash (used in) provided by investing activities Exchange rate impact on cash us-gaap_GoodwillForeignCurrencyTranslationGainLoss Effect of foreign currency adjustments us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease Decrease in cash and cash equivalents Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Cost of product revenue Counterparty Name [Axis] Counterparty Name [Domain] Provision for inventory anik_IncreaseDecreaseInLeaseLiabilities Operating lease liabilities The increase (decrease) during the reporting period in the lease liabilities. us-gaap_ContractWithCustomerLiability Contract with Customer, Liability, Total Commitments and Contingencies Disclosure [Text Block] Property and equipment, net Goodwill Balance Balance anik_RevenuesFromAgreementsAsPercentOfTotalRevenue Revenues From Agreements as Percent of Total Revenue The percent of total revenue that revenue from agreements comprises. us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Cash paid for tax withheld on vested restricted stock awards us-gaap_ProductWarrantyAccrual Standard and Extended Product Warranty Accrual, Ending Balance us-gaap_CostsAndExpenses Total operating expenses Repurchase from Open Market [Member] Represents the shares to be potentially repurchased from open market. anik_SeveranceBenefitFollowingRetirementTerm Severance Benefit Following Retirement, Term The period of time for the severance benefit to be paid following retirement. anik_SeveranceBenefitFollowingRetirement Severance Benefit Following Retirement The amount of severance benefit provided following a person's retirement. anik_NumberOfAdditionalSharesDeliverToCompanyIfASRAgreementSettled Number of Additional Shares Deliver to Company if ASR Agreement Settled The number of additional shares would have been deliver to the company if the ASR Agreement had been settled as of June 30, 2019. us-gaap_PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock Repurchases of common stock anik_ShareRepurchasedPecentage Share Repurchased, Pecentage The percentage of shares repurchased to estimated total number of shares expected to be repurchased under the agreement. Cash flows from investing activities: Elevess Trade Name [Member] Represents Elevess trade name. Retained Earnings [Member] Earnings Per Share [Text Block] anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal Total The aggregate carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of raw materials, work in process and finished goods. Common Stock Outstanding [Member] Represents common stock outstanding. Proceeds from exercise of equity awards Revenue Title of Individual [Domain] Title of Individual [Axis] Income taxes us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Stock Repurchase Program, Remaining Authorized Repurchase Amount Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block] Represents schedule of revenue and operating income, by geographical areas. Other Location [Member] Represents other location. Percentage of Revenue Represents the percentage of net revenue. Additional Paid-in Capital [Member] Share Repurchase Program [Domain] us-gaap_StockRepurchaseProgramAuthorizedAmount1 Stock Repurchase Program, Authorized Amount Provision for income taxes Income Tax Expense (Benefit), Total Accrued expenses, other current and long-term liabilities Equity Components [Axis] Share Repurchase Program [Axis] Equity Component [Domain] Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income before income taxes Manufactured Product, Other [Member] Cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period The 2017 Plan [Member] Represents the Anika Therapeutics, Inc. Omnibus Incentive Plan (the “2017 Plan”). Stock-based compensation expense us-gaap_AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense Revenue from Contract with Customer [Text Block] Amendment Flag Accounting Policies [Abstract] us-gaap_ComprehensiveIncomeNetOfTax Comprehensive income Selling, General and Administrative Expenses [Member] us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures Forfeiture of restricted stock us-gaap_GainLossOnSaleOfPropertyPlantEquipment Loss on disposal of fixed assets us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Current Fiscal Year End Date Cost of Sales [Member] Variable lease cost us-gaap_LeaseCost Total lease cost Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses, other current and long-term assets us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent Research and Development Expense [Member] Cash equivalents Represents the fair value disclosure for cash equivalents as of the balance sheet date. Document Fiscal Period Focus Operating lease cost Document Fiscal Year Focus Short-term lease cost Lease, Cost [Table Text Block] Document Period End Date Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019 Income Statement Location [Axis] Income Statement Location [Domain] Entity Emerging Growth Company Document Type Entity Small Business Document Information [Line Items] Document Information [Table] Accrued expenses and other current liabilities Total Service [Member] us-gaap_AreaOfRealEstateProperty Area of Real Estate Property Entity Filer Category Entity Current Reporting Status 2024 and thereafter anik_OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in and after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. Loss on impairment of intangible asset Impairment of Intangible Assets, Finite-lived Impairment Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block] Tabular disclosure of finite-lived and indefinite-lived intangible assets by major class. Stock options, SARs, RSAs, RSUs and PSUs (in shares) us-gaap_SharePrice Share Price us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Diluted weighted average common shares outstanding (in shares) Diluted shares used in the calculation of earnings per share (in shares) us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Stock-based compensation expense Entity Central Index Key Depreciation and amortization Entity Registrant Name us-gaap_InventoryRecallExpense Inventory Recall Expense Entity [Domain] Asset Class [Axis] Legal Entity [Axis] Asset Class [Domain] Statement [Table] Statement of Financial Position [Abstract] us-gaap_EarningsPerShareDiluted Net income (in dollars per share) anik_AccumulatedCurrencyTranslationAdjustment Accumulated Currency Translation Adjustment Represents the amount of the accumulated currency translation adjustment. Basic weighted average common shares outstanding (in shares) us-gaap_AmortizationOfIntangibleAssets Amortization of Intangible Assets, Total Accounts Payable and Accrued Liabilities Disclosure [Text Block] us-gaap_OperatingLeasesFutureMinimumPaymentsDue Total Diluted net income per share: us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent, Total us-gaap_AvailableForSaleSecurities Available-for-sale Securities, Total 2022 us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears us-gaap_EarningsPerShareBasic Net income (in dollars per share) 2023 us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears us-gaap_StockRepurchasedDuringPeriodShares Stock Repurchased During Period, Shares Repurchase of common stock (in shares) Basic net income per share: 2020 us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears Statement of Cash Flows [Abstract] 2021 us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears Entity Common Stock, Shares Outstanding (in shares) Statement of Stockholders' Equity [Abstract] 2019 us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent Clinical trial costs Represents accrued clinical trial costs current. Income Statement [Abstract] us-gaap_StockRepurchasedDuringPeriodValue Repurchase of common stock Research grants Represents accrued research grants current. Schedule of Accrued Liabilities [Table Text Block] US Treasury Bill Securities [Member] Investments [Domain] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Entity Shell Company Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Investment Type [Axis] Nature of Operations [Text Block] Non-cash operating lease cost us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Stock Options (in shares) us-gaap_TableTextBlock Notes Tables us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited Forfeiture of restricted stock (in shares) Issuance of common stock for equity awards (in shares) Issuance of common stock for equity awards (in shares) Selling, general & administrative Fair Value, Assets Measured on Recurring Basis [Table Text Block] Provision for doubtful accounts Issuance of common stock for equity awards Cash flows from financing activities: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Stock Options (in shares) Other long-term liabilities Orthobiologics [Member] Represents Orthobiologics. Dermal [Member] Represents Dermal. Surgical [Member] Represents Surgical. anik_OperatingLeaseWeightedAverageLeaseTerm Operating Lease, Weighted Average Lease Term Weighted average lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Raw materials us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity Deferred tax liability Finished goods Work-in-process Reported Value Measurement [Member] UNITED STATES Retained earnings Research & development Accumulated other comprehensive loss DePuy Mitek Inc [Member] The DePuy Mitek Inc. Money Market Funds [Member] Changes in operating assets and liabilities: us-gaap_StockholdersEquity Total stockholders’ equity Balance Balance us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Inventory Disclosure [Text Block] Operating lease liabilities Operating lease liabilities Schedule of Inventory, Current [Table Text Block] Class of Stock [Axis] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Present value of lease payments us-gaap_OperatingLeaseLiability Operating lease liability - current Less current portion included in Accrued expenses and other current liabilities Cash and Cash Equivalents Disclosure [Text Block] Gross Value Operating lease right-of-use assets us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Present value adjustment Deferred income taxes 2021 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2022 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2023 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive Thereafter us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive EX-101.PRE 11 anik-20190630_pre.xml XBRL PRESENTATION FILE GRAPHIC 12 morgan.jpg GRAPHIC begin 644 morgan.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.19.2
Document And Entity Information - shares
6 Months Ended
Jun. 30, 2019
Jul. 18, 2019
Document Information [Line Items]    
Entity Registrant Name Anika Therapeutics, Inc.  
Entity Central Index Key 0000898437  
Trading Symbol anik  
Current Fiscal Year End Date --12-31  
Entity Filer Category Accelerated Filer  
Entity Current Reporting Status Yes  
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Common Stock, Shares Outstanding (in shares)   13,782,928
Document Type 10-Q  
Document Period End Date Jun. 30, 2019  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Entity Shell Company false  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 69,407 $ 89,042
Investments 72,045 69,972
Accounts receivable, net of reserves of $1,089 and $1,525 at June 30, 2019 and December 31, 2018, respectively 23,073 20,775
Inventories, net 22,986 21,300
Prepaid expenses and other current assets 2,413 1,854
Total current assets 189,924 202,943
Property and equipment, net 52,960 54,111
Operating lease right-of-use assets 23,495
Other long-term assets 4,884 4,897
Intangible assets, net 8,303 9,191
Goodwill 7,798 7,851
Total assets 287,364 278,993
Current liabilities:    
Accounts payable 2,287 3,143
Accrued expenses and other current liabilities 8,101 8,146
Total current liabilities 10,388 11,289
Other long-term liabilities 373 550
Deferred tax liability 3,683 3,542
Operating lease liabilities 21,974
Commitments and contingencies (Note 13)
Stockholders’ equity:    
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 0 0
Common stock, $0.01 par value; 90,000 shares authorized, 13,785 and 14,210 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively 138 142
Additional paid-in-capital 24,329 50,763
Accumulated other comprehensive loss (5,696) (5,526)
Retained earnings 232,175 218,233
Total stockholders’ equity 250,946 263,612
Total liabilities and stockholders’ equity $ 287,364 $ 278,993
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)
shares in Thousands, $ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Accounts receivable, reserves $ 1,089 $ 1,525
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 1,250 1,250
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 90,000 90,000
Common stock, shares issued (in shares) 13,785 14,210
Common stock, shares outstanding (in shares) 13,785 14,210
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Revenue $ 30,418 $ 30,548 $ 55,141 $ 51,812
Operating expenses:        
Cost of product revenue 6,836 8,152 14,147 15,996
Research & development 4,165 4,733 8,423 9,895
Selling, general & administrative 7,502 6,417 15,174 22,507
Total operating expenses 18,503 19,302 37,744 48,398
Income from operations 11,915 11,246 17,397 3,414
Interest and other income, net 533 290 1,031 385
Income before income taxes 12,448 11,536 18,428 3,799
Provision for income taxes 3,013 1,444 4,486 394
Net income $ 9,435 $ 10,092 $ 13,942 $ 3,405
Basic net income per share:        
Net income (in dollars per share) $ 0.68 $ 0.69 $ 0.99 $ 0.23
Basic weighted average common shares outstanding (in shares) 13,916 14,652 14,054 14,666
Diluted net income per share:        
Net income (in dollars per share) $ 0.67 $ 0.68 $ 0.98 $ 0.23
Diluted weighted average common shares outstanding (in shares) 14,088 14,915 14,203 15,045
Net income $ 9,435 $ 10,092 $ 13,942 $ 3,405
Foreign currency translation adjustment 145 (951) (170) (331)
Comprehensive income 9,580 9,141 13,772 3,074
Product [Member]        
Revenue 30,413 30,542 55,130 51,800
Service [Member]        
Revenue $ 5 $ 6 $ 11 $ 12
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Common Stock Outstanding [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Balance (in shares) at Dec. 31, 2017 14,688        
Balance at Dec. 31, 2017 $ 147 $ 68,617 $ 199,511 $ (4,784) $ 263,491
Issuance of common stock for equity awards (in shares) 89        
Issuance of common stock for equity awards $ 1 511 512
Retirement of common stock for minimum tax withholdings (in shares) (32)        
Retirement of common stock for minimum tax withholdings $ (1) (1,735) (1,736)
Stock-based compensation expense 7,565 7,565
Net income (6,686) (6,686)
Other comprehensive Income (loss) 620 620
Issuance of common stock for equity awards (in shares) 89        
Balance (in shares) at Mar. 31, 2018 14,745        
Balance at Mar. 31, 2018 $ 147 74,958 192,825 (4,164) 263,766
Balance (in shares) at Dec. 31, 2017 14,688        
Balance at Dec. 31, 2017 $ 147 68,617 199,511 (4,784) 263,491
Net income         3,405
Balance (in shares) at Jun. 30, 2018 14,584        
Balance at Jun. 30, 2018 $ 146 48,656 202,916 (5,115) 246,603
Balance (in shares) at Mar. 31, 2018 14,745        
Balance at Mar. 31, 2018 $ 147 74,958 192,825 (4,164) 263,766
Issuance of common stock for equity awards (in shares) 273        
Issuance of common stock for equity awards $ 3 2,372 2,375
Stock-based compensation expense 1,322 1,322
Net income 10,091 10,092
Other comprehensive Income (loss) (951) (951)
Issuance of common stock for equity awards (in shares) 273        
Repurchase of common stock (in shares) (434)        
Repurchase of common stock $ (4) (29,996) (30,000)
Balance (in shares) at Jun. 30, 2018 14,584        
Balance at Jun. 30, 2018 $ 146 48,656 202,916 (5,115) 246,603
Balance (in shares) at Dec. 31, 2018 14,210        
Balance at Dec. 31, 2018 $ 142 50,763 218,233 (5,526) 263,612
Issuance of common stock for equity awards (in shares) 7        
Issuance of common stock for equity awards 5 5
Retirement of common stock for minimum tax withholdings (in shares) (3)        
Retirement of common stock for minimum tax withholdings (124) (124)
Stock-based compensation expense 1,386 1,386
Net income 4,507 4,507
Other comprehensive Income (loss) (315) (315)
Issuance of common stock for equity awards (in shares) 7        
Balance (in shares) at Mar. 31, 2019 14,214        
Balance at Mar. 31, 2019 $ 142 52,030 222,740 (5,841) 269,071
Balance (in shares) at Dec. 31, 2018 14,210        
Balance at Dec. 31, 2018 $ 142 50,763 218,233 (5,526) 263,612
Net income         13,942
Balance (in shares) at Jun. 30, 2019 13,785        
Balance at Jun. 30, 2019 $ 138 24,329 232,175 (5,696) 250,946
Balance (in shares) at Mar. 31, 2019 14,214        
Balance at Mar. 31, 2019 $ 142 52,030 222,740 (5,841) 269,071
Issuance of common stock for equity awards (in shares) 30        
Issuance of common stock for equity awards $ 1 851 852
Stock-based compensation expense 1,443 1,443
Net income 9,435 9,435
Other comprehensive Income (loss) 145 145
Issuance of common stock for equity awards (in shares) 30        
Forfeiture of restricted stock (in shares) (7)        
Forfeiture of restricted stock
Repurchase of common stock (in shares) (452)        
Repurchase of common stock $ (5) (29,995) (30,000)
Balance (in shares) at Jun. 30, 2019 13,785        
Balance at Jun. 30, 2019 $ 138 $ 24,329 $ 232,175 $ (5,696) $ 250,946
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Cash flows from operating activities:    
Net income $ 13,942 $ 3,405
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 2,943 2,920
Non-cash operating lease cost 591
Loss on disposal of fixed assets 721 172
Loss on impairment of intangible asset 281
Stock-based compensation expense 2,829 8,887
Deferred income taxes 120 63
Provision for doubtful accounts (6)
Provision for inventory 601 3,993
Accretion to amortized cost of investments (757)
Changes in operating assets and liabilities:    
Accounts receivable (2,293) 1,926
Inventories (3,033) (5,990)
Prepaid expenses, other current and long-term assets 356 790
Accounts payable (906) (194)
Operating lease liabilities (534)
Accrued expenses, other current and long-term liabilities (1,300) (100)
Income taxes 371 (1,803)
Net cash provided by operating activities 13,932 14,063
Cash flows from investing activities:    
Proceeds from maturity of investments 72,594 24,750
Purchase of investments (73,896) (14,000)
Purchase of property and equipment (2,131) (3,283)
Net cash (used in) provided by investing activities (3,433) 7,467
Cash flows from financing activities:    
Repurchases of common stock (30,000) (30,000)
Cash paid for tax withheld on vested restricted stock awards (125) (1,735)
Proceeds from exercise of equity awards 6 2,886
Net cash used in financing activities (30,119) (28,849)
Exchange rate impact on cash (15) 110
Decrease in cash and cash equivalents (19,635) (7,209)
Cash and cash equivalents at beginning of period 89,042 133,256
Cash and cash equivalents at end of period 69,407 126,047
Supplemental disclosure of cash flow information:    
Right-of-use assets obtained in exchange for operating lease liabilities as of January 1, 2019 24,110
Non-cash activities:    
Purchases of property and equipment included in accounts payable and accrued expenses $ 211 $ 462
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.19.2
Note 1 - Nature of Business
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Nature of Operations [Text Block]
1.
Nature of Business
 
Anika Therapeutics, Inc. (the “Company”) is a global, integrated orthopedic and regenerative medicines company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over
two
decades of global expertise developing, manufacturing, and commercializing products based on its proprietary Hyaluronic Acid (“HA”) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, viscosupplements which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
 
The Company is subject to risks common to companies in the biotechnology and medical device industries including, but
not
limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.19.2
Note 2 - Basis of Presentation
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Business Description and Basis of Presentation [Text Block]
2.
 
Basis of Presentation
 
The accompanying unaudited condensed consolidated financial statements and related notes have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”). The financial statements include the accounts of Anika Therapeutics, Inc. and its subsidiaries. Inter-company transactions and balances have been eliminated. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with US GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The
December 31, 2018
balances reported herein are derived from the audited consolidated financial statements. In the opinion of management, these unaudited condensed consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary to fairly state the condensed consolidated financial statements.
 
The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with the Company’s annual financial statements filed with its Annual Report on Form 
10
-K for the year ended
December 31, 2018.
The results of operations for the
three
- and
six
-month periods ended
June 30, 2019
are
not
necessarily indicative of the results to be expected for the year ended
December 
31,
2019.
 
Recent Accounting Pronouncements
 
In
February 2016,
the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)
No.
2016
-
02,
Leases
, which, among other things, results in the recognition of lease assets and lease liabilities on the Company’s balance sheets for virtually all leases. ASU
2016
-
02
supersedes most previous lease accounting guidance and is effective for interim and annual periods beginning after
December 15, 2018.
The Company adopted the new guidance as of
January 1, 2019
using the modified retrospective adoption method, which did
not
require restatement of prior periods. The adoption of this standard did
not
have a material impact on the condensed consolidated statement of operations. See Note
12
for further details.
 
In
August 2018,
the FASB issued ASU
No.
2018
-
15,
 
Intangibles – Goodwill and Other – Internal-Use Software (Subtopic
350
-
40
)
, which amends ASU
No.
2015
-
05,
 
Customers Accounting for Fees in a Cloud Computing Agreement
, to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. The most significant change will align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software and hosting arrangements that include an internal-use software license. Accordingly, the amendments in ASU
2018
-
15
require an entity in a hosting arrangement that is a service contract to follow the guidance in Subtopic
350
-
40
to determine which implementation costs to capitalize as assets related to the service contract and which costs to expense. ASU
2018
-
15
is effective for fiscal years and interim periods beginning after
December 15, 2019.
Early adoption is permitted, including adoption in any interim period. The Company is assessing ASU
2018
-
15
and the impact that adopting this new accounting standard will have on its consolidated financial statements and footnote disclosures. 
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.19.2
Note 3 - Revenue
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]
3.
 
Revenue
 
The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due and
may
require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. As of
June 30, 2019,
deferred revenue was
$50
thousand.
  
The Company has agreements with DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc. (“Mitek”) that include the grant of certain licenses, performance of development services, and supply of product. Revenues from the agreements with Mitek represent
68%
and
70%
of total Company revenues for the
three
- and
six
-month periods ended
June 30, 2019,
respectively. The Company has agreements with other customers that
may
include the delivery of a license and supply of product.
 
Product revenue by product group was as follows: 
 
    Three Months Ended June 30,   Six Months Ended June 30,
    2019   2018   2019   2018
Orthobiologics   $
26,462
    $
26,192
    $
48,210
    $
45,681
 
Surgical    
2,101
     
1,263
     
3,493
     
2,509
 
Dermal    
444
     
623
     
573
     
83
 
Other    
1,406
     
2,464
     
2,854
     
3,527
 
Product Revenue   $
30,413
    $
30,542
    $
55,130
    $
51,800
 
 
Total revenue by geographic location was as follows:
 
    Three Months Ended June 30,
    2019   2018
    Total
Revenue
  Percentage of
Revenue
  Total
Revenue
  Percentage of
Revenue
Geographic Location:                                
United States   $
22,937
     
76
%   $
24,773
     
81
%
Europe    
4,927
     
16
%    
3,498
     
11
%
Other    
2,554
     
8
%    
2,277
     
8
%
Total Revenue   $
30,418
     
100
%   $
30,548
     
100
%
 
    Six Months Ended June 30,
    2019   2018
    Total
Revenue
  Percentage of
Revenue
  Total
Revenue
  Percentage of
Revenue
Geographic Location:                                
United States   $
43,026
     
78
%   $
41,682
     
81
%
Europe    
7,454
     
14
%    
5,889
     
11
%
Other    
4,661
     
8
%    
4,241
     
8
%
Total Revenue   $
55,141
     
100
%   $
51,812
     
100
%
 
On
May 2, 2018,
the Company publicly disclosed a voluntary recall of certain lots of its HYAFF-based products, HYALOFAST, HYALOGRAFT C, and HYALOMATRIX. The Company initiated the recall after internal quality testing, which indicated that the products were at risk of
not
maintaining certain measures throughout their entire shelf life. While there was
no
indication of any safety or efficacy issue related to the products at the time, the Company removed the products from the field as a precautionary measure. During the
three
-month period ended
March 31, 2018,
the Company recorded a revenue reserve for this voluntary recall of
$1.1
million of which
$0.9
million was related to revenue recorded in prior periods. The adjustments related to the initial revenue reserve subsequent to
June 30, 2018
were immaterial. The revenue reserves impacted Dermal and Orthobiologics product groups and all geographic locations. Recall recovery activities were completed during the
fourth
quarter of
2018,
and product shipments resumed in
December 2018.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.19.2
Note 4 - Investments
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Cash and Cash Equivalents Disclosure [Text Block]
4.
 
Investments
 
All of the Company’s investments are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income, net of related income taxes. The Company held investments, including U.S. treasury bills totaling
$72.0
million and
$70.0
million as of
June 30, 2019
and
December 31, 2018,
respectively. Unrealized gains and losses as well as the associated tax impact on the Company’s available-for-sale securities were immaterial as of
June 30, 2019
and
December 31, 2018.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.19.2
Note 5 - Fair Value Measurements
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Fair Value Disclosures [Text Block]
5.
 
Fair Value Measurements
 
The Company’s investments are all classified within Level
1
of the fair value hierarchy and are valued based on quoted prices in active markets. For cash and cash equivalents, current receivables, accounts payable, and interest accrual, the carrying amounts approximate fair value because of the short maturity of these instruments, and therefore fair value information is
not
included in the table below. 
 
The fair value hierarchy of the Company's cash equivalents and investments at fair value was as follows:
 
        Fair Value Measurements at Reporting Date Using    
 
 
June 30, 2019
 
Quoted Prices in
Active Markets
for Identical Assets 
(Level 1)
 
Significant Other
Observable Inputs 
(Level 2)
 
Significant 
Unobservable Inputs 
(Level 3)
 
Amortized Cost
Cash equivalents:                                        
Money market funds   $
1,305
    $
1,305
    $
-
    $
-
    $
1,305
 
                                         
Investments:                                        
U.S. treasury bills   $
72,045
    $
72,045
    $
-
    $
-
    $
72,032
 
 
 
        Fair Value Measurements at Reporting Date Using    
 
 
December 31, 2018
 
Quoted Prices in
Active Markets
for Identical Assets 
(Level 1)
 
Significant Other
Observable Inputs 
(Level 2)
 
Significant 
Unobservable Inputs 
(Level 3)
 
Amortized Cost
Cash equivalents:                                        
Money market funds   $
4,984
    $
4,984
    $
-
    $
-
    $
4,984
 
                                         
Investments:                                        
U.S. treasury bills   $
69,972
    $
69,972
    $
-
    $
-
    $
69,972
 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.19.2
Note 6 - Equity Incentive Plan
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]
6.
Equity Incentive Plan
 
The Company estimates the fair value of stock options and stock appreciation rights (“SARs”) using the Black-Scholes valuation model. Fair value of restricted stock awards (“RSAs”) and restricted stock units (“RSUs”) are measured by the grant-date price of the Company’s shares. Fair value of performance restricted stock units (“PSUs”) is measured by the grant-date price of the Company’s shares with corresponding compensation cost recognized over the requisite service period. Compensation cost is recognized based on the estimated probabilities of achieving the performance goals. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related compensation cost that will be recorded in the period of the change. If the performance targets are
not
achieved,
no
compensation cost is recognized, and any previously recognized compensation cost is reversed. 
 
The fair value of each stock option award during the
six
-month periods ended
June 30, 2019
and
2018
was estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:
 
    Six Months Ended June 30,
    2019   2018
Risk free interest rate  
2.18%
-
2.54%
 
2.15%
-
2.75%
Expected volatility  
44.05%
-
44.72%
 
37.12%
-
40.81%
Expected life (years)  
 
3.5
 
 
4.0
-
4.5
Expected dividend yield  
 
0.00%
 
 
 
0.00%
 
 
The Company recorded
$1.4
million and
$1.3
million of stock-based compensation expense for the
three
-month periods ended
June 30, 2019
and
2018,
respectively. The Company recorded
$2.8
million and
$8.9
million of stock-based compensation expense for the
six
-month periods ended
June 30, 2019
and
2018,
respectively. Upon the retirement of the Company’s former Chief Executive Officer on
March 9, 2018,
all of his outstanding stock-based compensation awards vested in full and became exercisable in accordance with their terms, resulting in a
one
-time expense of
$6.2
million that was fully recognized during the
three
-month period ended
March 31, 2018.
  
The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees as follows:
 
    Three Months Ended June 30,   Six Months Ended June 30,
    2019   2018   2019   2018
Cost of product revenue   $
82
    $
(28
)   $
174
    $
(244
)
Research & development    
91
     
241
     
268
     
451
 
Selling, general & administrative    
1,270
     
1,109
     
2,387
     
8,680
 
Total stock-based compensation expense   $
1,443
    $
1,322
    $
2,829
    $
8,887
 
 
On
June 18, 2019,
the Company’s stockholders approved an amendment to the Anika Therapeutics, Inc.
2017
Omnibus Incentive Plan (the
“2017
Plan”). The amendment increased the number of shares of common stock reserved under the
2017
Plan by
1,500,000
from
1,200,000
to
2,700,000.
Additionally, the amendment provided greater clarity with respect to the sections governing minimum vesting and tax withholding to facilitate plan administration.
No
other provisions of the
2017
Plan were amended.
 
The following table sets forth share information for stock-based compensation awards granted and exercised during the
three
and
six
-month periods ended
June 30, 2019
and
2018:
 
    Three Months Ended June 30,   Six Months Ended June 30,
    2019   2018   2019   2018
Grants:                
Stock Options    
27,325
     
17,500
     
131,617
     
209,800
 
RSAs    
-
     
-
     
-
     
64,578
 
RSUs    
8,000
     
-
     
173,507
     
8,130
 
PSUs    
-
     
-
     
114,500
     
-
 
Exercises:                                
Stock Options    
22,400
     
273,123
     
22,900
     
284,548
 
SARs    
-
     
-
     
-
     
-
 
 
 During the
three
- and
six
-month periods ended
June 30, 2019,
the Company granted stock-based compensation awards in the form of stock options, PSUs and RSUs to employees and RSUs to non-employee directors, the majority of which become exercisable or vest ratably over a
three
-year period. The PSUs granted to employees contained performance conditions with business and financial targets. The business target, amounting to
30%
of the total performance conditions, will be measured based on achievement in the
2019
fiscal year, while the financial targets, amounting to
70%
of the total performance conditions, will ultimately be measured with respect to the Company’s operating results in the
2021
fiscal year. The Company recorded
$0.3
million and
$0.4
million of stock-based compensation expense associated with PSUs for the
three
- and
six
-month periods ended
June 30, 2019,
respectively.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.19.2
Note 7 - Earnings Per Share ("EPS")
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Earnings Per Share [Text Block]
7.
 
Earnings Per Share (“EPS”)
 
Basic EPS is calculated by dividing net income by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are
not
considered outstanding for purposes of calculating basic earnings per share. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding stock options, SARs, RSAs, RSUs, and PSUs using the treasury stock method.
 
The following table provides share information used in the calculation of the Company's basic and diluted earnings per share (in thousands):
 
    Three Months Ended June 30,   Six Months Ended June 30,
    2019   2018   2019   2018
Shares used in the calculation of basic earnings per share    
13,916
     
14,652
     
14,054
     
14,666
 
Effect of dilutive securities:                                
Stock options, SARs, RSAs, RSUs and PSUs    
172
     
263
     
149
     
379
 
Diluted shares used in the calculation of earnings per share    
14,088
     
14,915
     
14,203
     
15,045
 
 
Stock options of
1.0
million and
0.7
million shares were outstanding for the
three
-month periods ended
June 30, 2019
and
2018,
respectively, and were
not
included in the computation of diluted EPS because the awards’ impact on EPS would have been anti-dilutive. Stock options of
1.0
million and
0.6
million shares were outstanding for the
six
-month periods ended
June 30, 2019
and
2018
and were
not
included in the computation of diluted EPS because the awards’ impact on EPS would have been anti-dilutive. 
On
May 2, 2019,
the Company announced that its Board of Directors had authorized the repurchase of up to
$50.0
million shares of the Company’s common stock with
$30.0
million to be repurchased through an accelerated share repurchase program and up to
$20.0
million to be potentially repurchased on the open market from time-to-time. Through
June 30, 2019,
no
open market repurchases had been executed. On
May 7, 2019,
the Company entered into an accelerated share repurchase agreement with Morgan Stanley & Co. LLC (“Morgan Stanley”) pursuant to a Fixed Dollar Accelerated Share Repurchase Transaction (“ASR Agreement") to purchase
$30.0
million shares of the Company’s common stock. Pursuant to the terms of the ASR Agreement, the Company delivered
$30.0
million cash to Morgan Stanley and received an initial delivery of
0.5
million shares of the Company’s common stock on
May 8, 2019
based on a closing market price of
$39.85
and the applicable contractual discount. This was approximately
60%
of the then estimated total number of shares expected to be repurchased under the ASR Agreement. These shares were restored to the status of authorized but unissued shares. The initial delivery of shares resulted in an immediate reduction of the number of outstanding shares used to calculate the weighted-average of shares of the Company’s common stock outstanding for basic and diluted net income per share on the effective date of the ASR Agreement.
 
As of
June 30, 2019,
the Company has approximately
$12.0
million remaining under the ASR Agreement, which was recorded as an equity forward sale contract and was included in additional paid-in capital in stockholders’ equity in the condensed consolidated balance sheet as it met the criteria for equity accounting. Pursuant to the terms of the ASR Agreement, the final number of shares and the average purchase price will be determined at the end of the applicable purchase period, which is expected to occur in the
first
quarter of
2020.
Upon settlement of the ASR Agreement, the Company
may
receive additional shares or be required to either pay additional cash or deliver shares of its common stock (at its option) to Morgan Stanley, based on the forward price. If the ASR Agreement had been settled as of
June 30, 2019,
based on the volume-weighted average price since the effective date of the ASR Agreement, Morgan Stanley would have been required to deliver approximately
0.3
million additional shares to the Company’s common stock. However, the Company cannot predict the final number of shares to be received, or delivered, by it under the ASR Agreement. These shares are
not
included in the calculation of diluted weighted-average of shares of common stock outstanding during the period because the effect is anti-dilutive.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.19.2
Note 8 - Inventories
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Inventory Disclosure [Text Block]
8.
Inventories
 
Inventories consist of the following:
 
    June 30,
2019
  December 31,
2018
Raw materials   $
12,381
    $
13,688
 
Work-in-process    
6,399
     
4,626
 
Finished goods    
8,747
     
6,819
 
Total   $
27,527
    $
25,133
 
                 
Inventories   $
22,986
    $
21,300
 
Other long-term assets   $
4,541
    $
3,833
 
 
Other long-term assets include
$4.5
million and
$3.8
million of inventory expected to remain on hand beyond
one
year as of
June 30, 2019
and
December 31, 2018,
respectively. 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.19.2
Note 9 - Intangible Assets
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]
9.
Intangible Assets
 
Intangible assets as of
June 30, 2019
and
December 31, 2018
consisted of the following:
 
        June 30, 2019   December 31, 2018    
    Gross Value   Accumulated
Currency
Translation
Adjustment
  Impairment   Accumulated
Amortization
  Net
Book
Value
  Accumulated
Currency
Translation
Adjustment
  Accumulated
Amortization
  Net
Book
Value
  Useful
Life
Developed technology   $
17,100
    $
(2,864
)   $
(281
)   $
(9,189
)   $
4,766
    $
(2,824
)   $
(8,672
)   $
5,604
     
15
 
In-process research & development    
4,406
     
(1,191
)    
-
     
-
     
3,215
     
(1,168
)    
-
     
3,238
     
Indefinite
 
Distributor relationships    
4,700
     
(415
)    
-
     
(4,285
)    
-
     
(415
)    
(4,285
)    
-
     
5
 
Patents    
1,000
     
(172
)    
-
     
(506
)    
322
     
(169
)    
(482
)    
349
     
16
 
Elevess trade name    
1,000
     
-
     
-
     
(1,000
)    
-
     
-
     
(1,000
)    
-
     
9
 
Total   $
28,206
    $
(4,642
)   $
(281
)   $
(14,980
)   $
8,303
    $
(4,576
)   $
(14,439
)   $
9,191
     
 
 
 
 
The aggregate amortization expense related to intangible assets was
$0.2
million and
0.3
million for the
three
-month periods ended
June 30, 2019
and
2018,
respectively. The aggregate amortization expense related to intangible assets was
$0.5
million for the
six
-month periods ended
June 30, 2019
and
2018.
 
The Company recorded a
$0.3
million impairment charge for the HYALOSPINE developed technology asset in the
three
-month period ended
March 31, 2019.
HYALOSPINE was an adhesion prevention gel for use after spinal surgery and received initial CE Mark approval in
January 2015.
In
March 2019,
the Company made the decision
not
to renew the CE Mark as the product was
not
aligned with the Company’s core strategic focus. As a result, an impairment charge was recorded. This amount is included in selling, general & administrative expenses on the Company’s condensed consolidated statements of operations. 
 
Through
June 30, 2019,
except as set forth in this paragraph, there have
not
been any other events or changes in circumstances that indicate that the carrying value of the other acquired intangible assets
may
not
be recoverable. The Company was notified by the distributor of MEROGEL INJECTIBLE that it would
not
continue to order the product from the Company or market the product. As a result, the depreciation schedule of the remaining
$0.1
million of net book value was accelerated. The Company continues to monitor and evaluate the financial performance of its business including the impact of general economic conditions, to assess the potential for the fair value of the reporting unit to decline below its recorded amount. 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.19.2
Note 10 - Goodwill
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Goodwill Disclosure [Text Block]
10.
Goodwill
 
The Company completed its annual impairment review as of
November 30, 2018
and concluded that
no
impairment in the carrying value of goodwill exists as of that date. Through
June 30, 2019,
there have been
no
events or changes in circumstances that indicate that the carrying value of goodwill
may
not
be recoverable. Changes in the carrying value of goodwill were as follows:
 
    June 30,
2019
Balance at January 1, 2019   $
7,851
 
Effect of foreign currency adjustments    
(53
)
Balance at June 30, 2019   $
7,798
 
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.19.2
Note 11 - Accrued Expenses
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]
11.
Accrued Expenses
 
Accrued expenses consist of the following:
 
 
 
June 30,
2019
 
December 31,
2018
Compensation and related expenses   $
3,584
    $
4,446
 
Professional fees    
1,609
     
1,989
 
Operating lease liability - current    
1,101
     
-
 
Income taxes payable    
757
     
385
 
Research grants    
398
     
400
 
Clinical trial costs    
320
     
577
 
Other    
332
     
349
 
Total   $
8,101
    $
8,146
 
 
Included in Compensation and related expenses as of
June 30, 2019
are the accrued and unpaid costs related to the retirement of the Company’s former Chief Executive Officer as of
March 9, 2018.
On the same date, the Company and the former Chief Executive Officer entered into a release agreement related to terms in his employment agreement. Under the terms of these agreements, the former Chief Executive Officer is entitled to receive from the Company, as a result of his retirement, aggregate benefits of
$1.7
million over the
18
-month period subsequent to
March 9, 2018,
among other benefits. The unpaid amounts under these agreements are included in accrued expenses. As more fully described in Note
6,
all of the former Chief Executive Officer’s outstanding equity awards vested in full and became exercisable upon his retirement. The lease liability as of
June 30, 2019
is the result of the Company adopting ASU
2016
-
02
as of
January 1, 2019
as more fully described in Note
12.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.19.2
Note 12 - Operating Leases
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]
12.
Operating Leases
 
The Company adopted ASU
2016
-
02
as of
January 1, 2019
using the modified retrospective adoption method, which did
not
require it to restate prior periods, and there was
no
impact on retained earnings. The transition guidance associated with ASU
2016
-
02
also permitted certain practical expedients. The Company has elected the “package of
3”
practical expedients permitted under the transition guidance which eliminates the requirements to reassess prior conclusions about lease identification, lease classification, and initial direct costs. The Company also adopted the practical expedient to use hindsight to determine the lease term. The Company adopted an accounting policy which provides that leases with an initial term of
12
months or less and
no
purchase option the Company is reasonably certain of exercising will
not
be included within the lease right-of-use assets and lease liabilities on its consolidated balance sheet. The Company elected an accounting policy to combine the non-lease components (which include common area maintenance, taxes and insurance) with the related lease component. The Company elected this practical expedient to all asset classes upon the adoption of ASU
2016
-
02.
 
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. Leases with a term greater than
one
year are recognized on the balance sheet as right-of-use assets, lease liabilities, and, if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Lease liabilities and the corresponding right-of-use assets are recorded based on the present values of lease payments over the lease terms. The interest rate implicit in lease contracts is typically
not
readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do
not
depend on a rate or index are
not
included in the lease liability and are recognized as incurred. Lease contracts do
not
include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to the right-of-use assets
may
be required for items such as initial direct costs paid, incentives received or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability by using revised inputs as of the reassessment date, and adjust the right-of-use asset.
 
The Company has
two
primary leases, which are its real estate leases in Bedford, Massachusetts and Padova, Italy. The Company leases approximately
134,000
square feet of administrative, research and development, and manufacturing space in Bedford, Massachusetts (the “Bedford lease”), and approximately
33,000
square feet of office, research and development, training, and warehousing space in Padova, Italy (the “Padova lease”). The current term of the Bedford lease extends to
2022
with several lease renewal options into
2038,
and the current term of the Padova lease extends to
2032,
with a right to terminate at the Company’s option in
2026
without penalty.
 
The Company identified and assessed significant assumptions in recognizing the right-of-use asset and lease liability on
January 1, 2019
as follows:
 
Incremental borrowing rate
. The Company derives its incremental borrowing rate from information available at the lease commencement date in determining the present value of lease payments. The incremental borrowing rate represents a collateralized rate of interest the Company would have to pay to borrow over a similar term an amount equal to the lease payments in a similar economic environment. The Company’s lease agreements do
not
provide implicit rates. As the Company did
not
have any external borrowings at the transition date with comparable terms to its lease agreements, the Company estimated its incremental borrowing rate based on its credit quality, line of credit agreement and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of the lease. The weighted average discount rate at
June 30, 2019
is
4.1%.
 
Lease term.
The Company applied the hindsight practical expedient and as a result the lease term for the Bedford lease was determined to include all lease renewal options. There were
no
changes to the lease terms for its other leases. For the Padova lease, the Company considered the termination option when determining the lease term. The weighted average lease term at
June 30, 2019
is
17.3
years.
 
The components of lease expense and other information are as follows: 
 
    For the three months ended
June 30, 2019
  For the six months ended
June 30, 2019
Lease cost                
Operating lease cost   $
521
    $
1,043
 
Short-term lease cost    
4
     
6
 
Variable lease cost    
60
     
112
 
Total lease cost   $
585
    $
1,161
 
                 
Other information                
Operating cash flows from operating leases   $
497
    $
994
 
  
 
Future commitments due under these lease agreements as of
June 30, 2019
are as follows:
 
    Operating Lease Obligation As Of  
Years ending December 31,   June 30, 2019  
2019   $
994
   
2020    
2,025
   
2021    
2,024
   
2022    
1,981
   
2023    
1,965
   
Thereafter    
23,530
   
Present value adjustment    
(9,444
)  
Present value of lease payments    
23,075
   
Less current portion included in Accrued expenses and other current liabilities    
(1,101
)  
Operating lease liabilities   $
21,974
   
 
The following table summarizes the future minimum payments due for the Company’s operating leases under the prior lease guidance without the hindsight practical expedient for each of the next
five
years and the total thereafter as of
December 31, 2018:
 
2019   $
1,879
 
2020    
1,917
 
2021    
1,924
 
2022    
1,672
 
2023    
414
 
2024 and thereafter    
897
 
Total   $
8,703
 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.19.2
Note 13 - Commitments and Contingencies
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]
13.
Commitments and Contingencies 
 
In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company
may
also warrant that the products it manufactures do
not
infringe, violate, or breach any U.S. or international patent or intellectual property right, trade secret, or other proprietary information of any
third
party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company’s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had
no
accrued warranties as of
June 30, 2019
or
December 31, 2018
and has
no
history of claims paid.
 
The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does
not
expect the resolution of these occasional legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.19.2
Note 14 - Income Taxes
6 Months Ended
Jun. 30, 2019
Notes to Financial Statements  
Income Tax Disclosure [Text Block]
14.
Income Taxes
 
The provision for income taxes was
$3.0
million and
$4.5
million for the
three
- and
six
-month periods ended
June 30, 2019,
based on effective tax rates of
24.2%
and
24.3%,
respectively. The provision for income taxes was
$1.4
million and
$0.4
million for the
three
- and
six
-month periods ended
June 30, 2018,
based on effective tax rates of
12.5%
and
10.4%,
respectively. The net increase in the effective tax rate for the
three
- and
six
- month periods ended
June 30, 2019,
as compared to the same periods in
2018,
was primarily due to the limitation on the deductibility of executive compensation for accelerated stock vesting upon the retirement of the Company’s former Chief Executive Officer on
March 9, 2018
in addition to the windfall tax benefit the Company realized in
June 2018
related to exercises of employee equity awards. The Company realized an immaterial shortfall for the
three
- and
six
-month periods ended
June 30, 2019.
 
The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in Italy.  The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate.
 
In connection with the preparation of the financial statements, the Company assesses whether it was more likely than
not
that it would be able to utilize, in future periods, the net deferred tax assets associated with its net operating loss carry-forward. The Company has concluded that the positive evidence outweighs the negative evidence and, thus, the deferred tax assets
not
otherwise subject to a valuation allowance are realizable on a “more likely than
not”
basis. As such, the Company did
not
record a valuation allowance as of
June 30, 2019
or
December 31, 2018.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.19.2
Note 3 - Revenue (Tables)
6 Months Ended
Jun. 30, 2019
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
    Three Months Ended June 30,   Six Months Ended June 30,
    2019   2018   2019   2018
Orthobiologics   $
26,462
    $
26,192
    $
48,210
    $
45,681
 
Surgical    
2,101
     
1,263
     
3,493
     
2,509
 
Dermal    
444
     
623
     
573
     
83
 
Other    
1,406
     
2,464
     
2,854
     
3,527
 
Product Revenue   $
30,413
    $
30,542
    $
55,130
    $
51,800
 
Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]
    Three Months Ended June 30,
    2019   2018
    Total
Revenue
  Percentage of
Revenue
  Total
Revenue
  Percentage of
Revenue
Geographic Location:                                
United States   $
22,937
     
76
%   $
24,773
     
81
%
Europe    
4,927
     
16
%    
3,498
     
11
%
Other    
2,554
     
8
%    
2,277
     
8
%
Total Revenue   $
30,418
     
100
%   $
30,548
     
100
%
    Six Months Ended June 30,
    2019   2018
    Total
Revenue
  Percentage of
Revenue
  Total
Revenue
  Percentage of
Revenue
Geographic Location:                                
United States   $
43,026
     
78
%   $
41,682
     
81
%
Europe    
7,454
     
14
%    
5,889
     
11
%
Other    
4,661
     
8
%    
4,241
     
8
%
Total Revenue   $
55,141
     
100
%   $
51,812
     
100
%
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.19.2
Note 5 - Fair Value Measurements (Tables)
6 Months Ended
Jun. 30, 2019
Notes Tables  
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
        Fair Value Measurements at Reporting Date Using    
 
 
June 30, 2019
 
Quoted Prices in
Active Markets
for Identical Assets 
(Level 1)
 
Significant Other
Observable Inputs 
(Level 2)
 
Significant 
Unobservable Inputs 
(Level 3)
 
Amortized Cost
Cash equivalents:                                        
Money market funds   $
1,305
    $
1,305
    $
-
    $
-
    $
1,305
 
                                         
Investments:                                        
U.S. treasury bills   $
72,045
    $
72,045
    $
-
    $
-
    $
72,032
 
        Fair Value Measurements at Reporting Date Using    
 
 
December 31, 2018
 
Quoted Prices in
Active Markets
for Identical Assets 
(Level 1)
 
Significant Other
Observable Inputs 
(Level 2)
 
Significant 
Unobservable Inputs 
(Level 3)
 
Amortized Cost
Cash equivalents:                                        
Money market funds   $
4,984
    $
4,984
    $
-
    $
-
    $
4,984
 
                                         
Investments:                                        
U.S. treasury bills   $
69,972
    $
69,972
    $
-
    $
-
    $
69,972
 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.19.2
Note 6 - Equity Incentive Plan (Tables)
6 Months Ended
Jun. 30, 2019
Notes Tables  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
    Six Months Ended June 30,
    2019   2018
Risk free interest rate  
2.18%
-
2.54%
 
2.15%
-
2.75%
Expected volatility  
44.05%
-
44.72%
 
37.12%
-
40.81%
Expected life (years)  
 
3.5
 
 
4.0
-
4.5
Expected dividend yield  
 
0.00%
 
 
 
0.00%
 
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
    Three Months Ended June 30,   Six Months Ended June 30,
    2019   2018   2019   2018
Cost of product revenue   $
82
    $
(28
)   $
174
    $
(244
)
Research & development    
91
     
241
     
268
     
451
 
Selling, general & administrative    
1,270
     
1,109
     
2,387
     
8,680
 
Total stock-based compensation expense   $
1,443
    $
1,322
    $
2,829
    $
8,887
 
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]
    Three Months Ended June 30,   Six Months Ended June 30,
    2019   2018   2019   2018
Grants:                
Stock Options    
27,325
     
17,500
     
131,617
     
209,800
 
RSAs    
-
     
-
     
-
     
64,578
 
RSUs    
8,000
     
-
     
173,507
     
8,130
 
PSUs    
-
     
-
     
114,500
     
-
 
Exercises:                                
Stock Options    
22,400
     
273,123
     
22,900
     
284,548
 
SARs    
-
     
-
     
-
     
-
 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.19.2
Note 7 - Earnings Per Share ("EPS") (Tables)
6 Months Ended
Jun. 30, 2019
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
    Three Months Ended June 30,   Six Months Ended June 30,
    2019   2018   2019   2018
Shares used in the calculation of basic earnings per share    
13,916
     
14,652
     
14,054
     
14,666
 
Effect of dilutive securities:                                
Stock options, SARs, RSAs, RSUs and PSUs    
172
     
263
     
149
     
379
 
Diluted shares used in the calculation of earnings per share    
14,088
     
14,915
     
14,203
     
15,045
 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.19.2
Note 8 - Inventories (Tables)
6 Months Ended
Jun. 30, 2019
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
    June 30,
2019
  December 31,
2018
Raw materials   $
12,381
    $
13,688
 
Work-in-process    
6,399
     
4,626
 
Finished goods    
8,747
     
6,819
 
Total   $
27,527
    $
25,133
 
                 
Inventories   $
22,986
    $
21,300
 
Other long-term assets   $
4,541
    $
3,833
 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.19.2
Note 9 - Intangible Assets (Tables)
6 Months Ended
Jun. 30, 2019
Notes Tables  
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]
        June 30, 2019   December 31, 2018    
    Gross Value   Accumulated
Currency
Translation
Adjustment
  Impairment   Accumulated
Amortization
  Net
Book
Value
  Accumulated
Currency
Translation
Adjustment
  Accumulated
Amortization
  Net
Book
Value
  Useful
Life
Developed technology   $
17,100
    $
(2,864
)   $
(281
)   $
(9,189
)   $
4,766
    $
(2,824
)   $
(8,672
)   $
5,604
     
15
 
In-process research & development    
4,406
     
(1,191
)    
-
     
-
     
3,215
     
(1,168
)    
-
     
3,238
     
Indefinite
 
Distributor relationships    
4,700
     
(415
)    
-
     
(4,285
)    
-
     
(415
)    
(4,285
)    
-
     
5
 
Patents    
1,000
     
(172
)    
-
     
(506
)    
322
     
(169
)    
(482
)    
349
     
16
 
Elevess trade name    
1,000
     
-
     
-
     
(1,000
)    
-
     
-
     
(1,000
)    
-
     
9
 
Total   $
28,206
    $
(4,642
)   $
(281
)   $
(14,980
)   $
8,303
    $
(4,576
)   $
(14,439
)   $
9,191
     
 
 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.19.2
Note 10 - Goodwill (Tables)
6 Months Ended
Jun. 30, 2019
Notes Tables  
Schedule of Goodwill [Table Text Block]
    June 30,
2019
Balance at January 1, 2019   $
7,851
 
Effect of foreign currency adjustments    
(53
)
Balance at June 30, 2019   $
7,798
 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.19.2
Note 11 - Accrued Expenses (Tables)
6 Months Ended
Jun. 30, 2019
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
 
 
June 30,
2019
 
December 31,
2018
Compensation and related expenses   $
3,584
    $
4,446
 
Professional fees    
1,609
     
1,989
 
Operating lease liability - current    
1,101
     
-
 
Income taxes payable    
757
     
385
 
Research grants    
398
     
400
 
Clinical trial costs    
320
     
577
 
Other    
332
     
349
 
Total   $
8,101
    $
8,146
 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.19.2
Note 12 - Operating Leases (Tables)
6 Months Ended
Jun. 30, 2019
Notes Tables  
Lease, Cost [Table Text Block]
    For the three months ended
June 30, 2019
  For the six months ended
June 30, 2019
Lease cost                
Operating lease cost   $
521
    $
1,043
 
Short-term lease cost    
4
     
6
 
Variable lease cost    
60
     
112
 
Total lease cost   $
585
    $
1,161
 
                 
Other information                
Operating cash flows from operating leases   $
497
    $
994
 
Lessee, Operating Lease, Liability, Maturity [Table Text Block]
    Operating Lease Obligation As Of  
Years ending December 31,   June 30, 2019  
2019   $
994
   
2020    
2,025
   
2021    
2,024
   
2022    
1,981
   
2023    
1,965
   
Thereafter    
23,530
   
Present value adjustment    
(9,444
)  
Present value of lease payments    
23,075
   
Less current portion included in Accrued expenses and other current liabilities    
(1,101
)  
Operating lease liabilities   $
21,974
   
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
2019   $
1,879
 
2020    
1,917
 
2021    
1,924
 
2022    
1,672
 
2023    
414
 
2024 and thereafter    
897
 
Total   $
8,703
 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.19.2
Note 3 - Revenue (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2019
Mar. 31, 2018
Jun. 30, 2019
Dec. 31, 2017
Contract with Customer, Liability, Total $ 50   $ 50  
Inventory Recall Expense   $ 1,100   $ 900
DePuy Mitek Inc [Member]        
Revenues From Agreements as Percent of Total Revenue 68.00%   70.00%  
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.19.2
Note 3 - Revenue - Product Revenue by Product Group (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Revenue $ 30,418 $ 30,548 $ 55,141 $ 51,812
Orthobiologics [Member]        
Revenue 26,462 26,192 48,210 45,681
Surgical [Member]        
Revenue 2,101 1,263 3,493 2,509
Dermal [Member]        
Revenue 444 623 573 83
Manufactured Product, Other [Member]        
Revenue 1,406 2,464 2,854 3,527
Product [Member]        
Revenue $ 30,413 $ 30,542 $ 55,130 $ 51,800
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.19.2
Note 3 - Revenue - Total Revenue by Geographic Location (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Revenue $ 30,418 $ 30,548 $ 55,141 $ 51,812
Percentage of Revenue 100.00% 100.00% 100.00% 100.00%
UNITED STATES        
Revenue $ 22,937 $ 24,773 $ 43,026 $ 41,682
Percentage of Revenue 76.00% 81.00% 78.00% 81.00%
Europe [Member]        
Revenue $ 4,927 $ 3,498 $ 7,454 $ 5,889
Percentage of Revenue 16.00% 11.00% 14.00% 11.00%
Other Location [Member]        
Revenue $ 2,554 $ 2,277 $ 4,661 $ 4,241
Percentage of Revenue 8.00% 8.00% 8.00% 8.00%
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.19.2
Note 4 - Investments (Details Textual) - USD ($)
$ in Millions
Jun. 30, 2019
Dec. 31, 2018
US Treasury Bill Securities [Member]    
Available-for-sale Securities, Total $ 72 $ 70
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.19.2
Note 5 - Fair Value Measurements - Fair Value of Financial Instruments (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Investments $ 72,045 $ 69,972
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]    
Cash equivalents 1,305 4,984
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]    
Cash equivalents 1,305 4,984
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]    
Cash equivalents
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]    
Cash equivalents
Money Market Funds [Member] | Reported Value Measurement [Member]    
Cash equivalents 1,305 4,984
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member]    
Investments 72,045 69,972
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]    
Investments 72,045 69,972
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]    
Investments
US Treasury Securities [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]    
Investments
US Treasury Securities [Member] | Reported Value Measurement [Member]    
Investments $ 72,032 $ 69,972
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.19.2
Note 6 - Equity Incentive Plan (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 18, 2019
Jun. 30, 2019
Jun. 30, 2018
Mar. 31, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Share-based Payment Arrangement, Expense   $ 1,443 $ 1,322   $ 2,829 $ 8,887  
Stock Options, PSUs and RSUs to Employees and RSUs to Non-employee Directors [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period         3 years    
Performance Shares [Member]              
Share-based Payment Arrangement, Expense   $ 300     $ 400    
Performance Conditions, Business Target, Percentage of Performance Conditions Based on Achievement in Current Fiscal Year         30.00%    
Performance Conditions, Financial Target, Percentage of Performance Conditions Based on Company’s Operating Results in next Fiscal Year         70.00%    
The 2017 Plan [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized 1,500,000            
Common Stock, Capital Shares Reserved for Future Issuance 2,700,000           1,200,000
Chief Executive Officer [Member]              
Share-based Payment Arrangement, Expense       $ 6,200      
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.19.2
Note 6 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)
6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Expected life (years) (Year) 3 years 182 days  
Expected dividend yield 0.00% 0.00%
Minimum [Member]    
Risk free interest rate 2.18% 2.15%
Expected volatility 44.05% 37.12%
Expected life (years) (Year)   4 years
Maximum [Member]    
Risk free interest rate 2.54% 2.75%
Expected volatility 44.72% 40.81%
Expected life (years) (Year)   4 years 182 days
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.19.2
Note 6 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Stock-based compensation expense $ 1,443 $ 1,322 $ 2,829 $ 8,887
Cost of Sales [Member]        
Stock-based compensation expense 82 (28) 174 (244)
Research and Development Expense [Member]        
Stock-based compensation expense 91 241 268 451
Selling, General and Administrative Expenses [Member]        
Stock-based compensation expense $ 1,270 $ 1,109 $ 2,387 $ 8,680
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.19.2
Note 6 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details) - shares
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Share-based Payment Arrangement, Option [Member]        
Stock Options (in shares) 27,325 17,500 131,617 209,800
Stock Options (in shares) 22,400 273,123 22,900 284,548
Restricted Stock [Member]        
Equity Instruments Other than Options (in shares) 64,578
Restricted Stock Units (RSUs) [Member]        
Equity Instruments Other than Options (in shares) 8,000 173,507 8,130
Performance Restricted Stock Units [Member]        
Equity Instruments Other than Options (in shares) 114,500
Stock Appreciation Rights (SARs) [Member]        
SARs (in shares)
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.19.2
Note 7 - Earnings Per Share ("EPS") (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
2 Months Ended 3 Months Ended 6 Months Ended
May 08, 2019
May 07, 2019
Jun. 30, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
May 02, 2019
Stock Repurchase Program, Authorized Amount               $ 50,000
Payments for Repurchase of Common Stock           $ 30,000 $ 30,000  
Accelerated Stock Repurchase [Member]                
Stock Repurchase Program, Authorized Amount   $ 30,000           30,000
Payments for Repurchase of Common Stock   $ 30,000            
Stock Repurchased During Period, Shares 0.5              
Share Price $ 39.85              
Share Repurchased, Pecentage 60.00%              
Stock Repurchase Program, Remaining Authorized Repurchase Amount     $ 12,000 $ 12,000   $ 12,000    
Number of Additional Shares Deliver to Company if ASR Agreement Settled     0.3          
Repurchase from Open Market [Member]                
Stock Repurchase Program, Authorized Amount               $ 20,000
Share-based Payment Arrangement, Option [Member]                
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount       1.0 0.7 1.0 0.6  
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.19.2
Note 7 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) - shares
shares in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Basic weighted average common shares outstanding (in shares) 13,916 14,652 14,054 14,666
Stock options, SARs, RSAs, RSUs and PSUs (in shares) 172 263 149 379
Diluted shares used in the calculation of earnings per share (in shares) 14,088 14,915 14,203 15,045
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.19.2
Note 8 - Inventories (Details Textual) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Inventory, Noncurrent, Total $ 4,541 $ 3,833
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.19.2
Note 8 - Inventories - Summary of Inventories (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Raw materials $ 12,381 $ 13,688
Work-in-process 6,399 4,626
Finished goods 8,747 6,819
Total 27,527 25,133
Inventories, net 22,986 21,300
Inventory, Noncurrent, Total $ 4,541 $ 3,833
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.19.2
Note 9 - Intangible Assets (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Amortization of Intangible Assets, Total $ 200 $ 300 $ 500 $ 500  
Impairment of Intangible Assets, Finite-lived     281  
Intangible Assets, Net (Excluding Goodwill), Total 8,303   8,303   $ 9,191
HYALOSPINE Developed Technology Asset [Member]          
Impairment of Intangible Assets, Finite-lived 300        
MEROGEL INJECTIBLE Assets [Member]          
Intangible Assets, Net (Excluding Goodwill), Total $ 100   $ 100    
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.19.2
Note 9 - Intangible Assets - Summary of Intangible Assets (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Mar. 31, 2019
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Gross Value   $ 28,206    
Accumulated Currency Translation Adjustment   (4,642)   $ (4,576)
Impairment   (281)  
Accumulated Amortization   (14,980)   (14,439)
Intangible assets, net   8,303   9,191
In Process Research and Development [Member]        
Gross Value   4,406    
Accumulated Currency Translation Adjustment   (1,191)   (1,168)
Impairment      
Accumulated Amortization    
Intangible assets, net   3,215   3,238
Developed Technology Rights [Member]        
Gross Value   17,100    
Accumulated Currency Translation Adjustment   (2,864)   (2,824)
Impairment   (281)    
Accumulated Amortization   (9,189)   (8,672)
Intangible assets, net   4,766   5,604
Useful life (Year) 15 years      
Distribution Rights [Member]        
Gross Value   4,700    
Accumulated Currency Translation Adjustment   (415)   (415)
Impairment      
Accumulated Amortization   (4,285)   (4,285)
Intangible assets, net    
Useful life (Year) 5 years      
Patents [Member]        
Gross Value   1,000    
Accumulated Currency Translation Adjustment   (172)   (169)
Impairment      
Accumulated Amortization   (506)   (482)
Intangible assets, net   322   349
Useful life (Year) 16 years      
Elevess Trade Name [Member]        
Gross Value   1,000    
Accumulated Currency Translation Adjustment    
Impairment      
Accumulated Amortization   (1,000)   (1,000)
Intangible assets, net    
Useful life (Year) 9 years      
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.19.2
Note 10 - Goodwill (Details Textual)
$ in Thousands
Nov. 30, 2018
USD ($)
Goodwill, Impaired, Accumulated Impairment Loss $ 0
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.19.2
Note 10 - Goodwill - Changes in the Carrying Value of Goodwill (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2019
USD ($)
Balance $ 7,851
Effect of foreign currency adjustments (53)
Balance $ 7,798
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.19.2
Note 11 - Accrued Expenses (Details Textual) - Former Chief Executive Officer [Member]
$ in Millions
Mar. 08, 2018
USD ($)
Severance Benefit Following Retirement $ 1.7
Severance Benefit Following Retirement, Term 1 year 180 days
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.19.2
Note 11 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Compensation and related expenses $ 3,584 $ 4,446
Professional fees 1,609 1,989
Operating lease liability - current 1,101
Income taxes payable 757 385
Research grants 398 400
Clinical trial costs 320 577
Other 332 349
Total $ 8,101 $ 8,146
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.19.2
Note 12 - Operating Leases (Details Textual)
6 Months Ended
Jun. 30, 2019
ft²
Operating Lease, Weighted Average Discount Rate, Percent 4.10%
Operating Lease, Weighted Average Lease Term 17 years 109 days
Administrative, Research and Development, and Manufacturing Space in Bedford, MA [Member]  
Area of Real Estate Property 134,000
Office, Research and Development, Training, and Warehousing Space in Padova, Italy [Member]  
Area of Real Estate Property 33,000
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.19.2
Note 12 - Operating Leases - Lease Expense and Other Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2019
Operating lease cost $ 521 $ 1,043
Short-term lease cost 4 6
Variable lease cost 60 112
Total lease cost 585 1,161
Operating cash flows from operating leases $ 497 $ 994
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.19.2
Note 12 - Operating Leases - Future Minimum Rental Payments for Operating Leases (Details) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
2019 $ 994  
2020 2,025  
2021 2,024  
2022 1,981  
2023 1,965  
Thereafter 23,530  
Present value adjustment (9,444)  
Present value of lease payments 23,075  
Less current portion included in Accrued expenses and other current liabilities (1,101)
Operating lease liabilities $ 21,974
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.19.2
Note 12 - Operating Leases - Future Lease Commitments Under ASU 840 (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
2019 $ 1,879
2020 1,917
2021 1,924
2022 1,672
2023 414
2024 and thereafter 897
Total $ 8,703
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.19.2
Note 13 - Commitments and Contingencies (Details Textual) - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Standard and Extended Product Warranty Accrual, Ending Balance $ 0 $ 0
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.19.2
Note 14 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Dec. 31, 2018
Income Tax Expense (Benefit), Total $ 3,013 $ 1,444 $ 4,486 $ 394  
Effective Income Tax Rate Reconciliation, Percent, Total 24.20% 12.50% 24.30%   10.40%
Deferred Tax Assets, Valuation Allowance, Total $ 0   $ 0   $ 0
EXCEL 67 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 69 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 196 273 1 false 49 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.anikatherapeutics.com/20190630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.anikatherapeutics.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited- Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.anikatherapeutics.com/20190630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) Sheet http://www.anikatherapeutics.com/20190630/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-income-unaudited- Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.anikatherapeutics.com/20190630/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.anikatherapeutics.com/20190630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited- Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Nature of Business Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-1-nature-of-business Note 1 - Nature of Business Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Basis of Presentation Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-2-basis-of-presentation- Note 2 - Basis of Presentation Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Revenue Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-3-revenue Note 3 - Revenue Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Investments Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-4-investments Note 4 - Investments Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Fair Value Measurements Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-5-fair-value-measurements Note 5 - Fair Value Measurements Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Equity Incentive Plan Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-6-equity-incentive-plan Note 6 - Equity Incentive Plan Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Earnings Per Share ("EPS") Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-7-earnings-per-share-eps Note 7 - Earnings Per Share ("EPS") Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Inventories Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-8-inventories Note 8 - Inventories Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Intangible Assets Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-9-intangible-assets Note 9 - Intangible Assets Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Goodwill Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-10-goodwill Note 10 - Goodwill Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Accrued Expenses Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-11-accrued-expenses Note 11 - Accrued Expenses Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Operating Leases Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-12-operating-leases- Note 12 - Operating Leases Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Commitments and Contingencies Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-13-commitments-and-contingencies Note 13 - Commitments and Contingencies Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Income Taxes Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-14-income-taxes Note 14 - Income Taxes Notes 20 false false R21.htm 020 - Disclosure - Note 3 - Revenue (Tables) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-3-revenue-tables Note 3 - Revenue (Tables) Tables http://www.anikatherapeutics.com/20190630/role/statement-note-3-revenue 21 false false R22.htm 021 - Disclosure - Note 5 - Fair Value Measurements (Tables) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-5-fair-value-measurements-tables Note 5 - Fair Value Measurements (Tables) Tables http://www.anikatherapeutics.com/20190630/role/statement-note-5-fair-value-measurements 22 false false R23.htm 022 - Disclosure - Note 6 - Equity Incentive Plan (Tables) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-6-equity-incentive-plan-tables Note 6 - Equity Incentive Plan (Tables) Tables http://www.anikatherapeutics.com/20190630/role/statement-note-6-equity-incentive-plan 23 false false R24.htm 023 - Disclosure - Note 7 - Earnings Per Share ("EPS") (Tables) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-7-earnings-per-share-eps-tables Note 7 - Earnings Per Share ("EPS") (Tables) Tables http://www.anikatherapeutics.com/20190630/role/statement-note-7-earnings-per-share-eps 24 false false R25.htm 024 - Disclosure - Note 8 - Inventories (Tables) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-8-inventories-tables Note 8 - Inventories (Tables) Tables http://www.anikatherapeutics.com/20190630/role/statement-note-8-inventories 25 false false R26.htm 025 - Disclosure - Note 9 - Intangible Assets (Tables) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-9-intangible-assets-tables Note 9 - Intangible Assets (Tables) Tables http://www.anikatherapeutics.com/20190630/role/statement-note-9-intangible-assets 26 false false R27.htm 026 - Disclosure - Note 10 - Goodwill (Tables) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-10-goodwill-tables Note 10 - Goodwill (Tables) Tables http://www.anikatherapeutics.com/20190630/role/statement-note-10-goodwill 27 false false R28.htm 027 - Disclosure - Note 11 - Accrued Expenses (Tables) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-11-accrued-expenses-tables Note 11 - Accrued Expenses (Tables) Tables http://www.anikatherapeutics.com/20190630/role/statement-note-11-accrued-expenses 28 false false R29.htm 028 - Disclosure - Note 12 - Operating Leases (Tables) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-12-operating-leases-tables Note 12 - Operating Leases (Tables) Tables http://www.anikatherapeutics.com/20190630/role/statement-note-12-operating-leases- 29 false false R30.htm 029 - Disclosure - Note 3 - Revenue (Details Textual) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-3-revenue-details-textual Note 3 - Revenue (Details Textual) Details http://www.anikatherapeutics.com/20190630/role/statement-note-3-revenue-tables 30 false false R31.htm 030 - Disclosure - Note 3 - Revenue - Product Revenue by Product Group (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-3-revenue-product-revenue-by-product-group-details Note 3 - Revenue - Product Revenue by Product Group (Details) Details 31 false false R32.htm 031 - Disclosure - Note 3 - Revenue - Total Revenue by Geographic Location (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-3-revenue-total-revenue-by-geographic-location-details Note 3 - Revenue - Total Revenue by Geographic Location (Details) Details 32 false false R33.htm 032 - Disclosure - Note 4 - Investments (Details Textual) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-4-investments-details-textual Note 4 - Investments (Details Textual) Details http://www.anikatherapeutics.com/20190630/role/statement-note-4-investments 33 false false R34.htm 033 - Disclosure - Note 5 - Fair Value Measurements - Fair Value of Financial Instruments (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-5-fair-value-measurements-fair-value-of-financial-instruments-details Note 5 - Fair Value Measurements - Fair Value of Financial Instruments (Details) Details 34 false false R35.htm 034 - Disclosure - Note 6 - Equity Incentive Plan (Details Textual) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-6-equity-incentive-plan-details-textual Note 6 - Equity Incentive Plan (Details Textual) Details http://www.anikatherapeutics.com/20190630/role/statement-note-6-equity-incentive-plan-tables 35 false false R36.htm 035 - Disclosure - Note 6 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-6-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details Note 6 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) Details 36 false false R37.htm 036 - Disclosure - Note 6 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-6-equity-incentive-plan-total-stockbased-compensation-expense-details Note 6 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) Details 37 false false R38.htm 037 - Disclosure - Note 6 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-6-equity-incentive-plan-granted-and-exercised-stockbased-compensation-awards-details Note 6 - Equity Incentive Plan - Granted and Exercised Stock-based Compensation Awards (Details) Details 38 false false R39.htm 038 - Disclosure - Note 7 - Earnings Per Share ("EPS") (Details Textual) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-7-earnings-per-share-eps-details-textual Note 7 - Earnings Per Share ("EPS") (Details Textual) Details http://www.anikatherapeutics.com/20190630/role/statement-note-7-earnings-per-share-eps-tables 39 false false R40.htm 039 - Disclosure - Note 7 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-7-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details Note 7 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) Details http://www.anikatherapeutics.com/20190630/role/statement-note-7-earnings-per-share-eps-tables 40 false false R41.htm 040 - Disclosure - Note 8 - Inventories (Details Textual) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-8-inventories-details-textual Note 8 - Inventories (Details Textual) Details http://www.anikatherapeutics.com/20190630/role/statement-note-8-inventories-tables 41 false false R42.htm 041 - Disclosure - Note 8 - Inventories - Summary of Inventories (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-8-inventories-summary-of-inventories-details Note 8 - Inventories - Summary of Inventories (Details) Details 42 false false R43.htm 042 - Disclosure - Note 9 - Intangible Assets (Details Textual) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-9-intangible-assets-details-textual Note 9 - Intangible Assets (Details Textual) Details http://www.anikatherapeutics.com/20190630/role/statement-note-9-intangible-assets-tables 43 false false R44.htm 043 - Disclosure - Note 9 - Intangible Assets - Summary of Intangible Assets (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-9-intangible-assets-summary-of-intangible-assets-details Note 9 - Intangible Assets - Summary of Intangible Assets (Details) Details 44 false false R45.htm 044 - Disclosure - Note 10 - Goodwill (Details Textual) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-10-goodwill-details-textual Note 10 - Goodwill (Details Textual) Details http://www.anikatherapeutics.com/20190630/role/statement-note-10-goodwill-tables 45 false false R46.htm 045 - Disclosure - Note 10 - Goodwill - Changes in the Carrying Value of Goodwill (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-10-goodwill-changes-in-the-carrying-value-of-goodwill-details Note 10 - Goodwill - Changes in the Carrying Value of Goodwill (Details) Details 46 false false R47.htm 046 - Disclosure - Note 11 - Accrued Expenses (Details Textual) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-11-accrued-expenses-details-textual Note 11 - Accrued Expenses (Details Textual) Details http://www.anikatherapeutics.com/20190630/role/statement-note-11-accrued-expenses-tables 47 false false R48.htm 047 - Disclosure - Note 11 - Accrued Expenses - Summary of Accrued Expenses (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-11-accrued-expenses-summary-of-accrued-expenses-details Note 11 - Accrued Expenses - Summary of Accrued Expenses (Details) Details 48 false false R49.htm 048 - Disclosure - Note 12 - Operating Leases (Details Textual) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-12-operating-leases-details-textual Note 12 - Operating Leases (Details Textual) Details http://www.anikatherapeutics.com/20190630/role/statement-note-12-operating-leases-tables 49 false false R50.htm 049 - Disclosure - Note 12 - Operating Leases - Lease Expense and Other Information (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-12-operating-leases-lease-expense-and-other-information-details Note 12 - Operating Leases - Lease Expense and Other Information (Details) Details 50 false false R51.htm 050 - Disclosure - Note 12 - Operating Leases - Future Minimum Rental Payments for Operating Leases (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-12-operating-leases-future-minimum-rental-payments-for-operating-leases-details Note 12 - Operating Leases - Future Minimum Rental Payments for Operating Leases (Details) Details 51 false false R52.htm 051 - Disclosure - Note 12 - Operating Leases - Future Lease Commitments Under ASU 840 (Details) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-12-operating-leases-future-lease-commitments-under-asu-840-details Note 12 - Operating Leases - Future Lease Commitments Under ASU 840 (Details) Details 52 false false R53.htm 052 - Disclosure - Note 13 - Commitments and Contingencies (Details Textual) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-13-commitments-and-contingencies-details-textual Note 13 - Commitments and Contingencies (Details Textual) Details http://www.anikatherapeutics.com/20190630/role/statement-note-13-commitments-and-contingencies 53 false false R54.htm 053 - Disclosure - Note 14 - Income Taxes (Details Textual) Sheet http://www.anikatherapeutics.com/20190630/role/statement-note-14-income-taxes-details-textual Note 14 - Income Taxes (Details Textual) Details http://www.anikatherapeutics.com/20190630/role/statement-note-14-income-taxes 54 false false All Reports Book All Reports anik-20190630.xml anik-20190630.xsd anik-20190630_cal.xml anik-20190630_def.xml anik-20190630_lab.xml anik-20190630_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 73 0001171843-19-004913-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-19-004913-xbrl.zip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end